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Abstract 
 
Abelson Kinase Based Regulation of HNSCC Tumor Cell Invasion 
 
Karen E. Hayes 
 
Nearly 40,000 new cases of head and neck squamous cell carcinoma (HNSCC) are 
annually diagnosed in the United States.  The current standard of care for HNSCC 
patients consists of chemoradiation often combined with targeted therapeutic agents.  
However, the five-year survival rate for patients that relapse is < 50%.  Patients with 
recurrent or metastatic disease have a very poor prognosis and typical survive < 12 
months due to therapeutic resistance and loco-regional invasive spread.  HNSCC 
invasion is mediated in part by lamellipodia and invadopodia, two actin-based structures 
responsible for facilitating invasive movement.  Key signaling pathways that govern 
lamellipodia and invadopodia production are hyperactivated or overexpressed in 
HNSCC, including EGFR, Src, Erk 1/2, and cortactin.  The overall goal of this 
dissertation is to determine how these signaling components regulate lamellipodia and 
invadopodia production and function in HNSCC.  Three studies were completed that 
address these issues.  Study One reveals an anti-invasive function for Abl in 
invadopodia regulation in HNSCC, results that are contrary to the pro-invasive influence 
Abl has in breast and other cancer types. Study Two establishes a fundamental role for 
Src has in HNSCC invasion and metastasis through the use of the dual Src/Abl inhibitor 
saracatinib. In Study Three we determine the expression and activation levels of Erk 1/2 
in HNSCC patient samples and the role of Erk 1/2 cortactin phosphorylation in HNSCC 
adhesion, migration and lamellipodia persistence.  Collectively these studies shed new 
light into the fundamental mechanisms utilized during various steps in HNSCC invasion, 
providing the potential for refinement and development of new avenues for therapeutic 
intervention. 
 iii 
 
Acknowledgements 
 
Well I finally have reached the end of my journey; it has been a long and bumpy road.  
This is by no means a road that I have travel on my own, throughout my time at West 
Virginia University I have meet many kind people who have helped me along my way.  I 
would like to take this time to express my gratitude to the people who have enriched my 
life here at WVU.  First, I would like say that I am sincerely gratefully to the graduate 
school at WVU for giving me this opportunity, I would never been able to obtain a PhD 
without the financial assistance this program has provided.  I would also like to thank my 
committee members; you have pushed me to become a better research scientist, thank 
you for your insights and recommendations throughout my graduate career.  Next, I 
wish to express my sincerest gratitude to my mentor, Dr. Scott Weed, his guidance, 
instruction and patience have allowed me to develop as a scientist. It may have been a 
struggle but I think that the training wheels can now come off now.   
This brings me to all the members of the Weed laboratory past and present, thank you 
for your assistance great or small I will remember you always.  I would like to mention a 
few members personally, Jason Evans where would I be without you, probably lost in 
the labyrinth of halls at WVU, it has be a long haul but we made it.  I promise not to take 
your scissors ever again.  Dr. Amanda Ammar (aka Arnold Hammer), you have been 
such a good friend.  Thank you for caring enough to make sure I wasn’t being eaten by 
my cats.  Lesly Anne Lopez-Skinner, you may have moved many miles away to Texas 
many years ago but you are still one of my closest friends.  I hope our career paths will 
cross again because you are one of the few people I know that is just pure goodness.  
Elyse Walk, my IT guru, what will I do when you are not there to help me with my 
computer problems.  Steve Markwell, no one has ever made me laugh like you, just try 
not to burn down the laboratory after I’m gone. Finally to our honorary Weed lab 
member, Tammy Whitacre, you give so much of yourself to others; I can only hope to 
be as giving.  Also, you need to remember to take some time for yourself, take that 
vacation I’m always telling you to take.  
I would also like to thank the members of my family for their support.  To my mother, 
who has always been there to listen to my ranting and raving, nodding and agreeing 
with me even though I’m completely in the wrong.  I know I have you to thank for my 
stubbornness that has kept me going even through the worst of the times.  To my 
father; who is no longer on this mortal plain, you were always there for me even when 
you didn’t agree with what I was doing. Thank you both for being my safety net.  To my 
sister, we have traveled this bumpy collegiate road often together.  You have been there 
to lend a helping hand without question; I think the time we had the tub stuck on the 
stairs will be my most memorable moment.  Thank you so much, you will never know 
how truly grateful I am.  To my brother, yes I have finally made it; you can stop asking 
me “When are you going to graduate?”.    
 iv 
 
Table of Contents 
 
Abstract…………………………………………………….………………………… ii 
 
Acknowledgements………………………………………………………………… iii 
 
Table of Contents…………………………………………………………………… iv 
  
List of Figures ……………………………………………………………….............  vi 
  
Glossary………………………………………………………………………………        ix 
 
Literature Review ……………………………………………………………………   1 
 
Head and neck squamous cell carcinoma 
Methods of cancer cell motility and invasion 
Cortactin: A node of actin network regulation 
EGFR: Signaling and significance in HNSCC 
Erk1/2: Effector proteins for EGFR signaling 
Src: The first oncogene 
Abl: A kinase with dichotomous roles 
   
Study 1: Ableson Kinases Negatively Regulate Invadopodia Function and  
 
Invasion in Head and Neck Squamous Cell Carcinoma by Inhibiting  
 
an HB-EGF Autocrine Loop  …………………………….…………………      57  
 
Study 2: Saracatinib Impairs Head and Neck Squamous Cell Carcinoma  
 
Invasion by Disrupting Invadopodia Function.........................................    109  
 
Study 3: Cortactin Phosphorylated by ERK1/2 Localizes to Sites of Dynamic  
 
Actin Regulation and Is Required for Carcinoma Lamellipodia  
 
Persistence............................................................................................     147  
 
General Discussion ……………………………………………………..…………      192  
 
Appendix  
 
Quantitative Measurement of Invadopodia-mediated Extracellular 
 
Matrix Proteolysis in Single and Multicellular Contexts…………………      204 
 
 v 
 
Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse 
  
Model of Oral Squamous Cell Carcinoma ………………………………       215 
 
Revisiting the ERK/Src Cortactin Switch …………………………………      223 
 
Further Insights into Cortactin Conformational Regulation  ……………      226 
 
Oncogenic Src Requires a Wild-type Counterpart to Regulated  
 
Invadopodia Maturation ……………………………………………………      229 
 
Curriculum Vitae……………………………………………………………..      245 
  
 vi 
 
List of Figures and Tables 
 
Literature Review  
 
Figures 
1. Plasticity of tumor cell migration. 
 
2. Schematic diagram of cortactin structure with adapter and signaling partners. 
 
3. Schematic diagram of EGFR and conical MAPK signaling pathways. 
 
4. Erk1/2 signaling cascade and regulation of cellular processes. 
 
5. Schematic diagram of Src, activation and downstream signaling pathways. 
6. Schematic diagram of Abl structure, activation and downstream signaling  
 
pathways. 
 
Table 
1.  Table of cortactin SH3 binding proteins 
 
 
Study 1  
 
1 Abl expression inhibits invadopodia activity in HNSCC cells.  
 
2 Targeted inhibition of Abl family kinases with imatinib has divergent effects on  
 
invadopodia activity in HNSCC and breast cancer cells. 
 
3 Imatinib enhances HNSCC invasion through 3D collagen matrices. 
 
4 Elevated Src activity bypasses Abl family kinase regulation of invadopodia 
 
function.  
 
5 Imatinib activates the invadopodia kinase pathway in HNSCC cells. 
 
6 Imatinib induced HB-EGF stimulates HNSCC invadopodia ECM degradation. 
 
7 Targeted inhibition of the EGFR-Src pathway impairs HNSCC invadopodia 
 
activity. 
 
8 Schematic diagram of EGFR-invadopodia signaling pathways altered by Abl 
 vii 
 
 
inhibition in HNSCC. 
 
Supplemental Figures:  
 
1 Abl knockdown does not impact the number of HNSCC invadopodia.  
 
2 Abl knockdown does not impact matrix degradation in MDA-MB-231 cells.  
 
3 Determination of PDGFRα expression levels in OSC19, UMSCC1 and MDA- 
 
MB-231 cells.  
 
4 Abl and Arg expression levels in wild-type (WT) and Abl-/-/Arg-/- (DKO)  
 
mouse embryo fibroblasts (MEFs).  
 
5 Evaluation of imatinib on EGFR and Crk signaling. 
  
6 Targeted inhibition of the EGFR-Src pathway.  
 
7 Saracatinib impairs invadopodia activity in HNSCC and MDA-MB-231 cells. 
 
Study 2  
 
1. Effects of saracatinib on HNSCC proliferation, cell cycle progression, Erk1/2  
 
activation and in vitro invasion.  
 
2. Saracatinib inhibits Src activity and downstream Src substrate  
 
phosphorylation in HNSCC cell lines.  
 
3. Saracatinib inhibits Src activity, perineural invasion and cervical lymph node  
 
metastasis in orthotopic UMSCC1 tongue tumors.  
 
4. Saracatinib inhibits invadopodia formation and ECM degradation.  
 
5. MMP9 secretion and ECM degradation activity in HNSCC cells is blocked by  
 
saracatinib.  
 
Supplemental Figures:  
 
6. Specificity of human anti-pY421 cortactin antibody.  
 
 viii 
 
Study 3  
 
1. Specificity and validation of pS405 and pS418 phospho-specific cortactin  
 
antibodies.  
 
2. Growth factor-stimulated Erk 1/2 activation mediates phosphorylation of  
 
cortactin at serine 405 and 418.  
 
3. EGF-induced conversion of cortactin from 80kDa to 85kDa is impaired by Src  
 
and MEK1/2 inhibition.  
 
 
4. Cortactin tyrosine and serine phosphorylation resultant of v-Src activation are  
 
not interdependent.  
 
5. Targeted inhibition of MEK1/2 inhibits HNSCC cell motility.  
 
6. Cortactin phosphorylation at serine 405 and 418 regulates carcinoma cell  
 
migration and adhesion.  
 
7. Cortactin phosphorylation at serine 405 and 418 is required for lamellipodia  
 
persistence.  
 
 
 
  
 ix 
 
Glossary 
 
A    alanine  
Å    angstrom 
Abl (Abl1, c-Abl)      abelson tyrosine kinase 
ABP    actin binding protein  
ACK1             activated Cdc42-associated kinase 
ADAM            a disintegrin and metalloproteinase 
ADP   adenosine diphosphate  
AFAP110   actin filament-associated protein of 110 kDa 
Akt (PKB)       protein kinase B                 
AMAP1 (ASAP1)      AMY-1-binding protein 1 
ANOVA          analysis of variance 
Arf6                ADP-ribosylation factor 6 
Arg (Abl2)       Abelson-related gene 
Arp2/3   actin related protein 2/3  
AREG             amphiregullin 
ATM               ataxia telangiectasia mutated protein 
ATP    adenosine triphosphate 
BAX                Bcl-2-associated X protein 
Bcl-2               B-cell lymphoma 2 
BCR               breakpoint cluster region  
BCR-Abl         breakpoint cluster region- ableson 
bFGF    basic fibroblast growth factor 
BPGAP1        BCH domain-containing Cdc42GAP-like protein 
BSA               bovine serum albumin 
C    Celsius 
CAFs              cancer associated fibroblasts 
CAS    Crk-associated substrate 
Cbl                 Casitas B-lineage lymphoma gene 
CBP90  cortactin-binding protein 90 
CD2AP           CD2- associated protein 
Cdc42            cell division cycle 42, GTP binding protein 
CDK2             cyclin-dependent kinase 2 
CEF   chicken embryo fibroblast  
Cer    cerulean fluorescent protein 
CFP   cyan fluorescent protein 
CIN85              Cbl-interacting 85-kDa protein 
CIP4               Cdc42-interacting protein 
c-kit                 cellular homologue of the feline sarcoma viral oncogene v-kit  
c-Met              MNNG HOS transforming gene ; hepatocyte growth factor receptor 
CML               chronic mylogenous leukemia  
CMV   cytomegalovirus promoter  
CortBP1  cortactin binding protein 1 
CP   capping protein 
Crk I/II            Cdc2 related kinase 1/2 
 x 
 
Csk    C-terminal Src kinase  
CTTN   human cortactin gene  
Cttn    murine cortactin gene  
DAB               diaminobenzidine 
DAPI    4', 6-diamidino-2-phenylindole 
DDB1/2          damaged DNA-binding 1/2 
DDW               arginine-arginine-tryptophan 
BK channels large conductance calcium- and voltage-activated potassium 
channels 
DKO               double knockout  
DMEM            dulbecco’s modified eagle medium 
DMSO   dimethyl sulfoxide  
DNA    deoxyribonucleic acid  
DNAPK          DNA-activated protein kinase 
DOK               downstream of tyrosine kinase 
DRF    diaphanous-related formin  
DUSP             dual specific phosphatase 
E                    epithelial  
ECIS    electric cell-substrate impedance sensing  
ECM    extracellular matrix  
EDTA   ethylenediaminetetraacetic acid  
EGF    epidermal growth factor  
EGFR   epidermal growth factor receptor  
EMT    epithelial to mesenchymal transition  
EphR4            ephrin R4 
ERK1/2   extracellular signal regulated kinase1/2  
Ets                  E-twenty six  
F    filamentous  
FAB                F-actin binding  
FACS   fluorescence-activated cell sorting  
FAK    focal adhesion kinase  
FBS    fetal bovine serum 
Fer                 feline encephalitis virus-related kinase  
FGD1             faciogenital dysplasia protein 1  
FGF    fibroblast growth factor 
FGFR             fibroblast growth factor receptor 
FITC    fluorescein isothiocyanate 
FUS1              fusion 1 protein 
Fyn (Syn,Slk)  Fgr/Yes related novel protein 
G    globular 
GAP               GTPase-activating protein  
GCPR            g-coupled protein receptors 
GEF               guanine nucleotide exchange factor 
GFP    green fluorescent protein 
GIST              gastrointestinal stromal tumor  
Grb2               growth factor bound protein 2 
 xi 
 
GTP    guanosine-5’- triphosphate 
HA-tagged      hemaglutinin tagged        
HDAC1           histone deacetylases 1   
H & E              hematoxylin and eosin 
HER                Human Epidermal Growth Factor Receptor  
HGF    hepatocyte growth factor 
HIP1R            Huntingtin-interacting protein1 related 
HP                  helical proline  
HNSCC   head and neck squamous cell carcinoma 
IGFR              insulin-like growth factor 1 receptor 
IQGAP           IQ motif containing GTPase-activating protein 
IHC   immunohistochemistry  
JAK                Janus kinase 
JNK                c-Jun N-terminal kinase 
kDa    kiloDalton  
K-RAS            Kirsten rat sarcoma viral oncogene homolog 
KSR1             kinase suppressor of Ras1 
LSP1              lymphocyte-specific protein 1 
MAPK   mitogen-activated protein kinase  
mCh    mCherry fluorescent protein  
MDM2            murine double minute 2 
MEF    mouse embryonic fibroblast  
MEK1/2   MAP kinase kinase 1/2 
MIM                missing in metastatis 
MIBs    multiplexed inhibitor beads 
MLCII             myosin light chain II 
MLCK             myosin light chain kinase 
MMP    matrix metalloprotease 
Mr                   mass relative 
MT-MMP        matrix bound matrix metalloprotease 
MT1-MMP   matrix bound matrix metalloprotease 1 
mTor              mammalian target of rapamycin 
MTT               3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NADPH          nicotinamide adenine dinucleotide phosphatase 
NCK               non-catalytic region of tyrosine kinase adaptor protein  
NF-кB             nuclear factor-кB 
NI                   not infected 
NOXA             NADPH oxidase activator 
NPF    nucleation-promoting factor 
NSCLC           non-small cell lung carcinoma 
NTA    N-terminal acidic domain  
N-WASp         Neuronal Wiskott-Aldrich Syndrome Protein        
p120RASGAP   Ras GTPase activating protein, 120 kDa 
p190RhoGAP     Rho GTPase activating protein, 190 kDa 
Pak1    p21-activated protein kinase  
PAK3              p21-activated protein kinase 3 
 xii 
 
PBS   phosphate buffered saline  
pCAF/p300     P300/ CREB-binding protein-associated factor 
PDGF   platelet-derived growth factor  
PDGFR          platelet-derived growth factor receptor 
PI3K    phosphoinositide-3 kinase  
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ROS               reactive oxygen species 
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RTK    receptor tyrosine kinase  
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SH1                tyrosine kinase 
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SH3    Src homology 3  
SH4                Src homology 4 
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Shc                 Src homology 2 containing 
SHP-2   Src homology 2-containing tyrosine phosphatase  
SiRNA   small interfering ribonucleic acid 
SIRT1             silent mating type information regulation 2 homolog 1 (sirtuin) 
SNARE   soluble NSF attachment protein receptors 
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Src                 sarcoma kinase 
STAT              signal transducer and activator of transcription 
SYF    Src-/-Yes-/-Fyn-/-  
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Tg    transgenic 
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Trp53   transformation related protein 53 gene  
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TYM               triple tyrosine mutant 
uPAR             urokinase type plasminogen activator  
vAbl                viral Ableson 
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Literature Review 
 
Head and neck squamous cell carcinoma.  
Head and neck squamous cell carcinoma (HNSCC) arises in the mucosal epithelial 
linings of the oral cavity, oropharynx, nasopharynx, larynx and hypopharynx (1,2).  In 
the United States approximately 40,000 patients are diagnosed with HNSCC each year, 
comprising 3% to 5% of all cancer patients (3).  HNSCC can be classified as human 
papilloma virus (HPV)-positive or HPV-negative.  The major risk factors of HPV-
negative HNSCC are sustained tobacco and alcohol use, with 90% of HNSCC cases 
having a positive correlation.  Recently tobacco-associated HNSCC diagnoses have 
declined, likely due to the decrease in tobacco consumption in the United States over 
the last eleven years.  Conversely, the number of HPV-positive HNSCC patients 
continues to increase. (3-5). 
Presently, HPV-positive (predominantly HPV type-16) HNSCC patients comprise 
approximately 20% of all HNSCC cases, of which 60% to 80% are oropharyngeal-based 
cancers (5).  HPV is a small circular double stranded DNA virus encoding sequences for 
early proteins E1, E2 and E4-E7 and late proteins L1 and L2.  HPV transforms epithelial 
cells via E6- and E7-mediated regulation of tumor suppressors, p53 and Rb and other 
key components while E5 modulates epidermal growth factor receptor (EGFR) and 
platelet-derived growth factor receptor (PDGFR) internalization (5,6).  In general, HPV-
positive HNSCC primary tumors are smaller, poorly differentiated and have a 5-year 
survival rate between 70-80%.  This survival rate is significantly better than the 5-year 
rate for HPV-negative HNSCC, which is less than 50%.   Both HNSCC sub-types 
receive the same standard treatment consisting of tumor resection, post-operative 
irradiation therapy and/or platinum-based chemotherapy (3,4,7).  Regardless of HPV 
designation, recurrent and/or metastatic HNSCC patients have an abysmally poor 
prognosis with a median survival rate of less than one year despite the addition of 
concomitant treatment with the EGFR-targeted pharmacological agent cetuximab (4,8). 
In general HNSCC presents as a locoregional disease involving metastasis to cervical 
lymph nodes, but distant metastases arise occasionally in lungs, bone, or liver of 
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HNSCC patients (9).  Metastasis is a multi-faceted processes, involving invasion 
through the basement membrane and extracellular matrix (ECM), intravasation and 
extravasion through vascular endothelial layers, and colonization at distant sites (9,10).  
The heterogeneity of tumors and the complexity of the microenvironment perpetuate a 
multitude of proposed modes of cell invasion, from collective to single cell 
amoeboid/mesenchymal phenotypes (Figure 1) (11). 
Methods of cancer cell motility and invasion.   
Amoeboid invasion (blebbing or pseudopodal) is generated though physical force that 
permits rounded, poorly attached individual tumor cells to push through gaps in loose 
connective tissue and induce non-proteolytic deformation of the extracellular matrix.  
Amoeboid invasion utilizes bleb-like membrane protrusions, pseudopodia (Rac GTPase 
induced cylindrical actin-network based membrane protrusions), or filopodia (Cdc42 
GTPase mediated slender membrane protrusions containing cross-linked parallel 
filamentous (F)-actin bundles at the leading edge of polarized motile cells.  These 
structures assist in mediating the speed and trajectory of the cell during amoeboid 
Figure 1  Plasticity of tumor cell 
migration.  Modes of tumor cell migration 
are classified by cellular morphology and 
proteolytic activity.  Individual cell 
movements: amoeboid mediated by 
protease independent and contractile 
forces pushing through loose connective 
tissue, or mesenchymal mediated by 
protease-dependent degradation of 
extracellular matrix.  Collective cell 
movements:  multicellular streaming 
mediated by chemotactic signaling and 
pathways generated by matrix 
remodeling, or collective movement 
reliant focalized ECM degradation and 
cell-to-cell contacts to generate 
directionality. 
 
Friedl, P. and Wolf, K. (2010) J. Cell. 
Biol., 188(1), 11-19 (modified).   
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movement (11-13).  The myosin II influenced contractile forces utilized to push the cell 
forward are generated via Rho-mediated activation of the Rho-associated 
serine/threonine kinase (ROCK), resulting in simultaneous inactivating phosphorylation 
of myosin phosphatase and subsequent persistent phosphorylation of myosin light chain 
on threonine 18 and serine 19 to collectively drive cell contraction (14,15).  
Mesenchymal motility is a multi-step process dependent on proteolytic activity to 
remodel connective tissue.  Spindle shaped cells in response to spatial and temporal 
signaling extend actin-based protrusion classified as invadopodia.  Invadopodia are 
proteolytic actin-rich structures that degrade the ECM or basement membrane.  
Invadopodia-generated motility occurs via actomysin-mediated contraction that propels 
the cell forward along with retraction of cell posterior (16,17).  The plasticity of tumor 
cells allows transition from amoeboid and mesenchymal invasion (and vice versa) 
based on microenvironment conditions as well as intra- and extracellular signaling cues 
(11,18).     
Collective cell movement encompasses invading cellular streams and cellular sheets 
that maintain cell-cell contact with each other and possess focalized degradation of 
ECM at the invasive front.  Cellular stream invasion utilizes cancer associated 
fibroblasts (CAF) or mesenchymal tumor cells to generate microtracks in connective 
tissue, permitting chain-like migration (19).  The intercellular signaling generated from 
the cell-cell contact directs cellular collective movement (20).  Collective invasion is the 
primary invasion mode utilized by HNSCC (18). 
This dissertation focuses on two actin-generated organelles, lamellipodia and 
invadopodia, that are necessary for these modes of invasion.  Lamellipodial-based 2D 
invasion occurs at the leading edge of motile cells and possess little to no proteolytic 
activity.  Lamellipodia are dynamic structures that last only minutes in vitro; they are 
responsible for facilitating rapid directional movement.  Conversely, invadopodial-based 
2D invasion is mediated by proteolytic degradation of ECM on the ventral surface of the 
cell.  Invasion occurring via invadopodia is generally slow, with invadopodia structures 
lasting up to several hours (21).  Lamellipodia (or pseudopodia; the 3D equivalent) are 
thin sheet-like membrane protrusions induced by extrinsic chemokines or adhesion 
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signaling that function by attaching to the ECM and pulling the cell forward.  The 
prototypical Rho-family GTPases Rac1, RhoA and Cdc42, as well as receptor tyrosine 
kinases and phospholipids propagate cytoplasmic signaling responsible for stimulating 
branched actin-based cytoskeletal networks generating the force required to extend the 
membrane (22,23).  Actin nucleating promoting factors (NPFs) are responsible for 
lamellipodia extension, where the actin-related protein 2/3 (Arp 2/3) complex forms 
branched actin networks, while NPFs of the formin family (e.g.; mDia1), and Spire 
(Cordon Blue) facilitate straight actin filament formation that serves as the basis for 
subsequent branched Arp2/3-produced networks (24,25). 
First observed by Chen et. al., invadopodia are protrusive invasive structures that have 
focalized matrix proteolytic activity (26,27).  Invadopodia utilize many of the same 
regulatory and actin-nucleating proteins observed in lamellipodia. However, invadopodia 
also require the components needed to form microtubules and secrete matrix 
metalloproteases to facilitate ECM degradation.  This collective activity allows resulting 
membrane protrusions to penetrate the basement membrane in order to remodel ECM 
(28-30). Invadopodia are complex structures comprising of a central Arp 2/3-generated 
F-actin core.  Key actin polymerization regulators, including Arp 2/3, cortactin, Tks 5 and 
N-WASp localize to the core region and are required for invadopodia formation (30-34).   
Invadopodia are produced following stimulation by extracellular cues, where Ras family 
GTPases, such as CDC42/CDC42 GEF (Fgd1), non-receptor and receptor tyrosine 
kinases (RTKs) are activated (18,21,32,35-38).  Src-phosphorylated Tsk5 binds and 
recruits the adaptor proteins Nck, cortactin and N-WASp to pre-invadopodia sites 
(34,39,40).  WIP, Nck, and N-WASp bind Src or Abl/Arg tyrosine kinases, which in turn 
tyrosine-phosphorylate cortactin to create docking sites for multimeric protein 
complexes (see below for details) that amplify Arp 2/3-mediated actin branching and 
subsequent invadopodial membrane protrusion (30,36,37,41).  Additional actin binding 
proteins assist in modulating invadopodia activity.  For example, the actin binding 
protein cofilin regulates invadopodia assembly/disassembly by inducing barbed-end 
generation, Arp2/3 filament debranching and actin turnover (32,37,42).  Microtubules 
and intermediate filaments extend into nascent invadopodia and are essential for 
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elongation (43).  Invadopodia also contain radial, unbranched, bundled actin filaments 
that are polymerized by formins, where filament ends are uncapped by Ena/Vasp 
proteins to facilitate direct actin filament elongation by allowing preferential monomer 
addition at the “plus” end near the invadopodia tip (43-46).  Parallel actin filaments are 
bundled by the proteins fascin, α-actinin and caldesmon to provide structural integrity to 
the actin core (43,47-49).  The adhesion proteins talin and paxillin localize to 
invadopodia and mediate integrin-based contact with ECM, but oddly the adhesion 
proteins focal adhesion kinase (FAK) and vinculin are not found in invadopodia (49-51).  
On a cellular level, adhesion and ECM degradation are inversely but tightly regulated; 
where degradation of matrix at sites of adhesion is counterproductive to adhesion-
based force generation (16,18,52).  
Focalized ECM degradation occurs at tips and branch points of elongated invadopodia 
(16,18,52,53).  Several proteinases localize to invadopodia that are responsible for 
facilitating ECM degradation.  These include matrix metalloproteinases MT1-MMP 
(MMP14), MMP2, MMP9, ADAM-family sheddases, cathepsin, seprase, and urokinase 
type plasminogen activator (uPAR)) (21,29,54-59).  MT1-MMP is widely considered the 
major and essential zinc-dependent membrane-bound MMP in regulating and enabling 
invadopodia proteolytic activity (the last stage in functional invadopodia maturation), as 
manipulation of MT1-MMP expression or activity directly modulates matrix degradation 
and invasion (29,57,60-62).  MT1-MMP localization to invadopodia can occur through 
clatherin-mediated endocytosis (63-66) or by exocytic membrane trafficking (67-69).  
Although the majority of work imaging invadopodia has been performed in 2D settings, 
invadopodia are believed to exist in vivo, since invadopodia forming cancer cell lines are 
more invasive in xenografts models than lines that do not form invadopodia.  Also, 
primary cells from several tumor types, including HNSCC, bladder cancer and 
glioblastomas form functional invadopodia in classic 2D gelatin matrix degradation 
assays (70-73).  In addition, invadopodia-like structures have been imaged in 
physiological relevant in vivo and ex vivo microenvironments containing key proteins 
associated with invadopodia, including N-WASp, Tks5, cortactin and Arp 2/3 that result 
in proteolysis of 3D ECM (69,74-77).  Finally, actin-rich protrusive degradative 
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structures termed podosomes are related to invadopodia, but are found in non-
transformed cell types where they are essential for homeostatic invasive processes 
conducted by osteoclasts, macrophages, smooth muscle and endothelial cells (21,78). 
Cortactin: A node of actin network regulation.  
Wu and Parsons identified cortactin as a substrate of Src kinase that localizes to cortical 
F-actin over 20 years ago (79). Cortactin is a NPF that simultaneously activates Arp 2/3 
actin polymerization and also serves to stabilize resultant branched actin networks in 
lamellipodia and invadopodia (80).  Cortactin is overexpressed in several different 
cancer types, including HNSCC (30% of cases), breast (15% of cases), lung, and 
bladder.  Notably, cortactin overexpression in these and other tumor types is primarily 
due to amplification of the cortactin (CTTN) gene on chromosome 11q13 (81-86), where 
cortactin gene amplification has emerged as a prognostic marker for poor outcome, 
corresponding with increased risk for tumor recurrence and lymph node metastasis 
(84,87-90). 
Cortactin is a multi-domain, rod-shaped protein that folds back onto itself to form a 
“lollipop” shaped structure containing a globular region produced via intramolecular 
interactions (80,91).  Cortactin consists of five domains: an amino-terminal acidic 
domain (NTA), an F-actin binding domain (FAB), a helical region, a proline-rich region 
(PRR), and a Src-homology 3 domain (SH3) (Figure 2) (92).  The NTA region of 
cortactin binds Arp 2/3 via the highly conserved DDW amino acid sequence (amino 
acids 20-22) found in other NPF proteins (93-96) that directly activates in vitro Arp 2/3 
nucleation activity (97).  Arp 2/3 activation by cortactin is enhanced through additional 
indirect mechanisms that include the recruitment of cortactin binding proteins to other 
cortactin domains (41,98-100).  Adjacent to the NTA region, the F-actin binding domain 
consists of six and a half 37 amino tandem repeats that bind directly bind F-actin 
(79,101).  F-actin binding is regulated by acetylation/deacetylation of lysine residues 
within the repeats region.  The histone acetyltransferases pCAF/p300 and SIRT1 
acetylate cortactin and prevent F-actin binding, whereas the histone deacetylase 
HDAC6 deacetylates cortactin to facilitate F-actin re-binding (102-104).  Cortactin 
binding to F-actin results in increased cell migration and is necessary for invadopodia 
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formation and function (104-107).  The helical region contains a calpain cleavage site 
that results in impaired lamellipodia protrusion and increased migration when 
proteolyzed by calpain 2 (108).  The PRR and SH3 domains constitute regions that are 
responsible for receiving upstream signaling inputs via phosphorylation and regulated 
interaction of SH3 binding partners (Table 1) that ultimately govern downstream actin-
mediated cellular processes (21,80).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Schematic diagram of cortactin 
structure with adapter and signaling partners.   
The N-terminal acidic domain (NTA) binds Arp2/3 
via a conserved DDW sequence.  Adjacent to NTA 
domain, the F-actin binding repeat region (R1-R-6 
and 1/2), is regulated by cycles of 
acetylation/deacetylation.  The helical domain 
contains a calpain cleavage site.  Serine and 
tyrosine residues in the proline-rich region (PRR) are 
phosphorylated by Src family and MAPK kinases, 
creating docking sites for SH2 domain proteins or  
mediating conformational changes to allow ligand binding to the SH3 domain.  The 
carboxyl-terminal SH3 domain binds several proline-rich proteins regulating multiple 
diverse cellular processes.  Adaption from L. Kelley dissertation, 2010. 
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Cortactin SH3 Binding 
Protein  
Function  Reference  
Abl/Arg  Phosphorylation of Y421, Y470, Y486 regulating dorsal waves, lamellipodia and 
invadopodia  
(110,111,310)  
CBP90  A “brain specific” protein that bind cortactin at synaptosomal membrane, 
function unknown  
(377)  
ZO-1  Tight junction adaptor, binds cortactin regulating cell adhesion and spreading  (378-380)  
BPGAP1  RhoA-GAP, facilitates cortactin translocation to cell periphery increasing cell 
migration  
(381,382)  
HIP1R  Caps barbed ends inhibiting actin polymerization mediating clatherin-mediated 
endocytosis  
(383)  
BK channels  large conductance calcium- and voltage-activated potassium ion channels, 
cortactin mediates Src regulation of BK channel function  
(384,385)  
ASAP1/AMAP1  Recycling endosomes focal adhesions, invadopodia podosomes/ ARF6 GAP  (386-390)  
N-WASp  Neucleating promoting factor, enhances cortactin-based Arp2/3 nucleation 
activity  
(32,37,100,121,391-
393) 
Dynamin 2  GTPase, cortactin links dynamin2 and actin filament facilitating dynamin2 
remodeling of actin filaments, membrane trafficking  
(277,394-397)  
CortBP1/SHANK  Scaffold protein in postsynaptic sites, binds cortactin modulating actin 
remodeling  
(398-400)  
FGD1  CDC42-GEF, enhances cortactin mediated Arp2/3 actin polymerization  (401,402)  
Table 1.  Table of cortactin SH3 binding proteins. 
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The cortactin PRR contains three key tyrosine residues (Y421, Y470, and Y486 in 
humans) that are phosphorylated by the Src family kinases Src, Fyn, Syk, and Fer, as 
well as the Abl family kinases Abl and Arg (109-113).  Phosphorylation at these 
residues creating binding sites for the Src homology 2 (SH2) domain containing 
adaptors proteins Nck1 and Crk, as well as mediating Abl family kinase binding 
(100,110,111,114).  In the case of Nck1, the Nck1 SH2 domain binds pY421 and 
pY466, and recruits the Arp 2/3 NPF, N-WASp; N-WASp PRR domain binds cortacin 
SH3 domain creating a ternary complex that amplifies cortactin-based Arp2/3 nucleation 
activity indirectly through promoting N-WASp activation (41,100).  The net result of 
cortactin tyrosine phosphorylation is increased invasion and metastasis by enhancing 
lamellipodia persistence, dorsal wave formation and invadopodia ECM degradation 
activity (37,41,110,111,115-119).  Protein tyrosine phosphatase 1B (PTP1B) interacts 
WIP  Forms complex with N-WASp and cortactin enhancing Arp2/3 mediated actin 
polymerization  
(98,100,403)  
 Myosin Light Chain 
Kinase (MLCK)  
Cortactin/MLCK interaction enhances myosin light chain phosphorylation and 
positively regulates endothelial cell  barriers  
(404-407)  
Missing in Metastasis 
(MIM)  
Enhances cortactin mediated Arp 2/3 actin polymerization increasing cortactin 
induce motility. Src-mediated phosphorylation of cortactin is inhibited by MIM, 
enhancing cilia formation  
(408-410)  
CD2AP  Cortactin binds/recruits CD2AP to lamellipodia, CD2AP recruits barbed end 
capping protein (CP) to lamellipodia.  CD2AP binds cortactin and EGFR 
regulating EGFR endocytosis  
(411,412)  
ACK  ACK1 phosphorylates cortactin; ACK1/cortactin interaction mediates EGFR 
internalization  
(413)  
FAK  Non-receptor tyrosine kinase, FAK/Src complex binds and phosphorylates 
cortactin stimulating focal adhesion turnover and cell motility and regulates 
irradiation induced JAK activation.  
(133-135)  
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with and dephosphorylates cortactin, consequently reducing cortactin-mediated invasion 
and metastasis (120). 
Extracellular signal-regulated kinases Erk 1/2 (MAPK 3/1), are two related 
serine/threonine kinases that phosphorylate S405 and S418 in the cortactin PPR.  Erk 
phosphorylation causes a characteristic shift in the Mr of cortactin from 80 to 85 kDa in 
SDS-PAGE due to conformational alterations rather then simple addition of phosphate 
moieties (121-123).  The close proximity of the targeted serine and tyrosine 
phosphorylation sites (especially S418 and Y421) has led to proposals where interplay 
between these two different phosphorylation events function in tandem to regulate 
cortactin signaling inputs.  Work by Martinez-Quilles et al. (2004) with various tyrosine 
and serine cortactin phosphorylation mutants in in vitro biochemical assays indicated 
that serine phosphorylation by Erk 1/2 enhanced cortactin SH3 domain binding to the N-
WASp, PRR, resulting in N-WASp activation and Arp 2/3 activation apart from the 
tyrosine phosphorylation Nck1/N-WASp mechanism described above.  Phosphorylation 
by Src led to decreased N-WASp binding and reduced Arp 2/3 actin polymerization.  
This group hypothesized that phosphorylation of cortactin serves as an on/off switch, 
where serine phosphorylation disrupts the intra-molecular interactions holding cortactin 
in a globular form to allow proline-rich proteins (e.g. N-WASp) to bind the exposed SH3 
domain and become activated (the so-called “active” cortactin form).  Conversely, 
tyrosine phosphorylation was proposed to promote the closed conformation by 
permitting re-folding of cortactin into the globular “inactive” conformation. While the 
precise mechanism of how Src-based tyrosine phosphorylation promotes cortactin 
inactivation was unclear, it was proposed that the modes of the serine/tyrosine switch 
function independently (121).  Our lab (Study 3) demonstrated through the use of 
phosphospecific antibodies against cortactin Y421 and S418 that phosphorylation of 
serine and tyrosine residues occur simultaneously in cells, in contrast to these earlier 
findings (123,124). Collectively these results suggest that cortactin tyrosine 
phosphorylation does not confer a closed “inactive” conformation proposed by the 
“serine-tyrosine switch”.  
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In addition to Src-, Abl- and Erk-family kinases, cortactin is also targeted by a variety of 
other kinases. The serine/threonine kinase p21-associated kinase (PAK1) 
phosphorylates S405/S418 following activation of Rac1 to regulate N-WASp-mediated 
vesicle motility (125).  Phosphorylation of cortactin S113 by PAK3 in the first tandem 
repeat regulates cortactin binding to F-actin (126). Protein kinase D (PKD) targets 
cortactin at S298/S348, inhibiting WAVE2/Arp2/3 mediated actin polymerization (127-
129).  In addition to these examples, there are 15 additional cortactin phosphorylation 
sites identified by mass spectroscopy that currently have unknown functions (130).  
Moreover, integrin-mediated FAK modulation of cortactin activity has divergent effects in 
Src-dependent and Src-independent manner.  The FAK/Src complex binds and 
phosphorylates cortactin on Y421, Y470, and Y486 increasing focal adhesion turnover 
and cell motility (131-134).  Integrin engagement also confers radiation resistance via 
FAK/cortactin downregulation of JNK in a Src-independent manner (135).  
The carboxyl-terminal cortactin SH3 domain binds a multitude of different proteins 
(Table 1).  These binding partners mediate cortactin regulation of various actin-based 
processes including cellular signaling (Fgd1, BPGAP1, Abl family kinases), actin 
polymerization (N-WASp, WASp-interacting protein (WIP)), membrane deformation 
(missing in metastatis, (MIM)), cell-cell and cell-substrate adhesion (ZO1 and FAK), 
endocytic and exocytic membrane trafficking (ACK1, HIP1R, AMAP, dynamin2, 
CortBP1/SHANK2, CD2AP), and actomyosin-based contraction (myosin light chain 
kinase (MLCK) (80,136-138).  These processes are collectively involved in cell 
migration and utilized in the organization invadopodia assembly.  Several studies using 
deletion mutants have clearly determined that the cortactin SH3 domain is essential for 
proper invadopodia formation and function in cancer cell lines (37,125,139).  These 
results suggest cortactin creates a nexus for invadopodia regulation and subsequently 
serves as a driver of cancer cell invasion.   
EGFR: Signaling and significance in HNSCC. 
Epidermal growth factor receptor (EGFR, HER1, ErbB1) is a transmembrane tyrosine 
kinase that is a member of the ErbB family.  Other members include ErbB2 (HER2), 
ErbB3, and ErbB4 (140).  EGFR contains an N-terminal extracellular ligand binding 
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region (domains I-IV), a hydrophobic transmembrane region, and a C-terminal 
cytoplasmic consisting of tyrosine kinase and autophosphorylation regions that 
propagate “outside-in” signaling (Figure 3) (140,141).  There are thirteen distinct ligands 
that can bind one or more ErbB receptors, adding to the complexity of ErbB signaling 
(142,143).  ErbB ligands are produced in the “pro” form and then transported to the 
plasma membrane, where they are inserted into the membrane or are exocytosed.  In 
HNSCC, the sheddases ADAMS 10 or 17 cleave the pro-ligand to create an autocrine 
or paracrine signal (144,145).  Alternatively, the uncleaved EGFR ligand heparin 
binding-epidermal growth factor (HB-EGF) can bind adjacent cells to generate a 
juxtacrine signal (146).  Epidermal growth factor (EGF), transforming growth factor α 
(TGFα) and amphiregullin (AREG) are common ErbB ligands that preferentially bind 
EGFR and are overexpressed in HNSCC, although other EGFR ligands also play lesser 
roles in HNSCC progression (143,147,148).   
Following ligand binding, ErbB receptors undergo a conformational change exposing a 
“dimerization arm” in domain II of the receptor to permit hetero- or homo-dimerization 
with a second ErbB receptor. Dimerization activates the tyrosine kinase domain, 
facilitating cross autophosphorylation of ten tyrosine sites of dimerized ErbB receptor 
cytoplasmic tail.  The phosphorylation pattern varies depending on the ErbB/ligand 
combination (149,150).  Phosphorylated tyrosines in the EGFR cytoplasmic region bind 
SH2 domain-containing scaffold proteins (e.g. Shc, Crk, and Grb2) as well as 
downstream signaling proteins (e.g. STAT, PLCγ, and Cbl).  EGFR activation regulates 
several critical signaling pathways, mainly JAK2/STAT, RAS/Raf/MAPK, and 
PLCγ/PI3K/Akt to govern cellular processes that include proliferation, survival, and 
motility (Figure 3) (151-155).  EGFR signal attenuation occurs via clatherin-coated 
mediated endocytosis, with the targeting of EGFR-containing endosomes for surface 
recycling, degradation, or nuclear localization based on affinity of ligand and 
phosphorylation status.  ErbB receptors with weakly bound ligands (e.g.; EGFR/TGFα) 
are recycled from early endosomes back to cell surface, whereas highly phosphorylated 
ErbB receptors are targeted for lysosomal degradation via late endosomes.  
Termination of EGFR signaling is assured through SH2 domain-mediated binding of the 
E3 ubiquitinase Cbl to phosphorylated tyrosine 1045 on EGFR, leading to ubiquitination 
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of EGFR to target it for proteosome-mediated degradation (156-159).  EGFR is also 
targeted to the nucleus through importin β retrograde transport (160,161), where it 
regulates cell proliferation and DNA repair.  Nuclear EGFR is also an indicator of poor 
prognosis in cancer patients (162,163). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 In addition to elevated proliferation and survival, activated EGFR regulates cell motility 
and invasion in HNSCC and other cancer types.  EGFR activation stimulates activation 
of Src and Abl family tyrosine kinases that in turn govern the downstream production of 
Figure 3.  Schematic diagram of EGFR and conical MAPK signaling pathways. 
Summary of EGFR-based signal transduction.  EGFR extracellular region (domains (dm) 
I-IV) binds ligand, dimerizes and cross-phosphorylates a second ErbB receptor.  
Activated EGFR triggers three MAPK pathways: JAK/Stat, PI3K/Akt/mTOR, and 
RAS/RAF/Erk1/2 signaling cascades regulating transcription of genes that modulate 
cellular processes that induce tumorgenesis. Clatherin-mediated EGFR internalization is 
regulated by adaptor protein Crk.  E3 ubiquitin ligase Cbl targets EGFR for degradation.  
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lamellipodia and invadopodia (36,37,100,111,115,116,164-168).  Invasion and motility 
in HNSCC are directly inhibited with the small molecule EGFR targeting drug gefitinib 
(115,169,170).  EGFR activation in HNSCC also enhances MMP9 expression and 
activation (171,172).  These studies suggest a correlation between EGFR activity and 
pro-metastatic behavior in HNSCC. 
The majority of stage III and IV HNSCC patients develop locoregional reoccurrences 
and/or distant metastasis (4,141).  EGFR overexpression occurs in >90% of all HPV-
negative HNSCC, where it correlates with radiation resistant tumors and locoregional 
failures (170,173).  Up-regulation of EGFR signaling in HNSCC is further enhanced by 
the expression of EGFR ligands.  EGF is overexpressed in 65% of cases, TGFα in 90% 
and AREG in 45% ((170,174,175).   Recent work indicates that EGFR expression and 
activation levels are independent predictors of poor prognosis for HNSCC patients 
(176).  The observed high rate of elevated EGFR activation is likely not due to activating 
point mutations, which rarely arise in HNSCC.  However, a truncated version of EGFR 
(EGFRVIII) with deletion of exons 2-7 occurs in 17 - 42% of the HNSCC cases (177-
179).  Exon 2-7 deletion removes the extracellular domain, rendering it constitutively 
active and resistant to monoclonal antibody-based therapeutic inhibition (177,180,181).  
In addition to HNSCC, several other solid tumor types overexpress EGFR, including 
non-small cell lung carcinoma (NSCLC, 62%), breast cancer (50-70%) and 
glioblastomas (>50%) (182-184). 
Multiple therapeutic EGFR inhibitors exist today designed to disrupt or ablate EGFR 
dimerization or kinase activity.  Prominent examples include cetuximab, panitumumab, 
gefitinib, vandetanib, erlotinib and lapatinib.  EGFR targeted therapy can be subdivided 
into two categories; monoclonal antibodies or small molecule inhibitors (181,185).  
Cetuximab is a monoclonal antibody that has been approved for concomitant therapy 
with radiation or platinum-based chemotherapy for recurrent or metastatic HNSCC 
based on the increased response rate in phase III trial (8,141,186,187).  Gefitinib is a 
small molecular EGFR inhibitor approved for patient treatment.  However, combination 
therapy of gefitinib and methotrexate in phase III trial of chemoresistant 
recurrent/metastatic HNSCC patients did not improve overall response rate 
15 
 
(181,188,189).  The high percentage of different solid tumor types combined with 
sporadic success of targeted therapeutic approaches continues to keep EGFR in the 
spotlight as an important molecular target in head and neck oncology. 
Erk1/2: Effector proteins for EGFR signaling. 
Extracellular signal-regulated kinase 1 and 2 (Erk 1/2, MAPK 3/1) were the first 
discovered members of the mitogen-activated protein kinases (MAPK) kinase family 
and are ubiquitously expressed.  Erk 1/2 and other MAPK members including c-Jun N-
terminal kinase (JNK), p38 MAPK, and Erk5 are serine/threonine kinases activated by 
various extracellular cues (190,191).  Erk 1/2 proteins are comprised of an N-terminal 
domain that facilitates binding to ATP and a C-terminal catalytic domain containing a 
conserved “TXY” amino acid sequence targeted by upstream kinases.  A channel 
generated between the two terminal domains creates a binding pocket for Erk 1/2 
substrates (192-194).  
Erk 1/2 has approximately 180 substrates that impact proliferation, differentiation, 
cellular survival/apoptosis, differentiation, motility, and invasion (195,196).  Given the 
complexity of Erk 1/2 signaling network, Erk activity is tightly regulated in a spatial and 
temporal manner.  The subcellular localization of Erk proteins is determined by several 
factors, including binding of Erk 1/2 to the tethering proteins VDAC, SEF, or LSP1 at 
mitochondria, Golgi, or the plasma membrane, respectively (195).  Erk 1/2 
compartmentalization is also influenced by the duration and strength of upstream EGFR 
signals, where strongly EGF-activated EGFR generates a transient cytoplasmic signal, 
while weakly bound EGFR ligands initiate sustained Erk activation and relocation of Erk 
kinases to the nucleus (140,195). 
The mechanism of EGFR-mediated Erk 1/2 activation is well described.  Following 
EGFR activation, Src homology 2 containing (Shc) protein binds to phosphorylated 
tyrosines on the EGFR cytoplasmic domain.  This in turn recruits growth factor bound 
protein 2 (Grb2) and son of sevenless (SOS), a RAS guanine nucleotide exchange 
factor (GEF).  SOS activates one of three different RAS isoforms (H-RAS, N-RAS, or K-
RAS) by converting GDP-bound RAS to GTP-RAS (197).  RAF (A-RAF, B-RAF, or C-
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RAF) are a class serine/theronine kinases that localize to the plasma membrane and 
are activated by GTP-RAS. Activated RAF in turn phosphorylates mitogen-activated 
protein kinase kinase (MEK or MAP2K), resulting in MEK activation (191,195,198,199).  
The RAF/MEK complex is stabilized by the scaffold protein kinase suppressor of Ras 1 
(KSR1), which also recruits Erk 1/2 (200,201).  Activated MEK in turn phosphorylates 
Erk 1/2 on T183 and T185 to generate an active kinase (202,203).  Once activated, the 
protein complex disassociates and releases activate Erk 1/2, which either localizes to 
the nucleus to regulate transcription, or to specific cytoplasmic compartments to 
regulate other cellular processes (detailed in Figure 4) (191,195,198,199,204). 
Since Erk 1/2 controls an array of cellular processes, its activation cycle is tightly 
regulated.  Erk 1/2 is inactivated by MAPK phosphatases (PP2A and PP2C) (205)  and 
dual specific phosphatase (DUSP) (206).  Erk 1/2  itself also regulates several of the 
factors involved in the RAS activation pathway.  SOS phosphorylation by Erk 1/2 
disrupts the SOS/Grb2 interaction (207), Erk1/2-mediated phosphorylation of EGFR 
Y669 increases EGFR phosphoryaltion and inhibits EGFR degradation, enhancing 
EGFR activity (208) RAF and MEK are also inhibited by Erk 1/2 phosphorylation 
(209,209,210).  In addition, DUSP transcription is induced by Erk 1/2 phosphorylation of 
transcription factor Ets (211).  Collectively, Erk 1/2 activation regulates several  
feedback loops that converge at multiple levels to provide fine tuning of the Erk 1/2 
signaling cascade (191,212,213). 
In addition to EGFR, Erk 1/2 activation is facilitated by integrin signaling in a non-
canonical manner.  Integrin-mediated activation of FAK induces activation of Src, which 
initiates Ras activation to increase Erk 1/2 activity (214-216).  Erk activation stimulated 
by integrin engagement imparts multiple effects that manifest in increased invasion and 
metastasis in many tumor types.  HNSCC cells plated on fibronectin enhances Erk 1/2 
activation (217).  FAK activity induced by αVβ3 integrin engagement enhances Erk and 
Akt activation, increasing the aggressiveness of chronic myologenous leukemia (CML) 
(218). The aforementioned Erk1/2-mediated serine phosphorylation of cortactin 
regulates invadopodia proteolytic activity in HNSCC and melanoma cell lines 
(115,123,139) and lamellipodia formation in breast cancer lines (123).   
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In HNSCC patient samples with EGFR and TGFα overexpression, Erk activation 
correlates with more aggressive recurrent disease and regional lymph node metastasis 
(219).  Hyperactivation of Erk 1/2 can occur by activating mutations in kinases and 
Figure 4.  Erk1/2 signaling cascade and regulation of cellular processes. 
Summary of the RAS-RAF-MEK-ERK 1/2 activation cascade.  Following EGFR 
activation, the Grb2/Shc adapter complex activates SOS RAS-GEF activity, stimulating 
RAS to activate RAF.  RAF/MEK/Erk1/2 form a complex and signaling cascade, RAF 
activating MEK, MEK activating Erk 1/2.  Erk 1/2 regulates several cellular processes 
in the nucleus via several transcription factors to modulate proliferation, differentiation, 
cell survival, and migration.  Cytoplasmic Erk 1/2 regulation of migration and invasion, 
apoptosis, and Golgi fractionation is controlled in part by cytoplasmic location. Erk 1/2 
activity is tightly regulated via several negative feedback loops mediated by Erk 1/2.   
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regulators upstream of Erk activation cascade.  These include gain of function 
mutations in RAS (typically K-RAS) that stimulate cell proliferation in 30% of all cancer 
and 90% of pancreatic adenocarcinoma patients.  Generally, mutations in the P loop 
(G12) or catalytic region (Q61) of K-RAS renders K-RAS resistant to GAP inactivation.  
Downstream from RAS, B-RAF is commonly mutated in melanoma (39%) and papillary 
thyroid (38%) carcinomas.  This results in hyperactivation of the closely related C-RAF 
as described above.  However, RAS and RAF-activating mutations are seldom seen in 
HNSCC, suggesting Erk activation is more likely due to integrin engagement, EGFR 
activation or other factors (220). 
Given the central importance of Erk activity in human cancers, several pharmacological 
agents targeting the Erk 1/2 signaling pathway have been generated to date.  
Selumetinib (AZD6244, utilized in Study 3) inhibits Erk 1/2 via inhibition of MEK by 
functioning as a non-competitive ATP-binding inhibitor.  While well tolerated in early 
phase I clinical trials, no significant benefit in progression free survival was observed in 
colorectal or NSCLC patients treated with selumetinib in phase II trials (220-223).  Other 
MEK inhibitors in clinical or preclinical trials are CI 1040 (PD184-352) and U0126, which 
demonstrate some efficacy in preclinical work, but to date but have not been extensively 
tested in the clinic (220). Sorafenib, an inhibitor designed to target all major RAF 
isoforms, has shown some efficacy in a phase II trial of hepatocellular carcinoma, but 
did not increase the overall survival of patients in a phase III trial (220,224,225).  The 
overall ineffectiveness of MEK and RAF inhibitors in the clinic suggests that alternative 
MAPK pathways are likely compensating to overcome Erk 1/2 inhibition, or Erk is being 
activated by alternate mechanisms.   
Src: The first oncogene. 
Over a century ago, Peyton Rous discovered the first oncogene that caused cancer in 
chickens (226).  Termed v-Src, the human homolog c-Src was discovered years later 
and was subsequently identified as a proto oncogene in human cancers (227).  Src is 
one member of a kinase family that incorporates a number of related non-receptor 
tyrosine kinases including the closely homologous members Yes, and Fyn in epithelia.  
Src modulates several cellular processes, including cytoskeletal organization, cell-cell 
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interactions, cell-matrix adhesion, EMT, migration and invasion (228,229).  Src has a 
modular molecular structure, consisting of an N-terminal Src homology 4 (SH4) domain 
that is myristolyated to allow membrane association (230-232).  SH3 and SH2 domains 
are adjacent to the SH4 domain and function to mediate inactivating intramolecular 
interactions, as well as for binding to Src adapter and substrate proteins.  The SH1 
domain contains the catalytic region at the C-terminus (Figure 5) (229,231,233,234). 
 Within the C-terminal tail is a critical tyrosine residue (Y527) phosphorylated by C-
terminal Src kinase (CSK).  Phosphorylated (p)Y527 binds the SH2 domain to form a 
stable interaction that maintains Src in an inactivate state (235,236).  Inactivation is also 
reinforced by SH2/SH1 and SH3/linker region interactions (237). Src activation is 
accomplished through a multi-step process initiated by the binding of substrates and/or 
scaffolding proteins to the SH2 or SH3 domain to disrupt intramolecular interactions 
between the catalytic and linker regions.  Activation is further achieved through the 
action of the tyrosine phosphatases; PTP1B, SHP 1/2, PTPα, which dephosphorylates 
Src pY527, fully releasing the C-terminal tail from the SH2 domain to allow “opening” of 
Src into the active conformation (238-241).  Full activation is achieved by subsequent 
autophosphorylation of tyrosine 419 in the kinase domain (237).  In cellular contexts, 
integrin engagement stimulates formation of FAK/Src or p130CAS (CAS)/Src 
complexes through Src SH2 domain binding, achieving similar opening of the kinase 
and subsequent Src activation (242).  Alternatively, Src activation occurs downstream of 
G-coupled protein receptors (GCPR) or the receptor tyrosine kinases PDGFR, EGFR, 
FGFR, c-Met, and HER (165,243-250).  Src phosphorylates and activates receptor 
tyrosine kinases (e.g.; EGFR) and FAK, creating positive feedback loops that enhance 
Src activity.   
Src mediates cellular invasion and migration by phosphorylating several key 
components involved in these processes.  Phosphorylation of paxillin, p130CAS, and 
FAK disrupt focal adhesions, enhancing adhesion turnover and subsequent migration 
(242,251-254).  Src also hinders contractility by activation of p190RhoGAP (a Src 
substrate), inhibiting RhoA/Rho kinase/myosin light chain II (MLC II) mediated 
contraction (255-257). Alternately, Src induces RAS-activation to stimulate Erk 1/2 
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activation and phosphorylation of myosin light chain kinase (MLCK)/MLC II, increasing 
contractility and disassembly of focal adhesions (258,259).   
Src phosphorylates several key proteins involved in invadopodia assembly, maturation, 
and disassembly.  Src phosphorylates and regulates AMAP1 (Arf6 effector protein) and 
Tks 4/5, both events that serve to modulate invadopodia actin polymerization and 
localization of proteins that initiate invadopodia assembly. AMAP1 binds and localizes 
CIN85 and Cbl to invadopodia, increasing ECM degradation.  AMAP1 also binds 
cortactin and is required for driving breast cancer cell invasion (260-263).  Following Src 
phosphorylation, Tks 4/5 activates NADPH oxidase to stimulate reactive oxygen species 
(ROS) production, creating a possible positive feedback ROS-induced activation of Src.  
Tsk 5 also recruits several key invadopodial proteins including cortactin and Nck 
responsible for regulating invadopodia function (34,39,40,264-268).  In addition, Src 
mediates invadopodia maturation via regulation of MMP production and secretion by 
modulating PI3K, MAPK, and JAK/STAT activation (269-271).  Src modulates vesicle 
trafficking through phosphorylation of endophilin A2, Cdc42-interacting protein (CIP4), 
and dynamin2.  Src phosphorylation of CIP4 (Y471) inhibits CIP4 mediated endocytosis 
of MT1-MMP, which results in elevated surface expression of MT1-MMP, increasing 
invadopodia proteolytic activity (272).  Src phosphorylation of Endophilin A2 tyrosine 
315 functions in a similar manner, increasing invadopodia activity by inhibiting 
endophilin-induced MT-MMP endocytosis (273). In addition, dynamin requires Src 
phosphorylation at tyrosine sites 231/597 to mediate clathrin-coated endocytosis of 
MT1-MMP (274-277).   
Cortactin tyrosine phosphorylation is crucial for invadopodia maturation, where Src 
regulates cortactin phosphorylation directly or indirectly via Abl/Arg family kinases 
(37,41,110,111,115-119).  How Src controls invadopodia disassembly is not as clear, 
but Src phosphorylation of paxillin Y31 and Y118 promotes invadopodia disassembly, 
providing at least one mechanism (278,279).  Calpain 2 and PTP1B function together to 
regulate invadopodia function, where calpain induces invadopodia turnover potentially 
via Pyk2, WASP, and talin cleavage (Figure 5) (280,281).  
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Src overexpression frequently occurs in HNSCC, where its activation correlates with 
poor prognosis (282).  Src activation can be enhanced via several mechanisms that 
occur in HNSCC and other cancer types, including downregulation of CSK expression, 
PTP1B overexpression, activation of receptor tyrosine kinases, or activation of integrins 
Figure 5.  Schematic diagram of Src, activation and downstream signaling 
pathways. 
 Overview of Src-based signaling in invasion and proliferation.  Src becomes activated 
as described in the main text, where it stimulates several signaling cascades including 
RAS/RAF/MEK/MAPK, JAK/STAT, and PI3K/Akt cascades regulating transcription, 
proliferation, cell survival and angiogensis.  Src also phosphorylates several key 
components involved in contractile and mesenchymal-based migration and invasion. 
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through ECM alteration (283).   Importantly, ionizing radiation, which is frequently 
utilized as first line therapy in HNSCC and other cancers, stimulates Src activity due to 
the generation of reactive oxygen species (ROS) increasing the potential for triggering 
invasion and metastasis in radiation-resistant and recurrent tumors (284). 
The inhibition of Src activity has become an important pursuit for molecular therapeutics 
since Src is a key regulator of many of processes utilized in tumorigenesis.  Dasatinib, 
saracatinib, and bosutinib are three Src inhibitors undergoing phase I and II trials as 
single agents or combination therapy with conventional chemotherapeutics.  These 
inhibitors all function in a similar manner by blocking ATP binding to the SH1 catalytic 
domain and have off-target effects, one of which includes serendipitous inhibition of Abl 
family kinases (283,285).  Dasatinib (BM354825) treated HNSCC cell lines display 
reduced activation of Akt and Erk 1/2, resulting in impaired Bcl-2 expression, growth 
inhibition and increased apoptosis (286,287). In recent studies, dasatinib treatment 
inhibited invasion and metastasis of pancreatic cancer cell lines (288,289).  Preclinical 
trials with dasatinib-treated breast cancer cell lines showed reduced proliferation, 
migration and invasion (290-292).  However, recent phase II trails with breast cancer 
demonstrated minimal added benefit with dasatinib treatment (293-295).  Our laboratory 
(Study 2) and others have demonstrated that saracatinib (AZD0530) treatment inhibits 
Src and FAK activity in HNSCC cell lines, causing reduction in proliferation and 
migration in vitro and in vivo (296,297).  In several studies, saracatinib treatment 
inhibited pancreatic tumor xenograph growth and downstream phosphorylation of the 
Src substrates FAK, paxillin, and STATs (298,299).  Use of saracatinib in a phase II trial 
also demonstrated minimal efficacy in patients with advanced melanoma (300). 
Abl: A kinase with dichotomous roles. 
Abl (Abl1, c-Abl) and Arg (Abl2) are non-receptor tyrosine kinases with 90% homology 
in the N-terminal region but with extremely variable C-termini (< 28% homology) (301).  
The N-terminal domain, similar to Src, contains a capped region that may be post-
translationally modified by myristoylation, generating two isoforms (Abl1a and Abl1b) 
(302,303).  Adjacent to the capped region are highly conserved SH3 and SH2 domains 
(304).  Attached by a linker region to the SH2 domain, a tyrosine kinase domain targets 
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substrates with (L/I/V)-Y-x-x-P consensus sequence (305).  Abl family kinases have 
over one hundred identified and potential substrates (306).  Unlike other Src family 
kinases, Abl family kinases have a C-terminal region that consists of several proline-rich 
regions (Abl has four, Arg three) interspersed with three nuclear localization sequences 
(Abl only) (307,308).  Abl and Arg diverge structurally in the C-terminal region, where 
Abl consists of a DNA binding region, a G-actin binding domain, and a F-actin binding 
region with an embedded nuclear export sequence (309-312).  The Arg C-terminus 
includes two F-actin binding domains, a G-actin binding domain and a microtubule 
binding domain (Figure 6) (313,314).  These differences confer some of the divergent 
functions for Abl and Arg in the cell.  Arg is solely a cytoplasmic protein that functions to 
regulate actin-based lamellipodia and invadopodia, but additionally bundles actin 
filaments and connects actin networks with microtubules.  Abl shuttles between the 
cytoplasm, where it also regulates dynamic actin structures, and nucleus where it is key 
in governing transcription, cell cycle progression and DNA damage response (315,316). 
Abl family kinases, like Src, are tightly controlled by intramolecular interactions. Abl is 
held in an inactive conformation by binding of the myristolated tail within a hydrophobic 
pocket in the kinase domain (302,303,317). Interactions between the SH3 and SH2 
domains with the kinase domain also help hold Abl in an inactive state (304,317).  Abl 
becomes weakly activated by disruption of intramolecular interactions following binding 
of substrates/ adapter proteins to the SH3 and SH2 domains (302).  To achieve full 
kinase activity, Src phosphorylation of Abl or Abl trans-phosphorylation of Y245 in the 
linker region and Y412 in the kinase domain activation loop is mandatory (165,315,318-
320).  Additional Abl sites are phosphorylated that regulate protein stability (Y89 and 
Y261), kinase inhibition (Y272), activation (Y276), generation of potential SH2-binding 
sites (Y158, Y331, Y134, Y147, Y251, Y276), or are acetylated to control nuclear export 
(K730) (306). 
Abl family kinases are activated by several extracellular signals, EGFR, PDGFR, 
insulin-like growth factor 1 receptor (IGFR), integrin signaling, bacterial invasion, 
genotoxic and oxidative stress (165,308,321-323). Upon activation via RTK or integrins, 
activated Abl family kinases localize to the cell periphery, where they regulate actin-
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based processes including lamellipodia protrusion and invadopodia maturation 
(36,37,110,111,308,315,324,325).  Abl enhances actin polymerization via 
phosphorylation of the NPFs WAVE2, N-WASp and cortactin.  Abl also phosphorylates 
the adaptor protein Nck1 and the actin filament capping protein Ena, enhancing Ena-
mediated actin filament elongation (37,111,307,315,326,327).    
Abl kinases directly and indirectly modulate cell migration and invasion.  Arg 
phosphorylates p190RhoGAP, preventing binding to p120RasGAP and subsequent 
relocation of p190RhoGAP/p120RasGAP complex to cell periphery, thus preventing 
Rho GTPase activation reducing myosin-induced contractility (328,328,329).  PDGFR 
mediated Rac activation is modulated by Abl; although the mechanism has yet to be 
defined it is likely via Abl phosphorylation of SOS1 an RASGEF (330,331).  Abl-
mediated phosphorylation of CrkII (Y221) and paxillin disrupts the Crk/CAS/Paxillin/FAK 
complex, resulting in disassembly of focal adhesions (308,332-337).  Abl indirectly 
activates STAT3 to induce MMP1 transcription; Arg activates MT-MMP, MMP1, and 
MMP3 transcription in an undefined STAT3-independent manner.  Additionally, Abl/Arg 
potentially mediate MT1-MMP endocytosis by directly binding and phosphorylating 
MT1-MMP (324,325).  Collectively these cellular processes confer pro-invasive and 
anti-invasive phenotypes dependent on the substrate and cellular localization of Abl or 
Arg. 
Nuclear localization of Abl occurs in response to genotoxic or oxidative stress 
(321,322,338,339).  Ataxia telangiectasia mutated protein (ATM) activates Abl in 
response to DNA damage (340,341).  Activated Abl phosphorylates murine double 
minute 2 (MDM2) at tyrosine 394 an E3 ubiquitin ligase that targets p53 for degradation 
causing the disruption of the MDM2/p53 interaction protecting p53 from degradation 
(342-345).  Abl stabilizes ATM/p53 complex facilitating ATM serine phosphorylation of 
p53 and subsequent accumulation of p53 in the nucleus regulating cell cycle arrest 
and/or apoptosis by transcription of p21 and CDK2 or BAX, BCL2, PUMA, and NOXA 
(346,347).  Abl initiates DNA repair mechanisms or induces apopotosis by 
phosphorylating and activating several key proteins including ATM, several RAD 
proteins, damaged DNA-binding (DDB 1/2), and DNA-activated protein kinase (DNAPK) 
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(348-351).  Abl also regulates cell cycle progression, where phosphorylation of RNA 
polymerase II induces transcription of S phase genes and cell cycle progression from S 
to G2-M (342,352).  Collectively, Abl is considered a pro-apoptotic regulator following 
nuclear localization and activation (Figure 6) (316,353). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6.  Schematic diagram of Abl structure, activation and downstream 
signaling pathways. 
Abl a non-receptor tyrosine kinase becomes activated via external stimuli; 
phosphorylation and binding of SH3/SH2 binding partners containing proline-rich 
regions or phosphorylated tyrosines.  Activated Abl, in the cytoplasm, mediates 
processes utilized for motility and invasion (detailed in text).  In the nucleus, Abl 
regulates transcription directly or indirectly via transcription factors controling cell cycle 
arrest, DNA repair, and apoptosis. 
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 Abl activation is attenuated by several mechanisms including de-phosphorylation by 
tyrosine phosphatases including PTPN1 or PTP-PEST (354). Phosphatidylinositol-4,5-
bisphosphate (PIP2) binds Abl preventing substrate binding; the PIP2 inhibitory 
interaction is relieved by phospholipase C (PLC) hydrolysis of PIP2 (164,355). Caspase-
cleavage of Abl at Argine 565 or ubiquitinatation and proteosomal degradation 
downregulate Abl signaling (338,356-358). 
Abl has long been considered an oncogene in the context of the Philadelphia 
chromosome BCR-Abl gene product.  BCR-Abl an oncogenic fusion of the Abl kinase 
domain with the breakpoint cluster region (BCR), giving rise to a constitutively active Abl 
kinase by the removal of first exon and subsequent loss of inhibitory intramolecular 
interactions within Abl. BCR-Abl is associated with the onset and progression of chronic 
myelogenous leukemia (CML) (359,360).  The role of Abl in solid tumors is not as well 
defined, as recent work described below indicates that Abl family kinases function in a 
context dependent manner, possessing pro- or anti-oncogenic functions in cancer. 
 Research with a panel of breast cancer cell lines suggested that kinase activation and 
not expression of Abl family kinases correlates with breast cancer invasiveness 
(361,362).  Mader et.al. and others have shown the loss of invadopodia proteolytic 
activity with imatinib-treated breast cancer and melanoma cell lines, leads to the 
proposal of  an EGFR/Src/Arg/cortactin signaling pathway responsible for mediating 
invadopodia regulation (36,324).  The imatinib-mediated inhibition of ECM degradation 
in breast cancer lines can be attributed in part to regulation of MMP 1, 3, and MT1-MMP 
transcription and secretion regulated by Abl and Arg (324,325).  In NSCLC, inhibition of 
Abl with FUS1 or pharmacological agents reduced anchorage-independent growth, 
while Abl phosphorylation of Crk correlates with tumor cell aggressiveness (363).  
Collectively these studies suggest a pro-oncogenic role for Abl family kinases. 
Alternately, reduction of Abl expression in HNSCC is associated with a poor patient 
survival (364).  Inhibition of Abl expression or activity reduces invadopodia proteolytic 
function and invasion (115).  Similar results were observed in work on breast cancer 
lines by other groups, where Abl mediates EphrinB1/EphR4 inhibition of cell migration 
and suppresses TGFβ-induced epithelial-to-mesenchymal transition (EMT) (365).  
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Additionally, Frasca et al. demonstrated that HGF-simulated thyroid cancer cell lines 
treated with imatinib had elevated Erk and Akt activity, increased motility and an EMT-
like phenotype following long-term drug exposure (366).  These results indicate an anti-
oncogenic role for Abl. 
Imatinib mesylate (Gleevac, STI571) is a competitive ATP inhibitor and first line therapy 
for CML patients.  This compound is extremely effective, demonstrating a 90% overall 
response rate in patients following initial treatment (367).  Second line therapies that 
target Abl kinase in BCR-Abl containing malignancies include nilotinib, dasatinib, 
bafetinib (INNO-406) and decipere (DCC-2036).  These compounds have been 
developed to treat imatinib-refractory patients and are currently in pre-clinical, phase I 
and II trials (368).  Nilotinib and dastinib have a 50% complete response rate in phase II 
trials with imatinib-resistant CML patients (368).  The efficacy of Abl inhibitors in CML 
and gastrointestinal stromal tumor (GIST) patients supports a pro-oncogenic role, 
advocating the use of imatinib for patients with solid tumors (369).  Even though pre-
clinical studies have demonstrated efficacy with imatinib in NSCLC and breast cancer 
cell lines, clinical phase I and II trials have shown no therapeutic benefits.  In fact, 
disease progression was observed in a phase II prostate cancer trial.  Furthermore, a 
combined HNSCC/NSCLC phase II trial was terminated early due to detrimental effects 
in patients treated in the imabinib-containing arm (370-374,374-376).  The pro- and anti-
oncogenic impact of Abl inhibition in solid tumors necessitates further investigation to 
determine the underlying molecular determinates responsible for the opposing 
oncogenic roles of Abl kinases in human cancers.  
As detailed in this review, EGFR, Erk 1/2, Src, and Abl have complex signaling 
cascades dependent upon extracellular cues, upstream activators, cellular location, and 
downstream effectors.  In pre-clinical studies, EGFR, Erk 1/2, Src, and Abl have been 
shown to be crucial for tumorigenesis in several cancer types, including breast and 
HNSCC. Unfortunately, the various pharmacological agents targeting these kinases 
(EGFR, Src, Abl) or up-stream activators (RAS, RAF for Erk1/2) typically demonstrate 
negligible therapeutic benefit; in fact detrimental effects have been reported in 
pancreatic, NSCLC and HNSCC cancer patients.  Clarification and increased 
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understanding of the spatial and temporal molecular signaling of these key proteins is 
essential for improved therapy utilizing these pharmacological agents.  The specific goal 
of this dissertation is to clarify the regulation of key signaling molecules that modulate 
HNSCC invasion and metastasis. 
In Study 1, we elucidated the regulatory hierarchy of several proteins critical for invasion 
of HNSCC and breast cancer cell lines.  In particular, we focused on Abl, a protein that 
has opposing roles in tumorigenesis.  Our results demonstrate a divergent role for Abl 
function in invasion, where Abl kinase activity is pro-invasive in breast cancer and anti-
invasive in HNSCC.  Regardless of tumor type, the EGFR/Src pathway is crucial to 
mediate invasive regardless of divergent cellular response evoked with imatinib-treated 
HNSCC and breast cancer cell lines. 
In Study 2, we further established the crucial role Src in HNSCC metastasis in vitro and 
in vivo.  In addition, we examined effects of pharmacological inhibition of Src/Abl activity 
with saracatinib on downstream Src effectors and cellular processes important for 
tumorigenesis.  We determined that Src/Abl inhibition reduced HNSCC proliferation and 
invasion in accordance with impaired invadopodia formation and MMP secretion. 
Finally, in Study 3 we determined a functional role for Erk 1/2 activation and 
phosphorylation of the downstream substrate cortactin in HNSCC patient samples and 
cell lines, where we showed that Erk 1/2-mediated cortactin phosphorylation modulates 
HNSCC adhesion and promotes migration by prolonging lamellipodia persistence.  
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Abstract 
Head and neck squamous cell carcinoma (HNSCC) has a proclivity for locoregional 
invasion.  HNSCC mediates invasion in part through invadopodia-based proteolysis of 
the extracellular matrix (ECM).  Activation of Src, Erk1/2, Abl and Arg downstream of 
epidermal growth factor receptor (EGFR) modulates invadopodia activity through 
phosphorylation of the actin regulatory protein cortactin.  In MDA-MB-231 breast cancer 
cells, Abl and Arg function downstream of Src to phosphorylate cortactin, promoting 
invadopodia ECM degradation activity and thus assigning a pro-invasive role for 
Ableson kinases.  We report that Abl kinases have an opposite, negative regulatory role 
in HNSCC where they suppress invadopodia and tumor invasion.  Impairment of Abl 
expression or Abl kinase activity with imatinib mesylate enhanced HNSCC matrix 
degradation and 3D collagen invasion, functions that were impaired in MDA-MB-231.  
HNSCC lines with elevated EGFR and Src activation did not contain increased Abl or 
Arg kinase activity, suggesting Src could bypass Abl/Arg to phosphorylate cortactin and 
promote invadopodia ECM degradation.  Src transformed Abl-/-/Arg-/- fibroblasts 
produced ECM degrading invadopodia containing pY421 cortactin, indicating that 
Abl/Arg are dispensable for invadopodia function in this system.  Imatinib treated 
HNSCC cells had increased EGFR, Erk1/2 and Src activation, enhancing cortactin 
pY421 and pS405/418 required for invadopodia function.  Imatinib stimulated shedding 
of the EGFR ligand heparin-binding EGF-like growth factor (HB-EGF) from HNSCC 
cells, where soluble HB-EGF enhanced invadopodia ECM degradation in HNSCC but 
not in MDA-MB-231.  HNSCC cells treated with inhibitors of the EGFR invadopodia 
pathway indicated that EGFR and Src are required for invadopodia function.  
Collectively our results indicate that Abl kinases negatively regulate HNSCC invasive 
processes through suppression of an HB-EGF autocrine loop responsible for activating 
a EGFR-Src-cortactin cascade, in contrast to the invasion promoting functions of Abl 
kinases in breast and other cancer types.  Our results provide mechanistic support for 
recent failed HNSCC clinical trials utilizing imatinib.  
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Introduction 
HNSCC is an aggressive disease characterized by extensive locoregional invasion and 
cervical lymph node metastasis (1,2).  Overexpression of EGFR is common in HNSCC 
and correlates with enhanced invasion and nodal involvement (3-6).  EGFR inhibition as 
adjuvant therapy in HNSCC increases survival, highlighting the importance of 
downstream EGFR signaling pathways in HNSCC progression (7).  Downstream EGFR 
signaling cascades in HNSCC that promote invasion and metastasis utilize Src, Erk, PI3 
kinase, Akt and STATs (8-11), supporting a role for EGFR-generated signals as 
important regulators of invasion promoting pathways in HNSCC. 
Src kinase activation within the EGFR pathway is critical for driving tumor invasion 
(12,13).  Elevated Src expression and activity is frequently found in HNSCC and other 
tumor types, where it has become a focus for targeted therapeutic design (14,15).  
While Src targeted drugs have been developed and demonstrate anti-invasive 
properties in preclinical studies (16-19), recent phase II trials demonstrate virtually no 
benefit for HNSCC patients with monotherapeutic Src inhibitor treatment (19,20).  While 
combination therapy with receptor tyrosine kinase inhibitors increases efficacy (21-23), 
a clearer mechanistic understanding of how Src-based signaling governs HNSCC 
invasion is needed for the development of improved therapeutic strategies.  
In carcinomas, Src activation results in the formation of invadopodia, actin-rich 
membraneous protrusions responsible for extracellular matrix (ECM) proteolysis, 
allowing tumor cells to infiltrate the stroma and vasculature (24,25).  Src kinase activity 
regulates the cyclic development of non-degradative (pre-invadopodia) and active 
(mature) invadopodia (24,25).  Maturation of pre-invadopodia involves recruitment and 
activation of matrix metalloproteinase MMP-14 to initiate ECM degradation (26-28).  
Invadopodia maturation also involves increased F-actin polymerization responsible for 
driving plasma membrane protrusion (24,25,29).  A prominent component of the 
invadopodia F-actin core is cortactin, an F-actin binding protein that activates the actin- 
related protein (Arp)2/3 complex to stimulate branched actin polymerization (30-33).  
Cortactin binds neuronal Wiskott-Aldrich Syndrome protein (N-WASp), a second 
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activator of Arp2/3 complex following phosphorylation of cortactin S405 and S418 by 
Erk1/2 (33-35).  Cortactin modulates shifting of pre- to mature invadopodia through 
phosphorylation of two Src-targeted tyrosine residues (Y421 and Y470 in humans) 
(27,28,36).  Y421 and Y470 phosphorylation results in SH2-dependent recruitment of 
the adaptor protein NCK1, which in turn binds and activates N-WASp to promote 
additional Arp2/3 activation (28,37-39).  Along with tyrosine phosphorylation, cortactin 
domains that bind Arp2/3 and N-WASp are also required for invadopodia formation, 
collectively highlighting the importance of cortactin in invadopodia biogenesis and 
regulation (28,40,41).  
The Abelson kinases Abl and Arg regulate actin cytoskeletal remodeling during motility 
and invasion (42-44).  While Abl regulation of leukemic tumorigenesis is well 
established (45,46), Abl activity in solid tumors promotes multiple aspects of neoplastic 
progression, including increased invasion and metastasis (47-50).  Activation of Abl and 
Arg downstream of EGFR and Src leads to direct cortactin phosphorylation at Y421 and 
Y470 responsible for invadopodia maturation in breast cancer and melanoma cell lines 
(51-55).  In particular, Src-mediated activation of Arg and subsequent cortactin tyrosine 
phosphorylation has led to the proposal that Arg is the terminal kinase responsible for 
cortactin tyrosine phosphorylation required for invadopodia maturation (51,56). 
Since invasive HNSCC typically contains elevated EGFR and Src activity, we postulated 
that downstream activation of Abl kinases may regulate invadopodia through cortactin 
phosphorylation in this tumor type.  Paradoxically, we show that elimination of Abl 
expression results in enhanced invadopodia-based gelantinase activity in multiple 
HNSCC cells lines but not in MDA-MB-231 cells.  Inhibition of Abl family kinase activity 
with imatinib mesylate (STI571; Gleevac) in HNSCC cells resulted in enhanced 
invadopodia maturation and cell invasion, whereas these processes were impaired in 
MDA-MB-231.  Analysis of EGFR signaling indicates that EGFR and Src are 
hyperactivated in HNSCC compared to MDA-MB-231 cells.  Introduction of active Src 
into Abl-/-/Arg-/- cells induced invadopodia formation, ECM matrix degradation and 
cortactin tyrosine phosphorylation, suggesting that elevated Src activity can bypass the 
requirement for Abl or Arg in invadopodia maturation.  Imatinib treatment of HNSCC 
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cells resulted in dose-dependent activation of EGFR, Src and Erk1/2, resulting in 
elevated cortactin tyrosine and serine phosphorylation absent in treated MDA-MB-231 
cells.  Imatinib enhanced production and shedding of the EGFR ligand HB-EGF in 
HNSCC cells, where soluble HB-EGF stimulated HNSCC ECM degradation.  Inhibition 
of Src and Abl kinases with the dual specificity drug saracatinib suppressed EGFR 
activation and ECM degradation in HNSCC, suggesting that Src is responsible for 
mediating the pro-invasive signals resultant from imatinib-mediated Abl family kinase 
inactivation.  Our results indicate that in HNSCC Abl kinases serve to suppress 
invadopodia formation and tumor cell invasion by downregulating autocrine HB-EGF 
activation of the EGFR-Src-cortactin signaling pathway, in contrast to the pro-invasive 
function of Abl and Arg in breast and other solid tumors.  These results suggest that Abl 
kinase function in cancer invasion is context dependent, providing molecular insight into 
the mechanism behind the recent failure of clinical trials with imatinib in HNSCC 
patients (57). 
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Results 
Abl expression suppresses invadopodia activity in HNSCC cells  
Since HNSCC cells form invadopodia (36,58) and Abl kinases mediate invadopodia 
function in other tumor types (51,53,55), we evaluated the role of Abl in HNSCC 
invadopodia formation and function. HA-tagged Abl localized within UMSCC1 
invadopodia (Figure 1a) and in Src-expressing 1483 cells (Supplementary Figure 1a), 
implying a functional role.  This was investigated by knockdown of Abl expression using 
RNA interference (RNAi).  Stable UMSCC1 clones expressing an Abl-specific short 
hairpin RNA (shRNA2 and 3) reduced Abl expression by 65% compared to controls 
(Ctl2 and 8) (Figure 1b).  Expression of wild-type (WT) murine Abl in shRNA cells 
restored expression to endogenous levels (WT5 and 6).  Abl knockdown resulted in a 
44% increase in gelatin degradation compared to control (Ctl) and WT lines (Figure 1c-
d) without affecting the number of cells degrading ECM or the number of invadopodia 
per cell (Supplementary Figure 1b-c).  Abl knockdown in MDA-MB-231 cells did not 
impact matrix proteolysis (Supplementary Figure 2a-c), in agreement with previous 
results (51).  These data suggest that Abl expression negatively regulates invadopodia 
function in HNSCC cells, as opposed its invadopodia promoting role in other tumor cell 
types (51,53,55). 
Imatinib treatment enhances HNSCC invadopodia activity 
 To determine if Abl kinase activity was responsible for the negative regulatory effects 
on invadopodia function in HNSCC cells, OSC19 and UMSCC1 cells were treated with 
the Abl family kinase inhibitor imatinib mesylate.  Analysis of Crk phosphorylation 
confirmed partial inhibition of Abl kinase activity in imatinib-treated lines (Figure 2a).  
Imatinib treatment resulted in a dose-dependent increase in OSC19 and UMSCC1 ECM 
degradation, demonstrating a net 2.5-3.0-fold enhancement observed at the highest 
tolerated concentration (15 µM) (Figure 2b-c, 2e).  In contrast, MDA-MB-231 cells 
treated with imatinib resulted in a 70% reduction in matrix proteolysis (Figure 2d-e).  
The effects on treated HNSCC and MDA-MB-231 cells is likely Abl family kinase 
specific, since the alternative imatinib target PDGFR is not expressed in these lines 
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(Supplementary Figure 3).  These data indicate that imatinib impairment of Abl family 
kinase activity in HNSCC relieves the inhibitory effect of Abl on invadopodia function, 
promoting ECM degradation. 
Imatinib treatment stimulates HNSCC invasion  
To determine if imatinib-enhanced HNSCC invadopodia activity corresponds with 
increased invasive behavior, 3D invasion assays were conducted using tumor spheroids 
embedded in collagen I.  OSC19 and UMSCC1 cells treated with 10 µM imatinib 
resulted in enhanced invasion, whereas invasion of imatinib-treated MDA-MB-231 cells 
was inhibited after 24 h (Figure 3a-c).  Average invaded distances were increased by 
100 µM for OSC19 and 204 µM for UMSCC1 cells, while MDA-MB-231 invasion was 
suppressed by 47 µM (Figure 3d).  These results indicate that imatinib treatment has 
opposing effects on tumor cell invasion, enhancing HNSCC cell invasion while impairing 
the invasiveness of MDA-MB-231.   
Activated Src can bypass Abl and Arg to promote invadopodia formation 
To address the contrasting invasive roles of Abl family kinases in HNSCC and MDA-
MB-231 cells, protein levels and activation of known invadopodia kinases were 
evaluated.  Western blotting demonstrated increased Abl expression in HNSCC lines 
compared to MDA-MB-231 cells, whereas Arg protein levels were equivalent (Figure 
4a).  In spite of increased Abl expression in HNSCC cells, Abl activation was not 
enhanced, as evidenced by similar Crk pY221 levels between HNSCC and MDA-MB-
231 cells.  However, OSC19 and UMSCC1 consistently displayed increased EGFR and 
Src activity compared to MDA-MB-231 (Figure 4a).   
The increased Src activation in HNSCC cells suggested that active Src might directly 
regulate invadopodia activity independent of Abl and Arg.  To test this, Abl-/-/Arg-/- 
mouse embryo fibroblasts (DKO) were used to simultaneously evaluate the role of Abl 
and Arg on invadopodia function.  Lack of Abl and Arg expression in DKO cells was 
verified by immunoblotting (Supplementary Figure 4a).  EGF stimulation of wild-type 
(WT) MEFs demonstrated a threefold increase in cortactin pY421 over non-stimulated 
controls, whereas stimulated DKO cells showed a 1.5 fold increase over basal levels 
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(Figure 4b).  While these results confirm that Abl and Arg contribute to cortactin tyrosine 
phosphorylation, they also indicate that additional cortactin tyrosine kinases are utilized 
downstream of EGFR.  To determine if activated Src promotes invadopodia formation 
independent of Abl and Arg, WT and DKO cells transfected with activated Src (527F) 
were assayed for cortactin tyrosine phosphorylation, invadopodia formation and ECM 
proteolysis.  DKO cells expressing 527F Src contained abundant invadopodia with 
pY421 cortactin that degraded ECM, similar to 527F Src-transformed WT cells (Figure 
4c).  The ability of DKO cells to degrade gelatin matrix was dependent on Src kinase 
activity, since kinase inactive Src (K295M) failed to promote matrix proteolysis (Figure 
4d).  Expression of 527F Src in DKO cells resulted in an 86% increase in matrix 
degradation area compared to 527F Src-expressing WT cells (Figure 4d-e, 
Supplementary Figure 4b).  The amount of gelatin degradation per cell area in DKO 
527F Src cells was inhibited by 60% following re-expression of WT Abl (Figure 4d-e), in 
agreement with increased matrix degradation by UMSCC1 cells with Abl knockdown 
(Figure 1c-d).  Collectively these results indicate that Abl expression suppresses 
invadopodia activity in Src-transformed mouse embryo fibroblasts, and that Abl and Arg 
are not essential for cortactin tyrosine phosphorylation or invadopodia formation 
downstream of active Src. 
Imatinib treatment enhances activation of the EGFR-invadopodia signaling 
pathway in HNSCC 
To determine the basis for the differential regulation of invadopodia activity and invasion 
when Abl/Arg activity is suppressed in HNSCC and MDA-MB-231, cells treated with 
imatinib were evaluated for activation of EGFR and downstream invadopodia signaling 
components.  Increased EGFR activation was observed in imatinib-treated OSC19 and 
UMSCC1 cells, whereas no increase was observed in MDA-MB-231 (Figure 5a, 
Supplementary Figure 5a).  A corresponding activation pattern was found for Src and 
Erk.  Imatinib ablated Crk pY221 phosphorylation in MDA-MB-231, indicating that 
Abl/Arg-based signaling was inhibited.  Crk pY221 phosphorylation was partially 
impaired in imatinib-treated HNSCC lines (Figure 5a) and was further downregulated 
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when combined with the Src inhibitor SU6656 (59) (Supplementary Figure 5b), 
suggesting that Crk is targeted by Src and Abl kinases in HNSCC.  
Since Src and Erk regulate invadopodia in part by phosphorylating cortactin (28,36,40), 
cortactin tyrosine and serine phosphorylation was evaluated in imatinib-treated HNSCC 
and MDA-MB-231 cells.  The Erk-targeted cortactin residues S405 and S418 
demonstrated elevated phosphorylation in imatinib-treated OSC19 and UMSCC1 cells, 
corresponding with increased Erk 1/2 activation, while treated MDA-MB-231 cells did 
not demonstrate a substantial increase in cortactin phosphorylation (Figure 5b).  
Imatinib stimulated cortactin Y421 phosphorylation in HNSCC cells (Figure 5c), likely 
due to increased Src activation (Figure 5a).  These data support activation of the EGFR-
Src/Erk-cortactin pathway by imatinib in HNSCC cells that can bypass Abl/Arg inhibition 
to promote invadopodia activity and HNSCC invasion. 
Imatinib stimulates HB-EGF synthesis and promotes HNSCC invadopodia activity 
Imatinib treatment of multiple HNSCC lines results in synthesis and secretion of the 
EGFR ligand HB-EGF, enhancing EGFR activity (60).  Lysates from imatinib treated 
OSC19 and UMSCC1 cells contained increased HB-EGF compared to controls, 
whereas HB-EGF levels in MDA-MB-231 cells were unaltered (Figure 6a).  Conditioned 
media from imatinib-treated HNSCC cells contained increased soluble HB-EGF at levels 
2.5-3.0 fold higher than from MDA-MB-231 cells (Figure 6b).  Addition of recombinant 
HB-EGF to cells at concentrations equivalent to HB-EGF levels in imatinib-treated 
conditioned media enhanced ECM degradation activity by 86% in OSC19 and 30% in 
UMSCC1 cells, but did not increase invadopodia activity in MDA-MB-231 cells (Figure 
6c-d).  These results suggest that increased imatinib-induced HB-EGF expression and 
shedding by HNSCC cells produces an autocrine loop that stimulates EGFR activation 
responsible for enhancing invadopodia-mediated ECM proteolysis. 
Invadopodia ECM degradation promoted by impaired Abl kinase activity requires 
activation of EGFR and Src  
To further confirm that Src regulates HNSCC invadopodia downstream of EGFR apart 
from Abl kinases, pharmacological agents targeting EGFR, Src, or simultaneous Abl/Src 
66 
 
inhibition were evaluated for their impact on gelatin degradation in HNSCC.  UMSCC1 
cells treated with the EGFR inhibitor gefitinib at 5 µM reduced EGFR activation by 60% 
(Supplementary Figure 6a) and matrix degradation by 50% (Figure 7a).  Similar results 
were obtained with SU6656, where 15 µM treatment resulted in a 65% decrease of the 
Src-targeted Y410 in p130CAS (Supplementary Figure 6b) and a 50% reduction in 
matrix degradation (Figure 7b).  Treatment of UMSCC1 cells with the dual Abl 
kinase/Src inhibitor saracatinib, (61, 62) at 1 µM inhibited EGFR activity by 55%, Src 
activity by 93%, and Abl/Arg activity by 97% (Supplementary Figure 6c).  ECM 
proteolysis was impaired by 80% (Figure 7c).  Furthermore, the enhanced ECM 
degradation activity in UMSCC1 cells with Abl knockdown (Figure 1b-d) was abrogated 
with 10 µM SU6656 (Figure 7d; Supplementary Figure 6d).  These data indicate that the 
enhanced matrix degradation activity promoted by targeted Abl kinase inhibition in 
HNSCC requires intact EGFR-Src signaling.  Similar results were obtained with 
saracatinib in OSC19 and MDA-MB-231 cells (Supplementary Figure 7a-c). 
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Discussion 
The effects of Abl-based signaling in solid tumors are currently controversial.  Several 
studies have determined that Abl family kinase activity directly contributes to enhancing 
tumor proliferation, invasion and metastasis in breast and melanoma cell lines 
(47,48,51,53,55).  Abl family kinases also positively modulate tumorgenesis in gastric 
tumors (50) and non-small cell lung carcinoma (49).  On the other hand, recent reports 
indicate that suppression of Abl kinase activity by imatinib increases breast tumor 
growth (86), invasion (63) and inhibits epithelial-to-mesenchymal transition (64).  
Imatinib also enhances thyroid cancer cell invasion (65).  While these tumor stimulating 
findings have been attributed to use of mutationally modified Abl constructs or non-
physiological levels of imatinib (53), our results comparing HNSCC lines with MDA-MB-
231 cells indicate that Abl kinase inhibition by RNAi or clinically relevant imatinib 
concentrations yields opposite outcomes on tumor cell invasive events, suggesting that 
Abl kinases function to suppress HNSCC invasion by reducing invadopodia matrix 
degradation activity driven through the EGFR-Src-cortactin pathway.  
Src activation is central to invadopodia formation and maturation, where 
phosphorylation of numerous downstream cytoskeletal proteins is required for 
invadopodia biogenesis and ECM proteolytic activity (24,25).  Cortactin phosphorylation 
downstream of Src is involved in all stages of invadopodia formation (28,36,37,41).  Src, 
Abl and Arg directly phosphorylate cortactin (52,66,67), indicating that these kinases 
can promote cortactin-based Arp2/3 nucleation activity indirectly via NCK1 and N-
WASp.  Src can also phosphorylate and activate Abl and Arg downstream of EGFR and 
other growth factor receptors (54,68) and recent work has shown that removal of Abl or 
Arg by RNAi prevents invadopodia formation in Src transformed fibroblasts, MDA-MB-
231 breast cancer and melanoma cell lines (51,53,55).  While these studies indicate 
that Abl and Arg are the key cortactin kinases responsible for cortactin tyrosine 
phosphorylation in invadopodia (Figure 8a), we show that EGF stimulation of Abl/Arg-
null (DKO) fibroblasts enhances cortactin tyrosine phosphorylation, indicating that Src 
and/or other EGFR-activated cortactin targeting kinases phosphorylate cortactin apart 
from Abl or Arg.  Src-transformed Abl/Arg-null fibroblasts retain the ability to degrade 
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ECM and contain tyrosine phosphorylated cortactin within invadopodia, demonstrating 
that Abl family kinases are not essential in this system for invadopodia function driven 
by cortactin tyrosine phosphorylation.  Abl re-expression in DKO cells impaired Src-
generated ECM degradation, confirming an inhibitory role for Abl in invadopodia 
maturation similar to that observed in HNSCC cells.  These results indicate that 
elevated levels of Src activity commonly present in HNSCC lines (36) or due to ectopic 
expression of active Src forms can circumvent the requirement for Abl or Arg in 
regulating invadopodia activity through cortactin phosphorylation (Figure 8b).   
Imatinib-stimulated HNSCC invadopodia activity and invasion is likely due to increased 
activation of EGFR and associated downstream signaling, since imatinib treatment 
enhances EGFR, Src and Erk activation in HNSCC lines while having minimal impact 
on EGFR signaling in MDA-MB-231 cells.  Imatinib treatment of HNSCC cells results in 
increased cortactin phosphorylation at Src-targeted Y421 and Erk-targeted S405/S418, 
phosphorylation events present within invadopodia required for ECM matrix degradation 
activity (40,69,70).  As in other HNSCC lines (60), we observed that imatinib treatment 
increases synthesis and release of the EGFR ligand HB-EGF from OSC19 and 
UMSCC1 cells at concentrations 10-fold higher than MDA-MB-231 cells.  Application of 
HB-EGF at imatinib-treated conditioned media concentrations enhanced invadopodia 
activity in HNSCC but not in MDA-MB-231 cells.  This suggests that HNSCC cells 
lacking Abl or treated with imatinib generate an autocrine loop, where increased HB-
EGF synthesis and shedding in turn binds and activates EGFR to stimulate Src and Erk 
activation, leading to elevated cortactin phosphorylation and enhanced invadopodia 
ECM degradation (Figure 8b).  HB-EGF induction of HNSCC invadopodia activity likely 
occurs in part through stimulation and secretion of MMP9 (71,72), which localizes with 
UMSCC1 invadopodia at sites of ECM degradation (73).  While our data are congruent 
with these findings, it is possible that other EGFR ligands may also be upregulated by 
Abl kinase suppression.  The increased level of EGFR overexpression in HNSCC cells 
would render this tumor type more responsive to soluble HB-EGF than cell types that 
contain lower EGFR levels (e.g., MDA-MB-231), which may be the underlying reason 
for the differential response to Abl knockdown, imatinib and HB-EGF in our analyzed 
cell lines.  Whether such a scenario applies to other EGFR overexpressing cancers 
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and/or tumor types that display pro-invasive behavior in response to Abl kinase 
suppression will be important to determine. 
How Abl kinase inhibition promotes HB-EGF synthesis and shedding in HNSCC is 
unclear.  In addition to cytoskeletal regulation, Abl is a nuclear kinase and work in Abl-
null and imatinib-treated fibroblasts indicates that Abl functions to suppress NF-кB 
(nuclear factor-кB) activity through stabilization of the NF-кB regulator HDAC1 (74).  
Elevated NF-кB activity results in increased HB-EGF expression and EGFR activation 
(75), providing a link between Abl activation and negative regulation of HB-EGF 
expression.  High HB-EGF expression is linked to poor clinical prognosis in HNSCC 
(76) and low Abl expression in HNSCC correlates with late stage tumors with poor 
outcome (77), supporting a potential connection between Abl activity and HB-EGF 
levels in driving HNSCC progression. 
Pathway analysis with inhibitors of invadopodia signaling components confirmed that 
EGFR and Src activation in HNSCC is central to driving invadopodia-based ECM 
degradation.  Simultaneous inhibition of Src and Abl kinases decreased matrix 
degradation by UMSCC1 and OSC19 cells, reinforcing the point that the elevated 
invadopodia activity in HNSCC resultant from Abl kinase inhibition requires concurrent 
Src activation.  While preclinical studies on HNSCC lines has shown that saracatinib 
and the related inhibitor dasatinib impair cell invasion and display potent anti-tumor 
effects (9,17), phase II trials in HNSCC patients with either drug as a single agent 
yielded no benefit in spite of apparent Src inhibition (78,79).  In contrast, a phase II trial 
with imatinib administered to HNSCC and NSCLC patients was closed early due to lack 
of efficacy and antagonistic effects, with a patient subset displaying a worse clinical 
outcome in response to imatinib (57).  While not directly evaluated, these results 
support a role for Src inhibition in counteracting the pro-invasive effects of Abl kinase 
that would result in increased patient tumor progression.  Although some response has 
been achieved with imatinib in solid tumors with combination approaches (78,80-82), 
our results further emphasize the importance of careful patient selection and exclusion 
criteria for using imatinib or other Abl kinase inhibitors in HNSCC and other solid tumors 
that display similar characteristics.  
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We have determined that Abl kinases have a context-dependent role in regulating 
invadopodia function and tumor invasion.  In HNSCC cells Abl serves to suppress 
invadopodia ECM degradation and tumor invasion by preventing HB-EGF synthesis and 
extracellular shedding, where it is capable of activating the EGFR/Src/cortactin signaling 
pathway to accelerate invadopodia-based ECM degradation and tumor cell invasion.  
This is in contrast to MDA-MB-231 cells, a cell line commonly used to analyze 
invadopodia and invasive signaling, where Abl kinase inhibition prevents invadopodia 
activity and impairs invasiveness.  These results stress the need for further mechanistic 
insight into the signaling processes that regulate the pro- and anti-oncogenic roles of 
Abl in solid tumors in order to prevent detrimental affects of imatinib treatment in 
ongoing and future patient trials.  
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Material and Methods 
Plasmid constructs 
The lentiviral vector pLL5.0 (83) was used for Abl knockdown by subcloning a shRNA 
targeting human Abl oligonucleotide, (5’GCTCCGGGTCTTAGGCTAT3’; (84)) with HpaI 
and XhoI sites.  For Abl knockdown-rescue experiments, the resulting vector was 
modified to encode a 6X-HA epitope tag using BamHI and SbfI sites.  Human Abl cDNA 
was PCR amplified from pMSCV-puro Abl (85) and subcloned into EcoRI and BamHI 
digested pLL5.0 6X-HA.  Src-GFP constructs (WT, 527F, and 295M) were used as 
described (36).  
Cell culture, lentiviral infection and transfection 
UMSCC1, OSC19 and 1483 cells were maintained as described (36).  Abl-/-/Arg-/-, wild-
type MEFs, NIH3T3 and HEK 293T/17 cells were cultured as before (86).  MDA-MB-231 
cells were cultured in alpha Minimum Essential Media (Mediatech, Manassas, VA) 
supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan UT), and 1% 
penicillin-streptomycin.  
UMSCC1 cells stably infected with pLL5.0 6X-HA, pLL5.0 6X-HA Abl shRNA or pLL5.0 
co-expressing Abl shRNA and HA-tagged Abl were generated by puromycin selection 
following standard methods.  1483, Abl-/-/Arg-/- or wild-type MEF cells transiently 
expressing CMV-Src or HA-Abl constructs were transfected with the Nucleofector I 
device (Amaxa Biosystems, Berlin, Germany). 
Western blotting, antibodies and immunoprecipitation 
Western blotting of cell lysates was conducted as described (73).  Antibodies used 
were: anti-Src clone GD11 (1:1000; EMD Millipore, Billerica, MA), anti-pY418 Src 
(1:1000; Invitrogen, Carlsbad, CA), anti-p130CAS (1:1000; BD Biosciences, San Jose, 
CA), anti-pY410 p130CAS (1:1000; Cell Signaling Technology, Danvers, MA), anti-
cortactin clone 4F11(1 μg/ml, (86)), anti-pY421 cortactin (1:500; BD Biosciences), anti-
pS405 cortactin (1:2000; (70)), anti-pS418 cortactin (1:500; (70)), anti-ERK1/2 clone C-
14 (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), anti-pERK1/2 (1:1000; Santa 
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Cruz), anti-β-actin (1:10,000; EMD), anti-HA (1:200; Covance, Berkley, CA), anti-Crk 
(1:1000; BD), anti-pY221 Crk (1:1000; Cell Signaling), anti-PDGFR (1:200; Cell 
Signaling), anti-EGFR (1:1000, BD), anti-pY1068 EGFR (1:1000; BD), anti-Arg (1:500; 
EMD), anti-HB-EGF (1:200; EMD), and anti-Abl clone 8E9 (1:500; BD).  Blots were 
quantified as described (73). 
Immunoprecipitation was conducted from cells lysed in RIPA buffer (69).  Clarified 
lysates (250 µg) were incubated with 5 µg anti-cortactin antibody 4F11 for 2 h at 4 °C.  
Immune complexes were captured by incubation with 30 µL Protein A/G beads 
(ThermoFisher Scientific, Rockford, IL) for 1 h, washed with RIPA and analyzed by 
Western blotting.  
Invadopodia matrix degradation assays and fluorescence microscopy  
Cells were plated on Oregon Green 488-conjugated gelatin (Invitrogen, Grand Island, 
NY) coated coverslips (27,87).  In cases of inhibitor treatment, cells were allowed to 
attach for 1 h, then serum starved for 12 h in the presence of 10 µM GM6001 (Sigma) 
and either imatinib mesylate (LGM Pharmaceuticals, Boca Raton, FL), saracatnib 
(AstraZeneca, Alderley Park, Cheshire, United Kingdom), gefitinib (AstraZeneca) or 
SU6656 (EMD).  Serum-free media was replaced with complete media containing 10% 
FBS and kinase inhibitors for 12 h.  Cells were rinsed in PBS, fixed in fresh 4% 
paraformaldehyde and labeled as described (36).  Primary antibodies used were anti-
cortactin clone 4F11 (1:500), anti-cortactin EP1922Y (1:500; Novus Biologicals, 
Littleton, CO), anti-cort-pY421 (1:500), anti-Src GD11 (1:500), anti-Abl clone 8E9 
(1:200), anti-GFP (1:500; Invitrogen), and anti-HA (1:200).  Primary antibodies were 
visualized using Alexa Fluor 405 and 647 conjugated goat anti-rabbit or anti-mouse 
secondary antibodies (1:2000; Invitrogen).  F-actin was visualized using rhodamine-
conjugated phalloidin (1:500; Invitrogen).  Cells were mounted with ProLong Gold 
(Invitrogen) and images were acquired with a Zeiss LSM510 confocal microscope using 
AIM software (Carl Zeiss MicroImaging, Thornwood, NY).  Gelatin degradation was 
quantified as described previously (87).  In brief, ≥ 90 transiently transfected and ≥ 300 
lentiviral infected or inhibitor-treated cells evaluated for each condition.  For therapeutic 
treatments and RNAi stable cell lines, the area of degradation and cell area was 
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determined by analyzing the intensity of degraded gelatin or F-actin respectively in an 
entire field of view utilizing ImageJ software.  For transient transfections, the area of 
degradation and cell area was determined by Image J software on an individual cell 
basis.  The number of invadopodia per cell (n ≥ 50) and number of cells degrading 
matrix (n ≥ 100) were determined or each independent experiment (n = ≥ 3) (36).   
3-D spheroid invasion assays 
Cells were labeled with Vybrant® DiI (Invitrogen).  96 well plates were coated with 100 
µL of 1.5% noble agar (BD Biosciences, Sparks, MD) in Dulbecco’s PBS.  1 x 103 
(OSC19), 5 x 103 (UMSCC1), or 2.5 x 103 (MDA-MB-231) labeled cells were plated into 
individual wells for 48 h to form spheroids.  Two spheroids were transferred to a 
microcentrifuge tube and centrifuged at 1000 x g for 3 min.  The media was aspirated 
and replaced with 500 µL of 2 mg/mL rat tail collagen I (BD).  The spheroid mixture was 
transferred to an individual well of 24-well plate pre-coated with 400 µL solidified 2 
mg/mL collagen I.  Plates were incubated for 1 h at 37 °C then overlayed with 1 mL of 
complete media.  Spheroid invasion was visualized by fluorescence microscopy (Zeiss, 
Axiovert 200M) to establish the central z-axis (0 h) and imaged at 0 and 24 h by phase 
contrast microscopy.  Spheroids were pretreated for 24 h and maintained in media with 
DMSO vehicle or 10 µM imatinib.  Maximal radial distances for invaded cells was 
calculated using Axiovision 4.6 software (Zeiss).   
HB-EGF ELISA assays 
HB-EGF specific enzyme-linked immunosorbent assay (ELISA) was performed 
according to the manufacturer’s protocol (Abcam, Cambridge, MA). Cells were treated 
with imatinib (10µM) or DMSO for 12 h, washed with PBS and incubated for 24 h in 
serum-free media with imatinib or DMSO.  Conditioned media was concentrated to 500 
µL, and 100 µL of media incubated overnight at 4ºC in HB-EGF antibody-coated 
microplate strips.  Absorbance values were obtained at 450 nm with a Biotek Synergy 
H1 Hybrid Reader (Winooski, VT).  Standard curves were generated and results 
normalized to total cellular protein concentration for comparison across different cell 
lines.  
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Statistical analysis 
Differences in mean values between groups were evaluated using Students t-test and 
significance was determined at P < 0.05.  Scale bars represent confidence intervals 
(C.I.).  
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Figure Legends 
Figure 1  Abl expression inhibits  invadopodia activity in HNSCC cells.  (a) UMSCC1 
cells transfected with empty vector (HA-Ctl) or HA-tagged Abl (HA-Abl) were plated on 
Oregon Green 488-gelatin coated coverslips (pseudocolored white) and incubated for 
24 h.  Cells were fixed and labeled with anti-HA (blue), anti-cortactin (green) and 
rhodamine-phalloidin (F-Actin; red).  Boxed areas and corresponding insets denote 
regions of HA-Abl localization with invadopodia markers and regions of matrix 
degradation.  (b) Western blot analysis of Abl expression.  Cell lysates (100 µg) from 
UMSCC1 control (Ctl), shRNA Abl knockdown (shRNA) and wild-type (WT) Abl rescued 
shRNA cells.  Parallel blots were probed for β-actin to confirm equal protein loading 
across all lines.  Numbers denote different independent clones.  (c) Representative 
confocal images of gelatin matrix degradation assays conducted with the indicated 
UMSCC1 clonal cell lines described in (b).  Cells were plated on Oregon Green 488-
gelatin coated coverslips (pseudocolored white) for 9 h, fixed and labeled with an anti-
cortactin antibody (green) and rhodamine-phalloidin (F-Actin; red).  The amount of 
gelatin degradation per cell area from four independent experiments was quantified in 
(d).  Data are represented as mean ± C.I.; ** P≤0.01.  Scale bars: 10 µm in (a), 30 µm in 
(c).  
Figure 2  Targeted inhibition of Abl family kinases with imatinib has divergent effects on 
invadopodia activity in HNSCC and breast cancer cells.  (a) OSC19, UMSCC1 
(HNSCC) and MDA-MB-231 (breast cancer) cells were treated with the indicated 
concentrations of imatinib (STI571) for 24 h, lysed and 25 µg of cell lysate analyzed by 
Western blotting with anti-pY221 Crk to determine drug efficacy.  The ratio of pY221 Crk 
phosphorylation to total Crk levels determined by densitometry is displayed between 
blots.  Blots are representative from three to four independent experiments for each cell 
line.  (b) OSC19, (c) UMSCC1, and (d) MDA-MB-231 cells were plated on Oregon 
Green 488-gelatin coated coverslips (pseudocolored white) in complete media for 1 h to 
allow attachment.  Cells were then serum-starved and treated with GM6001 (10µM) and 
either imatinib (STI571) or DMSO vehicle (0 µM) concomitantly for 12 h.  After GM6001 
washout, cells were incubated with complete media containing 10% FBS for 12 h in the 
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presence or absence of imatinib.  Cells were fixed and labeled with an anti-cortactin 
antibody (green) and rhodamine-phalloidin (F-Actin; red) and visualized using confocal 
microscopy.  Representative images showing cortactin/F-Actin labeling and gelatin 
degradation for each line and indicated experimental condition are shown.  Insets 
denote areas of invadopodia activity indicated by the presence of overlapping 
cortactin/F-Actin puncta that co-localize with dark regions of Oregon Green 488-gelatin 
clearing.  Scale bars: 20 µm.  (e) Quantification of Oregon Green 488-gelatin 
degradation for OSC19, UMSCC1 and MDA-MB-231 cells treated with the indicated 
imatinib (STI571) concentrations.  Data from 3 independent experiments for each 
experimental condition are represented as mean ± C.I.; ** P≤0.01. 
Figure 3  Imatinib enhances HNSCC invasion through 3D collagen matrices.  (a) 
OSC19, (b) UMSCC1 and (c) MDA-MB-231 tumor cell spheroids pre-treated with 10 µM 
imatinib (STI571) or DMSO vehicle (0 µM) for 24 h were embedded in collagen I (0 h).  
Spheroids were further incubated in complete media without (0 µM) or with imatinib for 
an additional 24 h and invasion monitored by phase contrast microscopy.  White circles 
indicate the maximum radial distance traveled by invaded cells.  Scale bars: 200 µm.  
(d) Quantification of average invasive distance traveled by cells in each experimental 
condition (n ≥12 spheroids assayed per cell line and treatment).  Data are represented 
as mean ± C.I.; ** P≤0.01; * P≤0.05. 
Figure 4  Elevated Src activity bypasses Abl family kinase regulation of invadopodia 
function.  (a) UMSCC1, OSC19 and MDA-MB-231 cells grown in complete media were 
analyzed by Western blotting of total cell lysates (25-50 µg) for relative basal activation 
of EGFR, Src and Abl family kinases with the indicated phosphorylation-specific 
antibodies.  Lysates were immunoblotted in parallel for total EGFR, Src, Crk, Abl and 
Arg protein levels.  (b) Abl-/-/Arg-/- double knockout (DKO) and wild-type (WT) mouse 
embryo fibroblasts (MEFs) were serum starved overnight, then stimulated with 100 
ng/mL EGF for 15 min.  Control and stimulated cells were lysed, and 50 µg of total 
protein assayed by immunoblotting with phosphorylation-specific antibodies against 
cortactin pY421 (Cort pY421) and total cortactin.  The ratio of pY421 cortactin relative to 
total cortactin levels for each cell type and treatment are shown.  (c) WT and DKO cells 
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transiently expressing constitutive active Src (527F) were plated on Oregon Green 488-
gelatin coated coverslips for 12 h, fixed, and immunolabeled with anti-cortactin-pY421 
(blue), anti-cortactin (green) and rhodamine-phalloidin (F-Actin; red).  Cells and matrix 
were imaged by confocal microscopy.  Insets show co-localization of pY421 cortactin 
within invadopodia at areas corresponding with clearing of Oregon Green 488-gelatin 
(pseudocolored white).  DKO cells expressing GFP-tagged wild-type (WT), 527F, kinase 
inactive (K295M) Src, co-expressing 527F Src and wild-type (WT) Abl or wild-type (WT) 
MEFs expressing 527F Src were assayed for the percentage of cells degrading the 
ECM (d) and for normalized matrix degradation per cell area (e).  Data are represented 
as mean ± C.I. from 3 independent experiments. ** P≤0.01. 
Figure 5  Imatinib activates the invadopodia kinase pathway in HNSCC cells.  (a) 
OSC19, UMSCC1 and MDA-MB-231 cells grown in complete media were treated with 
DMSO vehicle (0 µM) or the indicated imatinib (STI571) concentrations for 24 h.  Cells 
were lysed and 25-50 µg of total cell protein were assayed by immunoblotting for 
activation of EGFR (pY1068), Src (pY418), Erk (pErk) and Abl/Arg kinases (pY221 Crk).  
Parallel blots were probed for corresponding levels of each assayed protein.  Ratios of 
phosphorylated/total protein are shown (represented as mean from ≥ 3 independent 
experiments).  All blots are representative images.  (b) Western blot analysis of 
cortactin S405 and S418 phosphorylation from cells treated and prepared in (a) with the 
indicated phosphorylation-specific antibodies.  A representative blot was stripped and 
reprobed with anti-cortactin to verify equal loading.  (c) OSC19, UMSCC1 and MDA-
MB-231 cells treated as in (a) were lysed and cortactin was immunoprecipitated from 
250 µg of cell extract.  Immune complexes were assayed by Western blotting for 
cortactin Y421 phosphorylation (anti-Cort-pY421).  Parallel blots with anti-pan-cortactin 
were conducted to verify cortactin immunoprecipitation.   
Figure 6  Imatinib induced HB-EGF stimulates HNSCC invadopodia ECM degradation.  
(a) OSC19, UMSCC1 and MDA-MB-231 cells treated with DMSO (0 µM) or imatinib 
mesylate (STI571, 10 µM) for 24 h were lysed and 100 µg cell protein assayed by 
Western blot analysis for HB-EGF.  Bracketed HB-EGF shows different HB-EGF post-
translationally modified forms.  Positive control (+ Ctl) recombinant HB-EGF ectodomain 
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is denoted by an asterisk (*).  A parallel blot was probed with anti-β-actin to confirm 
equal protein loading.  (b)  HB-EGF ELISA analysis of conditioned media from cells 
treated with the indicated imatinib (STI571) concentrations.  Concentrations of cleaved, 
soluble HB-EGF were adjusted in accordance with total cellular protein levels after 
treatment from each cell line to allow cross-comparison.  (c)  Soluble HB-EGF promotes 
HNSCC invadopodia ECM degradation. OSC19, UMSCC1, and MDA-MB-231 cells 
were plated on Oregon Green 488-gelatin coated coverslips in complete media for 2 h 
to allow attachment and stimulated with recombinant HB-EGF (0, 25, or 250 pg/mL) for 
7 h.  HB-EGF concentrations were calculated from average levels present in 
conditioned media of imatinib-treated cells.  Cells were fixed and labeled with an anti-
cortactin antibody (green) and rhodamine-phalloidin (F-Actin; red) and visualized using 
confocal microscopy.  Insets denote areas of invadopodia activity.  Scale bars: 20 µm.  
(d)  Quantification of Oregon Green 488-gelatin degradation from OSC19, UMSCC1 
and MDA-MB-231 cells treated with the indicated HB-EGF concentrations as in (c).  
Data are represented as mean ± C.I.; ** P≤0.01; *P ≤ 0.05. 
Figure 7  Targeted inhibition of the EGFR-Src pathway impairs HNSCC invadopodia 
activity.  UMSCC1 cells treated with the indicated concentrations of gefitinib (a), 
SU6656 (b) and saracatinib (c) for 24 h were fixed and evaluated for Oregon Green 
488-gelatin degradation by fluorescence microscopy with rhodamine-phalloidin and anti-
cortactin antibodies.  (d) UMSCC1 control (Ctl 8), shRNA Abl knockdown (shRNA 3) 
and Abl-rescued shRNA cells (WT 6) were treated with vehicle (0 µM) or SU6656 (10 
µM) and assayed for effects on Oregon Green 488-gelatin proteolysis as above.  Cells 
and matrix were imaged by confocal microscopy and the level of matrix degradation 
quantified for each treatment condition.  Data are represented as mean ± C.I.; ** 
P≤0.01; *P≤0.05. 
Figure 8  Schematic diagram of EGFR-invadopodia signaling pathways altered by Abl 
inhibition in HNSCC.  (a)  The current invadopodia pathway depicting EGFR activation 
to cortactin phosphorylation as primarily determined in breast cancer cell lines.  EGFR 
activation increases Src and Erk1/2 kinase activity, where Src stimulates Abl/Arg 
activation resulting in direct Abl/Arg cortactin tyrosine phosphorylation, while Erk1/2 
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directly phosphorylates cortactin S405/418.  (b)  In HNSCC, inhibition of Abl/Arg results 
in increased activation of EGFR through elevated HB-EGF synthesis and shedding, 
resulting in autocrine EGFR hyperstimulation.  This leads to elevated Src activity that 
bypasses Abl/Arg and directly phosphorylates cortactin.  Erk1/2 activation is also 
increased under these conditions, where the combined effect of enhanced Src and 
Erk1/2 activation increases cortactin phosphorylation and correlates with elevated 
HNSCC-mediated ECM degradation and invasion. 
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Supplementary Figure Legends 
Supplementary Figure 1  Abl knockdown does not impact the number of HNSCC 
invadopodia.  (a) Src transformed 1483 cells transiently expressing empty vector (HA-
Ctl) or HA-tagged Abl (HA-Abl) are plated on Oregon Green 488-gelatin coated 
coverslips (pseudocolored white) for 24 h, fixed and immunolabeled with anti-HA (blue), 
anti-cortactin (green), and rhodamine-phalloidin (F-Actin; red).  Insets demonstrate 
areas of overlapping invadopodia marker localization with areas of gelatin clearing.  
Scale bars: 10 µm.  Quantification of Abl knockdown on percentage of UMSCC1 cells 
degrading gelatin matrix (b) and invadopodia number per cell (c) from the assays 
conducted in Figure 1c.  Data are represented as mean ± C.I. 
Supplementary Figure 2  Abl knockdown does not impact matrix degradation in MDA-
MB-231 cells.  (a)  MDA-MB-231 cells that were non-infected (NI) or infected with 
lentivirus containing control shRNA (Ctl), Abl specific (shRNA) or Abl shRNA with WT 
Abl re-expressed (WT) were plated on Oregon Green 488-gelatin coated coverslips 
(pseudocolored white) for 24h, fixed and labeled with anti-HA (blue), anti-cortactin 
(green) and rhodamine-phalloidin (F-Actin; red). Scale bars: 10 µm.  (b)  MDA-MB-231 
cells infected as in (a) were lysed and 100 µg of cell lysate analyzed for Abl expression 
of by Western blot analysis.  Levels of β-actin were evaluated to verify equal protein 
loading.  (c) Quantification of Oregon Green 488-gelatin degradation from MDA-MB-231 
cells transfected as in (a).  Error bars indicate mean percentages of gelatin degradation 
± C.I. 
Supplementary Figure 3  Determination of PDGFRα expression levels in OSC19, 
UMSCC1 and MDA-MB-231 cells.  Total cell lysate (150 µg) from each indicated line 
was assayed for PDGFRα expression by immunoblotting with anti-PDGFRα antibodies.  
NIH3T3 fibroblast lysate was included as a positive control.  β-actin levels were assayed 
to verify equal protein loading. 
Supplementary Figure 4  Abl and Arg expression levels in wild-type (WT) and Abl-/-
/Arg-/- (DKO) mouse embryo fibroblasts (MEFs).  (a) Western blot analysis of Abl and 
Arg protein levels in WT and DKO MEFs with anti-Abl and -Arg antibodies.  β-actin 
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levels were evaluated to validate equivalent protein loading.  (b) DKO cells expressing 
GFP-tagged empty vector (Ctl), wild-type (WT), 527F, kinase inactive (K295M) Src, co-
expressing 527F Src and wild-type (WT) Abl or wild-type (WT) MEFs expressing 527F 
Src were plated on Oregon Green 488-gelatin and assayed for invadopodia formation 
and matrix degradation for 12 h.  Cells were fixed and imaged by confocal microscopy 
for anti-GFP (3E6; blue) or anti-Abl (yellow), and co-labelled with anti-cortactin (green) 
and rhodamine-phalloidin (F-Actin; red).  Boxed regions and insets denote comparable 
regions of invadopodia formation and gelatin degradation.  Scale bars: 10 µm. 
Supplementary Figure 5  Evaluation of imatinib on EGFR and Crk signaling.  (a) 
Prolonged Western exposure of the EGFR pY1068 signal from the corresponding 
representative panel in Figure 5a showing EGFR activation.  (b)  UMSCC1 cells were 
treated with indicated concentration of DMSO (0 µM), SU6656 and/or STI571 for 24 h, 
lysed and assayed by Western blot analysis for Crk Y221 phosphorylation.  Ratios of 
phosphorylated to total Crk levels are displayed.  Parallel blots were probed for β-actin 
to confirm equal protein loading. 
Supplementary  Figure 6  Targeted inhibition of the EGFR-Src pathway.  UMSCC1 
cells treated with the indicated concentrations of gefitinib (a), SU6656 (b) and 
saracatinib (c) for 24 h were lysed and 25-50 µg total protein analyzed for drug efficacy 
by Western blot analysis with the indicated phosphorylation specific antibodies.  (d) 
Western blot analysis of Src inhibition in UMSCC1 cells with manipulated Abl 
expression.  Cell lysates (50 µg) from UMSCC1 control (Ctl 8), shRNA Abl knockdown 
(shRNA 3) and Abl rescued shRNA cells (WT 6) treated with DMSO (0 µM) or SU6656 
(10 µM) for 24 h were immunoblotted with anti-pY418Src and anti-Src.  Parallel blots 
were probed for β-actin to confirm equal protein loading across all lines.  Ratios of 
phosphorylated to total Src levels are shown.   
Supplementary Figure 7  Saracatinib impairs invadopodia activity in HNSCC and 
MDA-MB-231 cells.  Western blot analysis of 25-50 µg of protein from (a) OSC19 and 
(b) MDA-MB-231 cells treated with DMSO (0 µM) or the indicated concentrations of 
saracatinib for 24 h.  Lysates were immunblotted for activation of EGFR (pY1068 
EGFR), Src (pY418 Src) and Abl family kinases (pY221 Crk).  Parallel blots were 
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probed with antibodies against the non-phosphorylated protein forms as indicated.  
Ratios of phosphorylated/total protein relative to control for each analyzed protein and 
treatment condition are shown.   (c)  Effects of saracatinib on invadopodia activity.  
OSC19, UMSCC1 and MDA-MB-231 cells plated on Oregon Green 488-gelatin were 
treated with either DMSO (0 µM) or the indicated saracatinib concentrations for 24 h.  
Cells were fixed and labeled with rhodamine-phalloidin and anti-cortactin antibodies.  
Cells and gelatin matrix were and imaged by confocal microscopy. The percentage of 
gelatin degradation per cell area calculated relative to controls.  Data are represented 
as mean ± C.I.; ** P ≤ 0.01; *P ≤ 0.05.  
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Abstract  
Elevated Src kinase activity is linked to the progression of solid tumors, including head 
and neck squamous cell carcinoma (HNSCC). Src regulates HNSCC proliferation and 
tumor invasion, with the Src-targeted small molecule inhibitor saracatinib displaying 
potent anti-invasive effects in preclinical studies. However, the pro-invasive cellular 
mechanism(s) perturbed by saracatinib are unclear. The anti-proliferative and anti-
invasive effects of saracatinib on HNSCC cell lines were therefore investigated in 
preclinical cell and mouse model systems. Saracatinib treatment inhibited growth, cell 
cycle progression and transwell Matrigel invasion in HNSCC cell lines. Dose-dependent 
decreases in Src activation and phosphorylation of the invasion-associated substrates 
focal adhesion kinase, p130 CAS and cortactin were also observed. While saracatinib 
did not significantly impact HNSCC tumor growth in a mouse orthotopic model of tongue 
squamous cell carcinoma, impaired perineural invasion and cervical lymph node 
metastasis was observed. Accordingly, saracatinib treatment displayed a dose-
dependent inhibitory effect on invadopodia formation, extracellular matrix degradation 
and matrix metalloprotease 9 activation. These results suggest that inhibition of Src 
kinase by saracatinib impairs the pro-invasive activity of HNSCC by inhibiting Src 
substrate phosphorylation important for invadopodia formation and associated matrix 
metalloprotease activity.  
 
 
Keywords: Saracatinib, Src, Head and Neck cancer, invadopodia, invasion, MMP 
 
  
111 
 
Abbreviations 
CAS- Crk-associated substrate  
c-Src- cellular Src kinase  
ECM- extracellular matrix  
FACS- fluorescence-activated cell sorting  
FAK- focal adhesion kinase  
FITC- fluorescein isothiocyanate  
HNSCC- head and neck squamous cell carcinoma  
IHC- immunohistochemistry  
SFK- Src family kinase 
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Introduction 
Tumor cell invasion and metastasis is a compounding problem in cancer management, 
with therapeutic intervention of tumor invasion becoming recognized as an increasingly 
relevant clinical factor (Dolgin, 2009). Increased activation of the proto-oncogene c-Src 
(Src) has been established in enhancing tumor progression in human cancer and 
corresponds with poor clinical outcome (Irby & Yeatman, 2000; Yeatman, 2004). Src is 
responsible for governing signaling pathways that regulate proliferation, angiogenesis, 
resistance to apoptosis, adhesion, motility and invasion (Summy & Gallick, 2006). High 
Src expression and/or activity is observed in metastases, supporting a role for Src in 
tumor progression by enhancing tumor invasion and metastatic potential (Summy & 
Gallick, 2003; Yeatman, 2004). Small molecules targeting Src kinase activity suppress 
proliferation, invasion and metastasis in preclinical settings (Summy & Gallick, 2006), 
and are currently being evaluated in clinical trials (Kopetz et al., 2007). 
Head and neck squamous cell carcinoma (HSNCC) is highly invasive, frequently 
metastasizing to cervical lymph nodes and corresponds with poor prognosis (Kramer et 
al., 2005). Src overexpression is common in HNSCC (van Oijen et al., 1998) and is 
activated following engagement of the epidermal growth factor receptor (EGFR), where 
it modulates HNSCC growth and invasion through several signaling pathways (Zhang et 
al., 2004). The small molecule Src kinase inhibitor dasatinib suppresses motility and 
invasion of HNSCC cells in vitro and in mouse xenografts models, corresponding with 
decreased Src activation and invasion-associated substrate phosphorylation (Johnson 
et al., 2005; Sen et al., 2009). Amplification and/or overexpression of Src substrates in 
HNSCC correlates with poor clinical outcome, potentially serving to magnify Src 
pathway effects on HNSCC invasion and metastasis (Kelley et al., 2008).  
HNSCC invasion and metastatic spread is mediated in part by the action of matrix 
metalloproteases (MMPs), with MMP1, MMP2, MMP9 and MT1-MMP activity 
associated with poor outcome (Rosenthal & Matrisian, 2006). MT1-MMP, MMP2 and 
MMP9 localize to invadopodia, actin-based ventral protrusions in invasive tumor cells 
that mediate focalized proteolysis of the extracellular matrix (ECM) (Linder, 2007; 
Weaver, 2006). Invadopodia formation is dependent on Src activity, which enhances 
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MMP2 and MMP9 secretion (Hsia et al., 2003; Mueller et al., 1992), and matrix 
degradation in HNSCC cells (Clark et al., 2007). The collective localization and action of 
MMPs at invadopodia allows matrix remodeling to accommodate primary tumor growth 
and to allow dissemination of encapsulated tumor cells to local and distant sites 
(Gimona et al., 2008). 
Saracatinib (AZD0530) is a recently developed anilinoquinazoline inhibitor designed to 
disrupt Src kinase activity (Hennequin et al., 2006; Summy & Gallick, 2006). Saracatinib 
exhibits inhibitory effects on tumor growth in some model systems (Herynk et al., 2006), 
but several preclinical reports suggest that the primary anticancer effects of saracatinib 
are impaired tumor cell migration and invasion in HNSCC and other cancer types 
(Green et al., 2009; Koppikar et al., 2008; Nozawa et al., 2008). The anti-invasive 
effects of saracatinib are consistent with the effects of Src kinase inhibition in HNSCC 
by dasatinib, another Src-targeted inhibitor (Johnson et al., 2005). Saracatinib is 
currently being evaluated in phase I/II clinical trials for efficacy against advanced stage 
HNSCC and other tumor types (Kopetz et al., 2007).  
Although saracatinib and other Src inhibitors are effective anti-invasive compounds, a 
complete understanding of the how therapeutic Src inhibition perturbs tumor invasion at 
the cellular level is lacking. We show that saracatinib inhibited Src activation and 
phosphorylation of the invadopodia regulatory proteins focal adhesion kinase (FAK), 
p130 Crk-associated substrate (CAS) and cortactin in HNSCC cells. Saracatinib 
suppressed HNSCC growth and cell cycle progression in a subset of HNSCC cell lines. 
Administration of saracatinib to nude mice containing orthotopic HNSCC tongue tumors 
inhibited Src activity, cortactin phosphorylation, perineural invasion and lymph node 
metastasis. We also demonstrated that saracatinib prevented invadopodia formation 
and ECM degradation in invasive HNSCC cells, as well as secretion and activation of 
MMP9. Collectively these results suggest that saracatinib exhibits anti-tumor effects in 
HNSCC by inhibiting invasion through the prevention of invadopodia formation. The 
ability of saracatinib to prevent invadopodia-mediated ECM proteolysis reveals a cellular 
process perturbed by Src inhibitors that is likely utilized in the progression of HNSCC 
and other invasive carcinomas containing high Src activity. 
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Materials and Methods 
Cell lines, antibodies and Western blotting 
HNSCC cell lines 1483, HN31, UMSCC 1, UMSCC19 and MSK 921 were maintained as 
described (Rothschild et al., 2006). Western blotting of cell lysates was conducted 
essentially as before (Rothschild et al., 2006). Western blotting of secreted MMP2 and 9 
was conducted on conditioned media, with volumes adjusted to compensate for 
variations in cell numbers using dimethyl sulfoxide (DMSO)-treated cell numbers as 
controls.  
Antibodies for immunoblotting included anti-Src (1:1000; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), anti-pY418 Src (1:1000; Invitrogen, Carlsbad, CA, USA), anti-
p130CAS (1:1000; BD Biosciences, San Jose, CA, USA), anti-pY410 p130CAS 
(1:1000; Cell Signaling Technology, Danvers, MA, USA), anti-FAK (1:1000; BD 
Biosciences), anti-pY861 FAK (1:1000; Invitrogen) and anti-cortactin (1μg/ml; 4F11 
(Rothschild et al., 2006)). For detection of human pY421 cortactin, a custom antibody 
was developed by 21st Century Biochemicals (Marlboro, MA, USA). Briefly, a synthetic 
cortactin peptide encompassing the sequence around tyrosine 421 (NH2- 
VpYEDAASFKL-COOH) was synthesized, phosphorylated and injected into rabbits. 
Immune serum was passed through a column containing agarose beads coupled to the 
equivalent non-phosphorylated peptide, and then passed over a second agarose 
column containing a partially overlapping phosphorylated peptide (NH2- 
LPSSPVpYEDAA-COOH). Bound antibodies were eluted, concentrated and screened 
for specificity by Western blotting against recombinant cortactin mutant proteins 
harboring phenylalanine-tyrosine point mutations at tyrosine 421 (Fig. 1, Supplemental 
Material). Anti-ERK1/2 (Cell Signaling) and anti-pT202/pY204 ERK1/2 (Cell Signaling) 
were used at 1:1000. Anti-MMP2 (1:500; Millipore, Billerica, MA, USA) was used to 
detect cellular MMP2 levels. Secreted MMP2 was detected with antibody CA-4001 
(1:100; Millipore). Cellular and secreted MMP9 was detected with monoclonal antibody 
9D4.2 (1:100; Millipore). All Western blots were quantified by densitometry and ImageJ 
analysis, and band intensities determined relative to non-treated controls.  
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Cell proliferation and cell cycle progression assays  
For cell proliferation assays, 4,000 cells were seeded overnight and treated with 0-10 
µM saracatinib (AstraZeneca, Cheshire, UK) for 5d. 100 μg of 3-(4,5-dimethylthiazol-2- 
yl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich, St. Louis, MO, USA) was added to 
each saracatinib treatment condition for 4h, cells were washed and the reduced dye 
extracted with a 75% isopropanol/2% HCl/23% H2O mixture. Dye absorbance was read 
at 490 nm with an automated plate reader.  
Cell cycle distribution was determined by fluorescence activated cell sorting (FACS) as 
previously described (Frederick et al., 2007).  
Invasion assays  
BioCoat Matrigel invasion chambers (BD Biosciences) were rehydrated with serum-free 
DMEM media for 2 h. 1 X 105 cells suspended in serum-free media were plated in the 
chamber insert and incubated for 2 h to allow attachment. The media in the upper and 
lower chambers was replaced, with serum-free DMEM added to the upper chamber and 
DMEM containing 5% FBS added to the lower chamber to generate a chemotactic 
gradient. Increasing doses of saracatinib (0-1 μM) of saracatinib as indicated (Fig. 1D) 
to the upper and lower chambers. Cells were allowed to invade for 12-24 h (depending 
on cell line), fixed with 10% buffered formalin phosphate (Fisher Scientific, Hanover 
Park, IL, USA) and rinsed with PBS. Non-invasive cells were removed from the interior 
of the chamber insert with a swab and the remaining cells were stained with 0.4% 
Crystal Violet solution (Fisher) for 15 min. Invasion was assessed by counting cells in 
four random 20X microscopic fields.  
Orthotopic xenograft assay of HNSCC invasion  
An in vivo mouse model of oral tongue squamous cell carcinoma was established as 
described (Myers et al., 2002) with minor modification using female athymic Foxn1nu/nu 
mice 4-5 weeks of age (Harlan Laboratories, Indianapolis, IN, USA). All animal 
procedures were conducted according to an approved protocol by the West Virginia 
University Animal Care and Use Committee. Anesthetized mice were injected with 2.5 x 
116 
 
104 UMSCC1 cells suspended in DMEM into the anterior ~1/3 of the tongue. After 10 d, 
treatment was initiated by daily oral gavage of 25mg/kg saracatinib suspended in a 
sterile solution of 0.5% methyl cellulose/0.1% polysorbate 80 (Tween 80, Sigma- 
Aldrich). Control animals were gavaged with the methylcellulose/Tween 80 vehicle. No 
overt difficulties were encountered when gavaging mice over time as the tumor size 
increased. Six mice were used for each treatment group. After 30 d of treatment, mice 
were euthanized by carbon dioxide inhalation and tumor volumes determined as 
described (Huang et al., 2002). Tongues, sublingual tissue containing the superficial 
cervical lymph nodes and the tracheoesophageal region, deep cervical and mediastinial  
lymph nodes, liver and lung were removed from each animal, rinsed, fixed and paraffin 
embedded for routine histological evaluation. 
Immunohistochemistry  
Human HNSCC cases were obtained from the West Virginia Tissue Bank and used 
under the approval of West Virginia University Institutional Review Board. Five- 
micrometer sections from human HNSCC and mouse tissue blocks were processed and 
immunolabeled or hematoxylin and eosin (H&E) stained using a Discovery XT 
automated staining system (Ventana Medical Systems, Tucson, AZ, USA). For 
immunohistochemistry, primary antibody conditions were: anti-total Src (Cell Signaling) 
1:600 in Dako diluent (Dako, Carpinteria, CA, USA) for 1 h, anti-pY416 Src family 
kinase (SFK) (Cell Signaling) 1:25 in phosphate saline solution (PSS) (Ventana) for 12 
h, anti-total cortactin (Novus Biologicals, Littleton, CO, USA) 1:700 in PSS for 1 h, 
antipY421 cortactin 1:50 in Tris-buffered saline containing 4% BSA for 1 h, and 
prediluted anti-cytokeratin 14 (Abcam, Cambridge, MA, USA) for 20 min. Primary 
antibodies were detected using the Omnimap antibody horseradish peroxidase kit 
(Ventana) and slides were counterstained with hematoxylin. Images were acquired as 
described (Rothschild et al., 2006). For quantifying pY416 Src and pY421 cortactin 
staining intensities, brightfield images from at least 5 randomly selected images were 
captured on an Olympus ZX70 Provis microscope (Olympus, Center Valley, PA, USA) 
with a 20x/0.70 UPlanApo objective and an Optronics MicroFire 1600x1200 color CCD 
camera (Optronics Inc, Goleta, CA, USA) using the StereoInvestigator imaging package 
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(MBF Bioscience, Williston, VT) with the same camera settings and brightfield 
correction enabled to ensure even illumination across the image. Brown 3,3'-
diaminobenzidine (DAB) staining was separated from blue hematoxylin staining using 
the color deconvolution plug-in function of ImageJ (NIH) as described (Park et al., 
2008). The vector values for the DAB staining were determined from ROIs with brown 
staining (R=0.425, G=0.600 and B=0.677 for pY421 cortactin; R=0.475, G= 0.653 and 
B=0.686 for pY416 Src). Brown images were inverted and intensities were measured 
inside the tumor tissue. The mean DAB intensities were averaged within the group to 
calculate ratios of phosphorylation-specific staining in treated vs. control tissues.  
Immunofluorescence labeling, confocal microscopy and image analysis  
UMSCC1 cells were plated on fluorescein isothiocyanate (FITC)-gelatin (Sigma) coated 
coverslips as described (Artym et al., 2006) for 2 h. Cells were left untreated or treated 
with saracatinib for 6 h, rinsed and fixed with 4% formaldehyde. Cells were 
permeabilized with 0.4% Triton-X/PBS for 4 minutes, then blocked in 5% BSA/PBS for 1 
h. To identify invadopodia, cells were incubated with rhodamine-conjugated phalloidin 
(1:1000; Invitrogen), anti-cortactin monoclonal antibody 4F11 (1 μg/ml) and polyclonal 
pTyr-100 (1:200; BD Biosciences) in 5% BSA/PBS for 1 h. After washing, cells were 
incubated in 5% BSA/PBS containing AlexaFluor 405 goat anti-rabbit and AlexaFluor 
647 goat anti-mouse secondary antibodies (Invitrogen) at 1:1000. Cells were rinsed and 
mounted in Fluoromount-G (SouthernBiotech, Birmingham, AL, USA).  
For quantifying saracatinib effects on invadopodia incidence and matrix degradation, 
eight-bit 1024x1024 pixel confocal images were acquired with a Zeiss LSM510 confocal 
microscope using AIM software (Carl Zeiss MicroImaging, Thronwood, NY, USA).  
Images were scanned with a 63x/1.4 NA Oil Plan-Apochromat objective at 1.3x zoom, 
yielding a resolution of 10.14 pixels/μm. All images of the FITC-gelatin were taken with 
the same parameters (pinhole size, laser intensity and gain) so image intensity would 
be comparable between samples. For invadopodia formation, a minimum of six 
independent fields comprising > 50 cells were analyzed for cells containing invadopodia 
compared to total cell number. For matrix degradation, cells were analyzed using 
ImageJ software. Actin images were adjusted to threshold values to include all cellular 
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regions, and the resulting images were used to calculate total cell areas in µm2. For 
quantifying matrix degradation, FITC-gelatin images were inverted so that regions with 
increased degradation would yield higher intensity values, ensuring selection of all 
areas of matrix degradation. The integrated density was reported as the amount of 
degradation per total cell area. A minimum of 15 cells was analyzed for each saracatinib 
concentration.  
Gelatin zymography  
UMSCC1 and 1483 cells were plated overnight at 5 X 106 in complete media and were 
treated with saracatinib at increasing dosage for 24 h, rinsed and incubated for 24 h in 
serum-free media containing the equivalent saracatinib dose. Cells were counted, and 
conditioned media collected and concentrated by ultrafiltration using Amicon Ultra-4 
centrifugal filter devices with a 10kDa molecular weight cutoff (Millipore). Zymography 
was conducted as described (Clark et al., 2007) with minor modification. Conditioned 
media (35 μl) was diluted in 2X non-reducing SDS-PAGE sample buffer and resolved on 
8% SDS-PAGE gels containing 1 mg/ml bovine gelatin (Sigma). Aliquots of serum-free 
DMEM and DMEM containing 10% FBS were used as negative and positive controls, 
respectively. MMP activity was renatured by washing gels in 2.5% Triton X-100 for 30 
min, followed by washing gels in Developing Buffer (50 mM Tris, 0.2M NaCl, 5mM 
CaCl2, 0.02% Brij 35) for 30 min at room temperature. Gels were then incubated in 
renewed Developing buffer for 24h at 37° C to allow MMP activity to proceed. Gels were 
stained with Coomassie Brilliant Blue R-250 (0.5% w/v) for 30 min, followed by 
destaining in water. Resulting gels were scanned using a FotoAnalyst Investigator 
(Fotodyne Inc, Hartland, WI, USA) and areas of gelatinase activity quantified using 
ImageJ. Results were adjusted relative to control DMSO treatment for gelatinase activity 
and cell counts for each treatment to compensate for variations in final cell numbers. 
Statistical analysis  
Differences in mean values between saracatinib treatment groups for invasion, 
invadopodia and gelatinase assays were evaluated using one-way ANOVA, followed by 
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Student-Newman-Keuls post hoc testing. Differences were considered significant at 
P<0.05, with all experimentation conducted at least in triplicate. 
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Results  
Saracatinib effects on HNSCC proliferation and invasion  
As a first step in our work, we characterized several HNSCC cell lines previously 
determined to have varying degrees of invasive and metastatic potential (Rothschild et 
al., 2006; Sano & Myers, 2007; Yang et al., 2004) for their response to saracatinib. To 
determine the effect of saracatinib treatment on proliferation in these lines, growth 
inhibition was assessed by 5d 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assays for cells treated with increasing doses of saracatinib (Fig. 1A). 
The HN31 and UMSCC1 lines were sensitive to growth inhibition by saracatinib, as 
indicated by sub-micromolar IC50 values (Fig. 1A). In contrast, the 1483 line 
demonstrated a marked resistance to saracatinib, with an IC50 = 7.60μM. Corresponding 
effects on cell cycle progression are also observed, with increasing saracatinib 
concentrations resulting in enhanced G1 checkpoint arrest in HN31 and UMSCC1 lines 
determined by FACS analysis (Fig. 1B). Saracatinib treatment did not alter the 
percentage of cells undergoing G2-M transition for either line. Arrest of G1 was not 
evident in 1483 cells treated with saracatinib concentrations up to 1μM, in agreement 
with resistance of this line in proliferation analysis (Fig. 1A). Erk1/2 activation, a potent 
driver of mitogenesis, was impaired in HN31 and UMSCC1 cells at concentrations 
above 0.5 μM as determined by Western blotting (Fig. 1C). Similar results were 
obtained for the invasive HNSCC lines MSK921 and UMSCC19 (data not shown). 
Erk1/2 activation was elevated in 1483 cells at doses up to 1μM (Fig. 1C), in agreement 
with the high IC50 value for this line (Fig. 1A). These data indicate that the HNSCC lines 
used in this study vary in their proliferative response to saracatinib treatment, and can 
be segregated into sensitive (HN31 and UMSCC1) and resistant (1483) populations.  
Next we evaluated the effect of saracatinib on HNSCC invasion in vitro using modified 
Boyden chamber transwell assays. In the absence of saracatinib, UMSCC1 and HN31 
cells displayed an invasive response to serum, averaging 4150 cells/aggregate field and 
1719 cells/aggregate field, respectively (Fig. 1D). 1483 cells were weakly invasive, with 
an average of 243 cells/aggregate field (Fig. 1D). Increased concentrations of 
saracatinib resulted in dose-dependent inhibition of HNSCC invasion for all tested lines, 
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with reduced invasion compared to control levels of 88% in UMSCC1, 70% in HN31, 
and 78% in 1483 cells at the highest evaluated dose (1.0 μM) (Fig. 1D). These results 
indicate that saracatinib directly impacts the ability of HNSCC cell lines to invade in an 
in vitro setting.  
Saracatinib inhibits Src activation and substrate phosphorylation in HNSCC cells 
To determine the impact of saracatinib on Src activity and phosphorylation of 
invadopodia-related Src substrates, dose-dependence experiments were performed on 
HN31, UMSCC1 and 1483 cells (Fig. 2). Cell lines were treated with increasing doses of 
saracatinib for 24 hours, lysed and assessed for phosphorylation by immunoblotting 
using anti-phosphorylation site-specific antibodies to detect Src activation (pY418) and 
specific Src phosphorylation sites in downstream substrates (pY410 p130 CAS, pY421 
cortactin and pY861 FAK). The phosphorylation of Src at Y418 was inhibited by 
saracatinib in all tested lines at concentrations between 0.5 and 1.0 μM (Fig. 2). 
Phosphorylation of cortactin at tyrosine 421 and FAK at tyrosine 861 was also reduced 
within the same range of saracatinib concentrations (FAK phosphorylation in 1483 cells 
could not be evaluated due to the absence of detectable FAK expression in this line). 
While phosphorylation of tyrosine 410 in p130 CAS was inhibited within this same dose 
range in UMSCC1 cells, we observed that p130 CAS phosphorylation was consistently 
inhibited at lower dose ranges (0.01-0.05 μM) in HN31 and 1483 cells (Fig. 2). 
Immunoblotting with antibodies against total p130 CAS, cortactin and FAK indicate that 
the expression levels of these proteins are somewhat reduced at high dose levels of 
saracatinib treatment (0.5-1μM), but not at levels accountable for the resultant decrease 
of tyrosine phosphorylation at the assayed sites (0.1-0.5μM).  
Saracatinib inhibits Src activation, invasion and cervical lymph node metastasis 
in an orthotopic mouse model of oral squamous cell carcinoma  
A mouse orthotopic model of tongue squamous cell carcinoma (Myers et al., 2002) that 
phenotypically mimics human HNSCC (Fig. 3) was utilized to evaluate the effects of 
saracatinib on HNSCC progression and invasion in an in vivo setting.  Athymic mice 
with UMSCC1 tongue tumors were randomized and treated with either vehicle or daily 
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with 25mg/kg saracatinib.  At the end of treatment (40d), mice from both groups had 
similar weight (24g) and mean tumor volumes (54.1mm3+ 2.3mm for controls; 
43.7mm3+ 4.6mm with saracatinib treatment).  The modest impact of saracatinib on 
UMSCC1 tumor growth was not statistically significant.  To determine the impact of 
saracatinib on Src activity, primary tumors were evaluated for Src and cortactin 
phosphorylation by immunohistochemistry.  Active Src (determined by pY416 SFK 
staining) and pY421 cortactin labeling in UMSCC1 tumors displayed similar patterns 
compared to human HNSCC (Fig. 3A).  Saracatinib treatment reduced the ratios of 
pY416 SFK and pY421 cortactin compared to control-treated mice (Figure 3A).   
Human HNSCC often displays perineural invasion with regional lymph node 
involvement.  Given the invasive nature of UMSCC1 cells (Fig. 1D), we evaluated the 
impact of saracatinib treatment on loco-regional tissue invasion and cervical lymph node 
metastasis in treated mice.  Soft tissues from the submental space through the 
tracheoesophageal region were evaluated for perineural invasion and cervical lymph 
node metastasis by immunostaining for the epithelial marker cytokeratin 14.  Similar to 
human tumors, extensive perineural invasion and metastasis to the superficial cervical 
lymph nodes was evident in 5/6 control treated mice (Fig. 3B).  Invasion and lymph 
node metastasis was found in 1/6 saracatinib-treated mice, and the remaining mice 
displayed a complete absence of cytokeratin-positive cells associated with nerves, 
sublingual glands, connective tissue or cervical lymph nodes (Fig. 3B).  These data 
demonstrate that the in vivo ability of saracatinib to down-regulate Src activity and 
cortactin phosphorylation correlates with decreased invasion and local lymph node 
metastasis.  
Saracatinib inhibits invadopodia formation and matrix degradation in UMSCC1 
cells  
UMSCC1 cells plated on fluorescently-labeled gelatin formed centrally localized ventral 
puncta enriched with cortactin, filamentous (F)-actin and phosphotyrosine (Fig. 4A, 
DMSO), three markers that define invadopodia (Bowden et al., 2006).  Spontaneous 
invadopodia formation was observed in 51% of UMSCC1 cells by confocal microscopy 
at a given time, corresponding with focalized areas of matrix clearing (FITC-gelatin) 
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(Fig. 4B, 0μM dosage point).  The gelatin matrix underneath UMSCC1 cells typically 
displayed degradation encompassing ~53% of the overlying cell area, reflecting the 
action of invadopodia-associated MMP activity (Fig. 4C).   
UMSCC1 cells plated on FITC-coated gelatin were treated with increasing 
concentrations of saracatinib, and invadopodia formation and matrix degradation was 
evaluated by confocal microscopy (Fig. 4).  The number of cells containing invadopodia 
was significantly decreased with increasing saracatinib dosage, with < 2% of cells 
having formed invadopodia at concentrations at or above 0.5 μM (Fig. 4B).  Effects on 
matrix degradation were more pronounced, where increased saracatinib dosage 
resulted in similar incremental decreases in degradation (Fig. 4C).  UMSCC1 cells 
treated with 1.0 μM saracatinib did not contain invadopodia and were incapable of 
degrading matrix (Fig. 4A).  These cells also lacked focal cortactin localization, had 
diminished phosphotyrosine levels at focal adhesions and contained disorganized F-
actin puncta on the ventral membrane surface where invadopodia typically form (Fig. 
4A, arrowheads). 
Saracatinib inhibits MMP9 secretion from HNSCC cells 
In addition to MT1-MMP, secretion and activation of MMP2 and MMP9 at invadopodia 
has been reported to be partially responsible for the observed effects on matrix 
degradation (Linder, 2007).  Src activity regulates MMP2 and MMP9 secretion in 
fibroblasts (Hsia et al., 2003).  We therefore determined the effect of saracatinib on 
MMP secretion.  Confocal immunofluorescence microscopy indicated that UMSCC1 
cells have MMP9-containing vesicles localized to invadopodia at sites that correspond 
with gelatin degradation (Fig. 5A), indicating that MMP9 is concentrated in UMSCC1 
invadopodia.  To evaluate the impact of saracatinib on MMP2 and MMP9 secretion and 
activity in HNSCC cells, total cell lysates and conditioned media from saracatinib- 
treated 1483 and UMSCC1 cells were analyzed for the presence of cellular and 
secreted MMP2 and MMP9 by Western blotting (Fig. 5B).  Saracatinib treatment 
resulted in modest decreases (up to 24%) in cellular MMP2 levels at concentrations to 1 
μM, while cellular MMP9 levels demonstrated up to a two-fold increase under the same 
concentration range.  Although secreted MMP2 was not detected in the media of either 
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cell line, both lines secreted detectible amounts of MMP9 (Fig. 5B).  Treatment of either 
line with saracatinib inhibited MMP9 secretion, and each line displayed differential drug 
sensitivity.  Detectible MMP9 secretion from 1483 cells was largely absent at the lowest 
evaluated concentration (0.01 μM) whereas secretion from the more invasive UMSCC1 
line was inhibited at concentrations of 0.5 μM and above (Fig. 5B).  The secreted MMP9 
from both lines displayed proteolytic activity when assayed by gelatin zymography (Fig. 
5C).  Saracatinib concentrations up to 0.1μM did not significantly affect MMP9 activity 
as determined by ANOVA analysis for both lines, although mean values for 1483 cells 
treated with these lower doses were consistently below control levels (Fig. 5C).  Higher 
saracatinib concentrations (0.5 μM and 1.0 μM) reduced MMP9 activity to respective 
mean values of 39% and 25% for control levels in 1483 cells, and 22% and 12% in 
UMSCC1 cells (Fig. 5B,C).  These data indicate that saracatinib treatment of HNSCC 
cells leads to selective inhibition of MMP9 secretion in 1483 and UMSCC1 cells, 
preventing efficient enzymatic degradation of extracellular matrix components. 
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Discussion 
The present study demonstrates that inhibition of HNSCC invasion in preclinical in vitro 
and in vivo settings by saracatinib directly corresponds to disruption of HNSCC 
invadopodia formation and function, identifying invadopodia as a potential downstream 
target of therapeutic Src kinase inhibition in HNSCC and other invasive human cancers.  
Invasive HNSCC presents a difficult problem in patient care, given the proximity of most 
tumors to multiple vital organ sites in the head and neck region.  Disregulation of 
signaling pathways that promote and sustain invasion impinge on adhesion- and 
cytoskeletal-associated proteins.  These proteins function in concert with MMPs to 
enable tumor cells to degrade and protrude through an encapsulating ECM, allowing 
movement into neighboring tissues.  The ability of saracatinib to ablate invadopodia and 
the associated invasive behavior of HNSCC cells in mice provides further evidence for a 
direct link between invadopodia activity and tumor invasion, shedding light on the 
specific invasion-promoting cellular processes perturbed by Src kinase inhibition.   
The HNSCC lines used in this study displayed differential responses to saracatinib in 
terms of anti-proliferate effects, with some lines (HN31 and UMSCC1) having 
submicromolar sensitivity, cell cycle inhibition and decreased ERK1/2 activity and others 
(1483) demonstrating resistance to the drug at concentrations up to 1 μM (Fig. 1A-C).  
While a recent study reported IC50 saracatinib values near 1 μM for five different 
HNSCC lines (Koppikar et al., 2008), our findings are in line with the wider range of IC50 
values reported for different HNSCC lines treated with the non-related Src kinase 
inhibitor dasatinib (Johnson et al., 2005) as well as in other tumor cell types (Boyer et 
al., 2002; Johnson et al., 2005; Jones et al., 2002).  These reports taken together with 
our data suggest that the HNSCC lines utilized in this study fall within the typical in vitro 
proliferative response profile to therapeutic Src inhibition.  While the underlying 
compensatory mechanism for saracatinib resistance in 1483 cells is unknown, future 
expression profiling of resistant and sensitive lines may provide insight into the 
molecular nature of saracatinib resistance, as has been recently conducted for the 
EGFR inhibitor gefitinib in a variety of HNSCC lines (Frederick et al., 2007).  
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Saracatinib treatment resulted in in vitro anti-invasive activity, impaired Src activation 
and tyrosine phosphorylation of FAK and p130 CAS in all analyzed HNSCC lines (Fig. 
1D; Fig. 2).  This is in accord with other studies on other HNSCC lines utilizing 
saracatinib or dasatinib as single agents (Johnson et al., 2005; Koppikar et al., 2008; 
Nozawa et al., 2008).  Tyrosine phosphorylation of FAK and p130 CAS have been 
commonly utilized as downstream indicators for preclinical therapeutic anti-Src efficacy, 
since Src-mediated phosphorylation of these proteins are critical events in enabling 
tumor invasiveness (Brabek et al., 2005; Zhao & Guan, 2009). In addition, we show that 
cortactin tyrosine phosphorylation was also reduced following saracatinib treatment 
(Fig. 2).  Cortactin is a Src substrate commonly overexpressed in invasive HNSCC and 
regulates invadopodia formation (Rodrigo et al., 2000; Rothschild et al., 2006; Weaver, 
2008).  Cortactin phosphorylation is important for tumor cell motility and matrix 
degradation at invadopodia (Ayala et al., 2008; Oser et al., 2009; Rothschild et al., 
2006).  These results suggest that cortactin tyrosine phosphorylation status can serve 
as an additional downstream monitor of Src activity and invasive potential in HNSCC 
cells where Src kinase function is impaired.   
While saracatinib was able to modestly decrease the size of in vivo UMSCC1 tongue 
tumors, the reduction in tumor size was not significant compared to untreated controls. 
UMSCC1 cell growth is inhibited by saracatinib in vitro (Fig. 1A), implying that 
microenvironmental factors such as inflammatory cytokines, growth factors, 
neoangiogenic and hypoxic aspects responsible for promoting and maintaining HNSCC 
growth (Pries & Wollenberg, 2006; Timar et al., 2005) may partially circumvent the 
growth-inhibitory effects of saracatinib in UMSCC1 xenografts.  On the other hand, 
saracatinib displays in vivo anti-invasive properties by potently inhibiting perineural 
invasion and cervical lymph node metastasis.  Suppressed Src activation and cortactin 
tyrosine phosphorylation in primary tumors (Fig. 4A) supports this conclusion, as 
signaling through these proteins promotes invasion and metastatic spread (Weaver, 
2008; Yeatman, 2004).  Recent findings in a comparable xenograft system utilizing mice 
treated with dasatinib demonstrated reduced Src and FAK activity (Sen et al., 2009).  
EGFR overexpression is common in HNSCC, resulting in enhanced Src activity, 
cortactin phosphorylation and tumor invasiveness (Koppikar et al., 2008; Rothschild et 
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al., 2006).  Clinical EGFR inhibitors also display anti-invasive activity and impair 
invadopodia formation in preclinical settings (Huang et al., 2002; Yamaguchi et al., 
2005; Yang et al., 2004), suggesting in light of our findings that inhibiting EGFR activity 
in HNSCC impairs Src activation and substrate phosphorylation required for invasion.  
This is supported by emerging rationale for dual targeting of EGFR and Src in treating 
advanced HNSCC (Egloff & Grandis, 2008).  
Elevated Src activity is necessary and essential for invadopodia formation (Chen et al., 
1985; Chen et al., 1984).  The ability of saracatinib to ablate invadopodia and 
associated matrix degradation demonstrates that a clinically utilized Src inhibitor 
disrupts a vital subcellular structure required for tumor invasion.  Src-induced 
invadopodia formation in carcinoma cells first targets cortactin and F-actin formation at 
matrix adhesion sites, forming a core preinvadopodia complex.  Recruitment of MT1-
MMP to preinvadopodia initiates matrix degradation and invadopodia maturation, with 
further maturation involving dissolution of the cortactin-F-actin complex, focal retention 
of MT1-MMP and continued proteolytic activity (Artym et al., 2006).  While rudimentary 
invadopodia-like F-actin structures formed in UMSCC1 cells treated with inhibitory 
concentrations of saracatinib, they do not contain cortactin (Fig. 4A), which is essential 
for invadopodia formation (Artym et al., 2006), indicating that Src kinase activity is 
required for cortactin localization to invadopodia.  Similar results have been shown 
through the use of kinase-inactive Src constructs (Bowden et al., 2006).  Tyrosine 
phosphorylation of invadopodia proteins is strongly linked with the ability to degrade 
extracellular matrix (Bowden et al., 2006), with Src phosphorylation of cortactin (Ayala 
et al., 2008), paxillin (Badowski et al., 2008), and ASAP1 (Bharti et al., 2007) requisite 
for invadopodia formation and/or proteolytic activity.  Src kinase inhibition therefore 
displays at least a two-fold effect on substrates in invadopodia by impairing proper 
preinvadopodia targeting and perturbing phosphotyrosine-based signaling dynamics 
involved in regulating invadopodia maturation and function.  Tyrosine phosphorylation in 
peripheral focal adhesions was observed in UMSCC1 cells, indicating saracatinib may 
also perturb focal adhesion formation and/or function given the critical role for Src and 
related kinases in these structures (Frame, 2004).   
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MMP activity is essential for HNSCC invadopodia formation and function (Clark et al., 
2007).  The impairment of MMP9 secretion and activation from HNSCC cells treated 
with saracatinib indicates that Src kinase activity is required for targeting and secretion 
of MMP9-containing vesicles at invadopodia.  This is in agreement with observed 
effects of Src kinase inhibition on MMP9 secretion in other tumor types (Cortes-
Reynosa et al., 2008; Lee et al., 2005).  The lack of apparent MMP2 secretion in the 
HNSCC lines used in our studies precluded evaluation of this metalloproteinase, and is 
likely characteristic to these lines since other HNSCC cells secrete MMP2 (Clark et al., 
2007).  Localization of transmembrane and secreted MMPs to invadopodia involves 
directed trafficking of vesicles emanating from the trans-Golgi network, where a 
dynamin-2-N-WASp-Arp2/3-cortactin complex has been implicated in coupling cortical 
actin regulation with invadopodia membrane dynamics (Buccione et al., 2004).  
Cortactin has been implicated as a key regulator of MT1-MMP surface expression and 
MMP2 and MMP9 secretion in HNSCC (Clark & Weaver, 2008; Clark et al., 2007).  
While it is currently unknown how cortactin regulates the targeting of MMP-containing 
vesicles, Src-mediated phosphorylation may play a vital role since tyrosine 
phosphorylation of cortactin increases its binding to vesicle-associated proteins (Ammer 
& Weed, 2008) and is required for efficient invadopodia-mediated ECM degradation 
(Ayala et al., 2008; Webb et al., 2007).   
Our results indicate that disruption of Src activity by saracatinib impairs HNSCC cell 
invasion and lymph node metastasis by preventing invadopodia formation and function, 
identifying a cellular mechanism that may be universally impacted by Src inhibition in 
invasive carcinoma cells. In addition to Src and related kinases, saracatinib also inhibits 
Abl kinase, an activity that has been exploited to evaluate imatinib-resistant chronic 
myelogenous leukemia (CML) cases expressing the constitutively active BCR-Abl 
Philadelphia chromosome gene product (Gwanmesia et al., 2009).  Along with the 
tumor-promoting activities in CML, elevated Abl kinase activity has been shown to be 
important in breast (Srinivasan & Plattner, 2006) and non small cell lung cancer (Lin et 
al., 2007), indicating Abl kinase activity has a functional role in solid tumor progression 
(Lin & Arlinghaus, 2008).  Abl expression has been evaluated in oral squamous cell 
carcinoma and correlates with tumor stage (Yanagawa et al., 2000), suggesting that 
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elevated Abl expression may contribute to HNSCC progression.  While a mechanism 
pertaining to Abl function in solid tumor invasion or invadopodia function has not been 
reported, Abl does bind and phosphorylate cortactin, (Boyle et al., 2007), raising the 
potential for Abl kinase to play a role in cortactin-based invadopodia function in HNSCC 
and other invasive Abl-expressing solid tumors.  Such a role for Abl in regulating tumor 
invasion would also likely be impaired by saracatinib and other dual Src/Abl inhibitory 
compounds.  
In addition to carcinoma invadopodia, Src-mediated processes in non-cancerous cell 
types involved in promoting invasion may also be impacted by Src family kinase 
inhibition.  The motility and protease remodeling ability of tumor stromal fibroblasts 
involved in enabling collective HNSCC invasion could be affected by impairing Src 
family kinases in vivo (Gaggioli et al., 2007), as well as the proinvasive properties of 
tumor-associated macrophages (Condeelis & Pollard, 2006). The ability of saracatinib 
and other Src inhibitors to impair functions of different cellular types that propagate 
tumor invasion provides the opportunity for the future discovery of additional Src-based 
cellular mechanisms utilized during tumor progression. 
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Figure Legends  
Figure 1  Effects of saracatinib on HNSCC proliferation, cell cycle progression, Erk1/2 
activation and in vitro invasion.  A. IC50 values for cell growth determined by 5 day MTT 
assays for the indicated HNSCC lines treated with 0-10 µM saracatinib.  Mean values 
are shown for each line from three independent assays.  B. Impact of saracatinib on 
HNSCC cell cycle progression.  HNSCC cell lines were treated with the indicated 
amounts of saracatinib for 24 hours, fixed labeled with propidium iodide to assess DNA 
content, and analyzed for cell cycle status by fluorescence-activated cell sorting.  
Results show the average percentage of cells in each cell cycle phase as indicated on 
the left. Bars, SD of two independent experiments.  C. Effects of saracatinib on Erk1/2 
activity.  HNSCC cells were treated with saracatinib for 24 hours at the indicated doses, 
lysed and analyzed by Western blotting with phosphorylation-specific (pErk1/2) and total 
Erk1/2 antibodies.  Blots shown are representative of three different experiments, with 
indicated band intensities shown relative to no treatment (0 µM) for each cell line.  D. 
Saracatinib inhibits in vitro HNSCC invasion. HNSCC cells (1x105) were plated in 
Matrigel-coated transwells alone or with increasing concentrations of saracatinib.  After 
2 h, invasion was stimulated with 5% FBS and cells were allowed to invade for 12 h 
(UMSCC1) or 24 h (HN31 and 1483).  Invaded cells were quantified by brightfield 
microscopy. Bars, SEM of three independent experiments. 
Figure 2  Saracatinib inhibits Src activity and downstream Src substrate 
phosphorylation in HNSCC cell lines.  HN31, UMSCC1 and 1483 cells were treated with 
DMSO vehicle or saracatinib (0.01-1 μM) for 24 h.  Cells were lysed and total protein 
amounts were analyzed by Western blotting with total or phosphorylation site-specific 
antibodies for Src and the indicated substrates.  Blots shown are representative of at 
least four independent experiments, with band intensities for each substrate quantified 
relative to the untreated (0 µM) condition for each cell line.   
Figure 3  Saracatinib inhibits Src activity, perineural invasion and cervical lymph node 
metastasis in orthotopic UMSCC1 tongue tumors.  A. UMSCC1 tongue tumors from 
representative control-treated or saracatinib-treated mice were sectioned and stained 
with hematoxylin and eosin (H&E) or by IHC with the indicated antibodies (left).  A case 
139 
 
of human HNSCC was evaluated in parallel as a positive control.  The pY416 SFK and 
pY421 cortactin ratios from saracatinib treated to control levels are indicated.  Bars, 100 
μm.  B. Locoregional invasion and lymph node metastasis is inhibited by saracatinib. 
Submental and associated tracheoesophageal tissue from control treated and 
saracatinib treated mice was immunostained for cytokeratin 14 to detect cells of 
epithelial origin.  Magnified regions containing a single sublingual nerve and superficial 
cervical lymph node are shown for clarity. Inset shows a magnified cortical region of 
superficial cervical lymph nodes from control and saracatinib treated mice.  Arrowheads 
denote metastasized UMSCC1 cells.  N; sublingual nerve, ED; excretory duct. Bars 100 
μm; inset, 50 μm. 
Figure 4  Saracatinib inhibits invadopodia formation and ECM degradation.  A. 
Representative images of UMSCC1 cells treated with different saracatinib 
concentrations. UMSCC1 cells plated on FITC-gelatin coated coverslips (pseudocolored 
white) for 2 h were treated with saracatinib as indicated (left) for 6 h.  Cells were labeled 
to visualize F-actin (red), cortactin (green) and phosphotyrosine (blue).  Arrows denote 
invadopodia and corresponding colocalized areas of focal matrix degradation with 
invadopodia components.  Treatment with 1.0 μM saracatinib resulted in F-actin 
aggregates lacking cortactin but accumulated at cytoplasmic sites where invadopodia 
typically occur (arrowheads).  Bar, 10 μm.  B. UMSCC1 cells treated with increasing 
concentrations of saracatinib were stained as in A and quantified to determine the 
percentage of cells that produced functional invadopodia, presented as the mean ± 
SEM.  All treatment groups were significantly different from each another based on a 
one-way ANOVA (p<0.05) except 0 and 0.01 μM, and 0.5 and 1.0 μM pairs.  C. 
Saracatinib decreases the ability of UNSCC1 cells to degrade ECM.  The percentage of 
gelatin degradation per cell area for the cell population analyzed in B is shown with the 
mean ± SEM.  
Figure 5  MMP9 secretion and ECM degradation activity in HNSCC cells is blocked by 
saracatinib.  A. Localization of MMP9-containing vesicles in UMSCC1 invadopodia.  
Top: UMSCC1 cells plated on FITC-coated gelatin coverslips for 2 h were fixed and 
labeled with antibodies against cortactin and MMP9.  The merged image indicates 
140 
 
areas of cortactin and MMP9 co-localization (yellow; white arrows) that correspond with 
sites of focal gelatin degradation (black arrows).  Bar; 10 µm, Asterisk; regions of global 
matrix degradation due to secreted protease activity. Bottom: Magnified view of 
indicated Top region.  B. Inhibition of MMP9 secretion by saracatinib.  Total cell lysates 
(cell) and aliquots of normalized conditioned media containing secreted MMPs (sec) 
from 1483 and UMSCC1 cells treated with increasing doses of saracatinib (bottom) 
were assayed for the presence of MMP2 and MMP9 by immunoblotting.  Band 
intensities relative to control (0 µM) are shown for each treatment condition; secreted 
MMP2 was not detected and therefore not quantified.  C. Gelatin zymography of MMP9 
activity.  Representative zymograms from conditioned media of 1483 or UMSCC1 cells 
cultured with the indicated saracatinib concentrations (bottom).  DMEM was used as a 
negative control (M), DMEM containing 10% FBS (FBS) was used as a positive control 
for zymography. Graphs, densitometric analysis of MMP9 zymography.  Percentage of 
MMP9 gelatin clearing is represented and the mean ± SEM for each cell line from three 
independent experiments. 
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Supplementary Figure Legends 
Supplementary Figure 1  Specificity of human anti-pY421 cortactin antibody.  SYF 
fibroblasts lacking Src, Yes and Fyn were cotransfected with a the temperature-
sensitive Src allele La29 along with expression vectors encoding recombinant wild-type 
human cortactin (WT) or cortactin mutants containing tyrosine-phenylalanine 
substitutions at the indicated Src-targeted codons and held at the non-permissive 
temperature (41º) or switched to the permissive temperature (35°).  TYM; triple tyrosine-
phenylalanine cortactin mutant lacking all three Src-targeted sites.  Cells were lysed and 
analyzed by Western blot analysis with anti-pY421 cortactin (left).  The blot was stripped 
and reprobed with anti-cortactin monoclonal antibody 4F11 (right).  The position of 
molecular weight markers is noted on the left in kilodaltons.  
147 
 
 
Study 3: Cortactin Phosphorylated by ERK1/2 Localizes to 
Sites of Dynamic Actin Regulation and is Required for 
Carcinoma Lamellipodia Persistence 
 
 
Laura C. Kelley1,2, Karen E. Hayes1,2, Amanda Gatesman Ammer1,2, Karen H. Martin1 
and Scott A. Weed1* 
 
1Department of Neurobiology and Anatomy, Program in Cancer Cell Biology, Mary Babb 
Randolph Cancer Center, West Virginia University, Morgantown, West Virginia, United 
States of America 
 
 
 
Published in Plos One 2010 Nov;5(11):e1384, 1-13. 
 
 
 
 
*Corresponding author:  
Scott A. Weed  
West Virginia University  
Mary Babb Randolph Cancer Center  
Morgantown, WV 26506-9300  
Phone: 304-293-3016  
Fax: 304-293-4667  
Email: sweed@hsc.wvu.edu  
 
2Note: These authors contributed equally to this manuscript  
Running title: ERK1/2 regulates cortactin  
148 
 
Abstract  
Background  
Tumor cell motility and invasion is governed by dynamic regulation of the cortical actin 
cytoskeleton.  The actin-binding protein cortactin is commonly upregulated in multiple 
cancer types and is associated with increased invasion and metastasis.  Cortactin 
regulates actin nucleation through the actin related protein (Arp)2/3 complex, stabilizing 
the cortical actin cytoskeleton.  Cortactin is regulated by multiple phosphorylation 
events, including phosphorylation of S405 and S418 by extracellular regulated kinase 
(ERK)1/2.  ERK1/2 phosphorylation of cortactin has emerged as an important positive 
regulatory event, enabling cortactin to bind and activate the Arp2/3 regulator neuronal 
Wiskott-Aldrich syndrome protein (N-WASp), promoting actin polymerization and 
enhancing cell migration and tumor cell invasiveness.  
Methodology/Principal Findings  
In this report we have developed phosphorylation-specific antibodies against cortactin 
phosphorylated at S405 and S418 to analyze the subcellular localization of this cortactin 
form in tumor cells and patient samples by microscopy.  We evaluated the interplay 
between cortactin S405 and S418 phosphorylation with cortactin tyrosine 
phosphorylation in regulating cortactin conformational forms by Western blotting.  
Cortactin is simultaneously phosphorylated at S405/418 and Y421 in tumor cells, and 
through the use of point mutant constructs we determined that serine and tyrosine 
phosphorylation events lack any co-dependency.  Expression of S405/418 
phosphorylation-null constructs impaired carcinoma motility and adhesion, and also 
inhibited lamellipodia persistence monitored by live cell imaging. 
Conclusions/Significance  
Cortactin phosphorylated at S405/418 is localized to sites of dynamic actin assembly in 
tumor cells.  Concurrent phosphorylation of cortactin by ERK1/2 and tyrosine kinases 
enables cells with the ability to regulate actin dynamics through N-WASp and other 
effector proteins by synchronizing upstream regulatory pathways, confirming cortactin 
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as an important node in actin-based signal transduction. Reduced lamellipodia 
persistence in cells with S405/418A expression identifies an essential motility-based 
process reliant on ERK1/2 signaling, providing additional understanding as to how this 
vital signaling pathway impacts tumor cell migration.  
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Introduction  
Tumor cell motility and invasion is a central problem in cancer that is paramount in 
contributing to metastasis [1].  Tumor cells move through successive series of 
coordinated and integrated stages, with formation of protrusive membranous structures 
including filopodia, invadopodia and lamellipodia required for initiation and maintenance 
of invasion and migration [2,3,4,5].  Central to the movement of most carcinoma cell 
types undergoing single or collective migration is the production of lamellipodia at the 
leading edge of the cell.  Lamellipodia are planar protrusive extensions of the plasma 
membrane produced by motile cells in two- and three-dimensional settings [6].  
Lamellipodia extension drives cell migration through integrin-based adhesion with the 
underlying substratum, providing the necessary traction for contractile-based 
translocation of the cell body to generate productive movement [7].  It is generally 
accepted that dynamic regulation of the cortical actin cytoskeleton through cycles of 
actin polymerization and depolymerization are responsible for generating the propulsive 
force needed for lamellipodia extension [8].  
The actin cytoskeleton within lamellipodia is governed by the activity of numerous actin- 
binding proteins.  One element central to the formation of lamellipodia actin networks is 
activation of the actin-related (Arp) 2/3 complex, which nucleates filamentous (F-) actin 
polymerization within lamellipodia [9].  Arp2/3 complex binds to the sides of pre-existing 
F-actin, where upon activation the Arp2 and Arp3 subunits mimic the fast growing 
(“barbed” or “+”) end of an actin filament, allowing for the rapid addition of actin 
monomers to the complex and subsequent filament extension [4]. The resulting Arp2/3- 
F-actin networks comprise an organized branched array of F-actin filaments that 
contribute to lamellipodia extension, with Arp2/3 localized at filament branch points 
[8,9].  Arp2/3 branch points are metastable, allowing for rapid breakdown of Arp2/3-F- 
actin networks by filament debranching [10].  Debranched F-actin filaments are further 
disassembled through the severing activity of members of the actin depolymerizing 
factor/cofilin family, which ultimately dissolve F-actin filaments to promote 
depolymerization, recycling actin monomers for additional rounds of polymerization and 
lamellipodia extension [11].  
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Arp2/3 activation is controlled by the activity of several actin nucleation promoting 
factors (NPFs).  The best characterized NPFs to date are members of the Wiskott- 
Aldrich syndrome protein (WASp) family, which include the WASp and WAVE protein 
subgroups [12,13].  In many cell types, regulation of Arp2/3 activity by the WASp 
proteins N-WASp and WAVE2 are largely responsible for generating the actin network 
used for creating and regulating lamellipodia, filopodia and invadopodia [4,12,14], 
making these NPFs critical mediators of cell motility and invasion.  
Another well-characterized NPF independent of the WASp protein family is the cortical 
actin-binding protein cortactin [15,16].  Cortactin directly binds Arp2/3 complex [17,18] 
and activates Arp2/3 complex nucleation activity in vitro, albeit at a lesser degree than 
WASp-family proteins [18,19].  In addition to actin nucleation, a unique function of 
cortactin is its ability to prevent spontaneous debranching of Arp2/3-F-actin networks by 
simultaneous binding to Arp2/3 and F-actin, prolonging the lifetime of branched 
filaments [19].  While the biochemical features of cortactin seem to point to a 
straightforward role in lamellipodia actin regulation, studies of cortactin function in 
lamellipodia have proven controversial, suggesting to a more complex role in cell 
migration.  For instance, RNA interference studies have yielded conflicting results in 
regards to lamellipodia dynamics, with cortactin knockdown resulting in decreased 
lamellipodia stability and reduced persistence [20,21,22], whereas similar studies in 
different cell types suggest cortactin downregulation increases the length of extending 
lamellipodia [23].  Furthermore, recent analysis of fibroblast lamellipodia dynamics in 
cortactin-/- cells indicates that cortactin does not play a role in directly regulating 
lamellipodia protrusion or Arp2/3-based actin dynamics, but rather is important in 
mediating upstream activation of the small GTPases Rac1 and Cdc42, which in turn 
regulate WAVE2 and N-WASp activity [24].  While these reported discrepancies 
regarding cortactin function in lamellipodia have yet to be fully reconciled, it is clear that 
cortactin is an important regulator for normal and tumor cell migration in many cell 
systems [25,26].  An unambiguous role for cortactin has been shown in invadopodia, 
where removal of cortactin by RNA interference ablates invadopodia formation in 
multiple invasive tumor cell types [27,28,29].  
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Besides regulating Arp2/3-based cortical actin networks by direct interactions, cortactin 
also functions as a key mediator in several kinase-based signal transduction cascades 
that serve to indirectly govern Arp2/3 activity and subsequent cell movement.  Cortactin 
is a well-defined target for Src kinase [30], phosphorylating human cortactin on tyrosine 
residues Y421, Y470 and Y486 within the proline-rich (PR) carboxyl-terminal domain 
[31].  Several other tyrosine kinases target these residues [32,33,34,35], indicating that 
they collectively form a “hot spot” region as a point of convergence for multiple signaling 
pathways.  Cortactin phosphorylated at tyrosines 421, 470 and/or 486 creates Src 
homology (SH)2 docking sites for several phosphorylating kinases, as well as the 
adaptor proteins Crk [36] and Nck1 [37].  In the case of Nck1, Nck1/cortactin complexes 
interact with N-WASp or WASp interacting protein through the Nck1 SH3 domain to 
stimulate Arp2/3-dependent actin nucleation [37], which in cooperation with Arg kinase 
has been recently demonstrated to be important for regulating lamellipodia protrusion 
and leading edge adhesion formation [38].  The cortactin/Nck1 complex is also required 
to stimulate actin polymerization essential for invadopodia function in invasive breast 
cancer cells [39].  These studies are in agreement with the localization of tyrosine 
phosphorylated cortactin within lamellipodia and invadopodia [40], lending mechanistic 
insight into the long recognized pro-migratory and pro-invasive properties associated 
with cortactin tyrosine phosphorylation [29,31,41,42].  
In addition to tyrosine phosphorylation, cortactin is a target for multiple serine/threonine 
kinases [43].  Stimulation of tumor cells with epidermal growth factor (EGF) results in 
increased serine/threonine phosphorylation of serine residues 405 and 418 within the 
PR domain, coincident with a characteristic shift in cortactin electrophoretic mobility 
from 80 kDa to 85 kDa in SDS-PAGE [44,45].  The mobility shift and phosphorylation of 
S405/S418 are impaired by pharmacologic inhibition of mitogen activated 
protein/extracellular signal regulated kinase kinase (MEK)1/2, and direct biochemical 
evidence indicates that the MEK effector kinases ERK1/2 directly phosphorylate 
cortactin at these sites [45].  Phosphorylation of S405/S418 enhances binding of the 
cortactin carboxyl-terminal SH3 domain to N-WASp and activates N-WASp NPF activity, 
indicating a functional role in stimulating Arp2/3-mediated actin dynamics independent 
of tyrosine phosphorylation [46].  This is supported by studies expressing 
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phosphorylation-null and phosphomimetic point mutant constructs in cells, suggesting 
that S405/S418 phosphorylation plays a critical role in regulating cellular actin 
polymerization necessary to promote cell motility [47] and invadopodia function [29].  In 
addition, p21 activated kinase 1 (PAK1) phosphorylates cortactin at S405/S418, serving 
to stimulate N-WASp activity required for clathrin-independent endocytosis [48].  While 
studies to date implicate a positive regulatory function for cortactin S405/418 
phosphorylation in promoting N-WASp-mediated Arp2/3 actin structures, the subcellular 
localization of phosphorylated S405/418 cortactin, as well as the precise role S405/418 
phosphorylation plays in regulating lamellipodia dynamics have not been evaluated.  
In this study, we have generated site-specific antibodies against phosphorylated 
cortactin S405 and S418 to determine the spatial and temporal localization of cortactin 
in dynamic actin structures and human tumors, and to evaluate signaling interplay 
between cortactin tyrosine and serine phosphorylation events.  We also determined the 
effects of S405/418 cortactin phosphorylation on EGF-induced cell migration, adhesion 
and lamellipodia dynamics in carcinoma cells.  
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Materials and Methods  
DNA Constructs and siRNA  
For Myc-tagged human cortactin expression constructs, the wild-type human cortactin 
cDNA subcloned into pcDNA FLAG2AB [49] was used as a template for producing point 
mutants by site-directed mutagenesis (QuickChange; Stratagene, La Jolla, CA). Codon 
alterations in human cortactin were: S405A, S418A, S405A/S418A, Y421F, Y470F, 
Y486F, Y421F/Y470F/Y486F and W492K. Cortactin cDNAs were amplified by PCR as 
BamHI-EcoRI fragments and subcloned into BamHI-EcoRI digested pRK5Myc [50].  
Murine GFP-tagged expression constructs were produced using pcDNA3FLAG2AB 
wild-type murine cortactin [17] as the template for mutagenesis, then subcloned as 
EcoRI-KpnI PCR fragments into pAcGFP-C1 (Clontech, Mountain View, CA).  The 
temperature-sensitive vSrc LA29 construct was previously described [51].  mCherry-β- 
actin was obtained from D. Schafer (University of Virginia), with the parent construct 
produced by R. Tsien (University of California, San Diego).  Small interfering (si)RNA 
targeting rodent cortactin (5’-GCTTCGAGAGAATGTCTTC-3’) was purchased from 
Thermo Scientific (Waltham, MA)  
Cell lines and Transfection  
The HNSCC cell lines 1483 [52], UMSCC1 and UMSCC2 [53] were maintained as 
described [41].  SYF cells were obtained from the American Type Culture Collection 
(Manassas, VA) and maintained according to the supplied protocol.  The rat mammary 
adneocarcinoma line MTLn3 was maintained in aMEM supplemented with 10% fetal 
bovine serum, 1% L-glutamine and 1% penicillin-streptomycin.  Transient transfections 
were conducted with 3 x 106 cells and 2µg of plasmid construct or siRNA using the 
Nucleofector I device (Amaxa Biosystems, Berlin, Germany).  
Antibodies  
Antibodies against phosphorylated serine 405 (pS405) and serine 418 (pS418) of 
human cortactin were produced by 21st Century Biochemicals (Marlboro, MA).  
Synthetic phosphorylated cortactin peptides containing the sequences NH2- 
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KTQTPPV[pS]PAPQPTC-COOH (cortactin pS405) and NH2-TEERLPS[pS]PV-COOH 
(cortactin pS418) were produced, conjugated to keyhole limpet cyanine and injected 
into rabbits.  Immune serum was screened by enzyme-linked immunosorbent assay 
against the appropriate phosphorylated cortactin peptide coupled to bovine serum 
albumin.  High-titer bleeds were identified for each peptide, and immune serum was 
passed two successive times through chromatography columns containing agarose 
beads coupled to the equivalent non-phosphorylated peptide.  The flow through material 
for each peptide was subsequently passed twice through chromatography columns 
containing beads conjugated to the matched phosphorylated cortactin peptide.  After 
extensive washing, bound antibodies for each phosphorylation site were eluted, 
concentrated and screened for specificity by Western blotting against recombinant 
cortactin mutant proteins harboring alanine-serine point mutations at serine 405 or 418, 
respectively (Fig. 1A).  The anti-pS405 and anti-pS418 cortactin antibodies are currently 
available through Protea Biosciences (Morgantown, WV).  Anti-cortactin (4F11) was 
used as described [41].  Anti-pY421 cortactin and anti-pY418 Src were from Invitrogen 
(Carlsbad, CA).  Anti-ERK1/2 and pERK1/2 were from Cell Signaling (Danvers, MA).  
Anti-Myc epitope tag (4A6) was from Millipore (Billerica, MA). Anti-GFP (JL-8) was 
fromClontech (Mountain View, CA) and anti-β-actin was from EMD4Biosciences (San 
Diego, CA).  
Western blotting and Immunoprecipitation  
Western blotting was conducted as described [41].  Primary antibody dilutions used 
were: anti-pS405 cortactin (1:4000), anti-pS418 cortactin (1:500), anti-cortactin 
(1:1000), anti-pY-421 cortactin (1:2000), anti-ERK1/2 (1:2000), anti-pERK (1:2000), 
anti-pY418 Src, anti-GFP (1:1000) and anti-β-actin (1:5000).  Immunoprecipitations 
were performed as described [40] using 5µg of precipitating antibody captured with 40µl 
of a 50% Protein A/G bead slurry (Thermo Fisher Scientific, Pittsburgh, PA).  In some 
cases cells were treated with selumetinib (AZD6244; ARRY-142886) or saracatinib 
(AZD0530) for 24h prior to immuoprecipitation and Western blotting analysis.  
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Microscopy  
UMSCC2 cells were plated on fibronectin-coated coverslips (10µg/ml; Sigma, St Louis, 
MO) and allowed to attach before serum starvation for 16 h.  Cells were stimulated with 
100ng/ml EGF (Millipore) for 1h before fixation.  UMSCC1 cells plated on FITC-gelatin 
(Sigma) for 8 h were processed for confocal microscopy using Zeiss LSM 510 Meta 
system (Thornwood, NY) as described [49].  Anti-pS418 cortactin was used at 1:1000, 
4F11 at 1:500 and rhodamine-conjugated phalloidin at 1:1000 (Invitrogen, Carlsbad, 
CA).  
For immunohistochemistry, HNSCC tissue blocks were obtained from the West Virginia 
University Tissue Bank and used under approval of the West Virginia University 
Institutional Review Board.  Five-micrometer sections from formalin-fixed, paraffin- 
embedded blocks were processed for immunostaining using the Discovery XT 
automated staining system (Ventana, Tucon AZ).  Briefly, after deparaffinization and 
antigen retrieval, sections were incubated with monoclonal rabbit anti-cortactin (Novus, 
Littleton, CO) at 1:2000, anti-pS418 cortactin at 1:25 and anti-pERK1/2 at 1:100 
dilutions.   All primary antibodies were incubated in Dako diluent (Dako, Carpinteria, CA) 
for 1 h.  Primary antibodies were detected with the Omnimap antibody horseradish 
peroxidase kit (Ventana).  Slides were counterstained with hematoxylin and post- 
counterstained with bluing reagent (Ventana). Images were visualized with an Olympus 
AX70 microscope and captured using the MicroBrightfield system (Williston, VT).  
Live cell imaging was conducted using MTLn3 cells starved for 3 h with serum-free 
media prior to stimulation with 100ng/ml EGF.  Cells were plated on delta-T glass 
bottom dishes (Fisher) coated with 10µg/ml fibronectin (Sigma).  Immediately following 
EGF addition, cells were imaged by differential interference contrast using a Nikon 
TE2000 inverted microscope equipped with a Roper CoolSNAP HQ charge-coupled 
device camera (Photometrics, Tucson, AZ).  Images were captured every 5 s for 15 min 
(181 total frames).  A Nikon LiveScan SFC swept field microscope was used for imaging 
cells expressing mCherry-actin.  In all cases, GFP-cortactin expressing cells were 
identified by fluorescence microcopy prior to imaging.  Kymograms were produced by 
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extracting 1 pixel-width strips from each movie frame at points of initial and maximal 
lamellipodia extension, and assembled using ImageJ (v1.40).  
Electric Cell Substrate Impedance Sensing  
To assay cell motility and adhesion, 5 x 105 cells were plated into 8-well electric cell 
substrate impedance sensing dishes (ECIS; Applied Biophysics, Troy, NY).  For motility 
measurements, cells were allowed to adhere overnight on 8W1E dishes to form a 
monolayer.  Adhesion was assayed immediately after plating cells onto 8W10E dishes.  
Measurements were conducted for 24 h at 45kHz, with reading taken at 1 min intervals.  
Cells treated with selumetinib were serum starved 24 h in the presence of drug prior to 
ECIS.  
Statistical Analysis  
Differences in mean groups for migration, adhesion and kymography between control 
and treated groups were evaluated using one way ANOVA, followed by Student- 
Newman-Keuls post hoc testing.  All differences were considered significant at p< 0.05.  
A minimum of three experimental groups were used for all analyses. 
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Results  
 
Localization of pS418 cortactin with dynamic cortical actin structures  
We developed antibodies specific to phosphoserine 405 (pS405) and phosphoserine 
418 (pS418) of human cortactin to facilitate analysis of these sites.  To validate antibody 
specificity, epitope (Myc)-tagged cortactin constructs containing wild-type (WT) 
cortactin, cortactin with individual serine to alanine mutations at serine 405 (S405A), 
418 (S418A) or with both mutated in tandem (S405,418A) were produced and 
transfected into 1483 cells.  Total cell lysates were blotted with anti-pS405 or anti- 
pS418 antibodies (Figure 1A).  The anti-pS405 antibody recognized the WT and S418A 
cortactin variants, failing to blot constructs containing the S405A mutation.  Conversely, 
anti-pS418 blotted WT and S405A, failing to recognize cortactin constructs with S418A 
mutations.  All cortactin variants were recognized by an anti-cortactin monoclonal 
antibody (Figure 1A), indicating equivalent expression of the assayed constructs.  
These results indicate that the anti-pS405 and anti-pS418 antibodies specifically 
recognize their cognate phosphorylated cortactin epitope, and that no interdependence 
exists between phosphorylation of cortactin S405 and S418.  
To determine the subcellular localization of serine phosphorylated cortactin, we 
conducted indirect immunofluoresence studies on cells producing lamellipodia and 
invadopodia, two actin-based structures that depend in part on N-WASp activity.  While 
the anti-pS405 antibody yielded non-specific staining in our hands (data not shown), 
anti-pS418 specifically labeled lamellipodia and cytoplasmic puncta (presumably 
vesicles) in UMSCC2 cells.  In cells with a motile phenotype, anti-pS418 localized with 
cortactin and F-actin in these regions (Figure 1B, top row).  Labeling of UMSCC1 cells 
plated on FITC-coated gelatin matrix with anti-pS418 indicated specific localization to a 
subset of invadopodia that coincided with cortactin, F-actin and areas of gelatin clearing 
indicative of matrix metalloproteinase mediated invadopodia activity (Figure 1B, middle 
and bottom rows).  
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In solid human tumors, cortactin and cortactin phosphorylated on tyrosine 421 (pY421) 
localizes to invasive tumor fronts and to cell-cell junctions [41,49].  To determine the 
location of pS418 cortactin in tumor tissue, head and neck squamous cell carcinoma 
(HNSCC) cases were sectioned and stained with anti-pS418 (Figure 1C).  Cortactin 
pS418 was abundant in HNSCC cell cytoplasm and was enriched in areas of cell-cell 
contact, displaying a pattern similar to sections labeled with a total cortactin antibody 
(Cort).  These tumor regions also contained activated ERK1/2, as evidenced by 
pronounced cytoplasmic and nuclear staining of phosphorylated ERK1/2 in serial 
sections (Figure 1C).  
 
Growth factor mediated phosphorylation of cortactin S405/418 is MEK dependent  
Previous biochemical work has implicated chemical inhibition of MEK and subsequent 
blocking of ERK1/2 activation as a major pathway responsible for cortactin S405/418 
phosphorylation [45].  To further evaluate the role of the MEK-ERK1/2 pathway on 
cortactin phosphorylation, we utilized the anti-pS405 and pS418 cortactin antibodies to 
directly test the effects of MEK inhibition on cortactin pS405/418.  Western blot analysis 
of cell extracts from EGF- and serum-stimulated UMSCC1 cells with anti-pS405 and 
pS418 antibodies displayed similar phosphorylation kinetics of S405 and S418, with 
phosphorylation of both sites first evident 10 min after stimulation (Figure 2A) and 
remaining phosphorylated up to 2 h (data not shown).  Treatment of UMSCC1 or 1483 
cells with the small molecule MEK inhibitor selumetinib [54] reduced EGF-stimulated 
cortactin S405/418 phosphorylation in a dose-dependent manner, where near 
elimination of phosphorylation at both serine residues occurred at doses > 1µM (Figure 
2B).  ERK1/2 activity was also reduced under similar dose conditions, although 
complete ablation of ERK1/2 phosphorylation was observed at doses > 5µM (Figure 
2B).  These data suggest that the MEK-ERK pathway is largely responsible for growth- 
factor induced cortactin S405/418 phosphorylation in HNSCC cells, in agreement with 
previous findings in other cell types [45].  
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The 80kDa to 85kDa cortactin conformational shift is associated with serine and 
tyrosine phosphorylation  
Based on sequence analysis, the largest and most prominent cortactin isoform 
(cortactin “A” or “SV1”) encodes a 61.5kDa protein [55,56].  This cortactin form 
frequently migrates as an 80/85kDa doublet in SDS-PAGE [30,57] that has been 
attributed to conformational alterations within the polypeptide chain [15,45].  Shifting 
from the 80kDa to 85kDa form is seen in response to EGF, with the resulting 85kDa 
band associated with S405/418 phosphorylation [44,45].  To directly assess the 
presence of pS405/418 in the two cortactin conformational isomers, serum-starved 
UMSCC2 (Figure 3A) and 1483 (Figure 3B) cells were stimulated with EGF and the 
cortactin forms in cell lysates were analyzed at successive time points with anti-pS405 
and anti-pS418 antibodies.  S405/418 phosphorylation was maintained in the 85kDa 
cortactin form in both cell lines following serum starvation, despite of the lack of ERK1/2 
activity (0 min, Figure 3A and Figure 3B).  EGF stimulation resulted in complete 
conversion of the 80kDa to the 85kDa cortactin form by 1 h after EGF treatment in both 
cell lines (Figure 3A and Figure 3B).  Cortactin pS405 and pS418 was observed 
primarily in the 85kDa form and increased at both sites during the entire time course, 
whereas ERK1/2 activity peaked at 15 min and rapidly declined afterwards (Figure 3A 
and Figure 3B).  Interestingly, the phosphorylation of S405 was also associated with an 
increase appearance of cortactin degradation in UMSCC2 cells (Figure 3A).  It is 
uncertain whether these products represent increased overall cortactin degradation, or if 
the net cortactin degradation is constant but is selectively identified by the pS405 
antibody in response to EGF treatment and phosphorylation.  EGF-induced Src 
activation and cortactin pY421 phosphorylation was sustained throughout the entire 
time course in UMSCC2 cells (Figure 3A), indicating that cortactin can be 
simultaneously phosphorylated by ERK1/2 and Src or potentially other EGF-stimulated 
cortactin tyrosine kinases.  Pretreatment of UMSCC2 cells with the Src family kinase 
inhibitor saracatinib at 10µM or selumetinib at 1µM completely impaired the cortactin 
shift from 80kDa to 85kDa (Figure 3C).  The exclusive presence of pS405 and pS418 in 
the EGF-induced 85kDa cortactin form, as well as the ability of MEK inhibition to impair 
the cortactin shift is consistent with results obtained from previous work [45].  Our 
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results also identified EGF-induced Src-mediated phosphorylation of cortactin at 
tyrosine 421 as a necessary mediator of the cortactin shift.  
Cortactin serine phosphorylation in vivo is independent from tyrosine 
phosphorylation  
EGF treatment of UMSCC2 cells resulted in phosphorylation of cortactin S405/418 and 
cortactin pY421 (Figure 3A).  A previous in vitro study evaluating the impact of cortactin 
phosphorylation on N-WASp activation determined that S405/418 phosphorylation by 
ERK1/2 enables the cortactin SH3 domain to stimulate N-WASp Arp2/3 activation, while 
Src phosphorylation downregulates N-WASp activity and counteracts the effects of 
S405/418 phosphorylation [46].  This proposed “on-off switch” postulates that cortactin 
serine and tyrosine phosphorylation are mutually exclusive events governing the ability 
of cortactin to regulate N-WASp activity and downstream actin reorganization [58].  
Using the available antibodies reactive against cortactin pS405 and pY421, we sought 
to determine if these two different classes of phosphorylation events are interdependent 
in any manner.  Cortactin depleted SYF fibroblasts (null for the Src, Yes and Fyn 
kinases) were co-transfected with the temperature-sensitive vSrc construct tsLa29-GFP 
[51] to activate the Src and ERK1/2 signaling pathways, along with constructs encoding 
wild-type cortactin or the following Myc-tagged cortactin mutants: Y421F, Y470F, 
Y486F, Y421/Y470/Y486F (TPM), S405A, S418A, S405/418A (Figure 4A).  A W492K 
cortactin mutant was also included, as this mutant abolishes the ability of the cortactin 
SH3 domain to interact with corresponding SH3 binding proteins [59].  After shifting to 
35ºC for 2 h to activate tsLa29-GFP, the serine and tyrosine cortactin mutants were 
analyzed for phosphorylation at Y421 and S405 by SDS-PAGE and Western blotting 
(Figure 4B).  Mutations to S405 and S418 alone and in combination did not impact the 
ability of these constructs to be phosphorylated on Y421, as indicated by their 
recognition with the anti-pY421 antibody (Figure 4B).  Similarly, mutations to Y421, 
Y470, and Y486, alone and in combination (TYM) did not affect the ability of these 
constructs to be phosphorylated on S405.  These data indicate that cortactin is 
simultaneously phosphorylated at S405 and Y421 downstream of vSrc activation, 
suggesting in this system that phospho-regulation of cortactin SH3 domain function is 
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not governed in vivo by the serine-tyrosine “on-off switch” mechanism proposed from 
previous in vitro experimentation [46,58].  
S405/418 phosphorylation is required for efficient tumor cell motility and 
adhesion  
To evaluate the role of cortactin S405/418 phosphorylation on carcinoma cell migration, 
1483 and UMSCC1 cells were treated with selumetinib and assayed for effects on 
motility by ECIS (Figure 5).  Selumetinib treatment impaired the motility of both cell 
types in a dose-dependent manner, corresponding to the observed decreases in 
S405/418 phosphorylation (Figure 2B).  Since MEK inhibition likely impaired the 
phosphorylation of other proteins involved in motility in addition to cortactin, we directly 
assessed the impact of cortactin S405/418 phosphorylation on cell migration using 
phosphorylation-null cortactin expression constructs.  MTLn3 rat mammary 
adneocarcinoma cells were initially transfected with a siRNA targeted against rodent 
cortactin, followed by transfection with GFP-tagged human wild-type (WT), S405A, 
S418A and S405/418A cortactin constructs.  Cortactin siRNA reduced endogenous 
cortactin levels to > 90%, having no impact on expression of the human GFP-labeled 
variants (Figure 6A).  MTLn3 cells with cortactin knockdown (si) displayed a 29% 
reduction in motility compared to control (Ctl) (Figure 6B).  Expression of wild-type 
human GFP-cortactin (WT) led to a 2-fold increase in motility, presumably due to 
increased expression of this variant over endogenous (Ctl) levels (Figure 6A).  
Expression of S405A, S418A or S405,418A cortactin resulted in an 49% average 
decrease in cell migration for each cortactin mutant, indicating that phosphorylation of 
S405 and S418 are both vital in maintaining optimal carcinoma cell motility (Figure 6B).  
Since lamellipodia formation is required for detached cells to adhere to the ECM, we 
conducted ECIS assays to determine the effects of cortactin S405/418 phosphorylation 
on cell adhesion.  MTLn3 cells lacking cortactin expression (si) exhibited a 50% 
decrease in cell adhesion compared to control (Ctl) cells.  Expression of wild type (WT) 
GFP-cortactin restored adhesion to levels similar to Ctl, whereas expression of S405A, 
S418A or S405/418A cortactin mutants all reduced adhesion to levels 42-58% of Ctl, 
failing to restore adhesion to levels above cortactin si cells (Figure 6C).  These results 
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suggest that S405/418 phosphorylation is critical for carcinoma cell motility and 
adhesion, representing an important pro-migratory substrate targeted by the MEK- 
ERK1/2 pathway.  
Cortactin S405/418 phosphorylation is required for carcinoma cell lamellipodia 
persistence  
Given the localization of pS418 cortactin within lamellipodia (Figure 1B) and the effects 
of cortactin S405/418A expression on cell motility, we evaluated the impact of cortactin 
S405/418 phosphorylation on lamellipodia dynamics using live-cell imaging and 
kymographic analysis.  Serum-starved MTLn3 cells expressing mCherry-β-actin and 
containing endogenous cortactin knockdown alone (si), rescued with human GFP- wild- 
type cortactin (si+WT) or with GFP-cortactin S405/418A (si+S405,418) were stimulated 
with EGF for 15 min.  Lamellipodia dynamics were monitored by time lapse video 
microscopy (Figures S1-S4) and assayed by kymography (Figure 7A).  EGF-stimulated 
MTLn3 cells produced an initial dominant lamellipodia that reached maximal extension 
between 1.5 and 3 min, and retracted to the point of origin between 5-7 min [60,61].  
Control MTLn3 cells containing mCherry-β-actin displayed similar extension-retraction 
kinetics when assayed by kymography (Figure 7B and Figure S1).  While no differences 
were observed in lamellipodia protrusion rates in any of the assayed cellular conditions 
(Figure 7A), cortactin knockdown (si) increased lamellipodia extension by an average of 
5.8 µm over the maximum extension length observed in control cells (Figure 7A and B).  
Lamellipodia formed in cortactin si cells failed to effectively retract lamellipodia, 
demonstrating a ~2-fold increase in average lamellipodia persistence over control levels 
(Figure 7A and Figure S2).  These results are consistent with the observed increase in 
lamellipodia extension and persistence observed when MTLn3 cells contact EGF- 
coated bead matrices [23].  These effects are fully rescued to control levels upon 
expression of WT GFP-cortactin (si+WT; Figure 7A and B).  Although expression of 
GFP-cortactin S405/418A in cortactin si cells did not impact EGF-induced lamellipodia 
extension, average lamellipodia persistence was reduced by 46%, from 195 sec in 
si+WT cells to 106 sec in si+405,418 cells (Figure 7A).  The lamellipodia in si+405,418 
cells displayed series of multiple short extensions and retractions, had enhanced ruffling 
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and appeared more labile than control or si+WT cells (Figure 7B: Figures S1 and S2 
compared to Figure S4).  These results suggest that S405/418 phosphorylation is vital 
in regulating lamellipodia actin dynamics responsible for proper protrusive behavior. 
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Discussion  
While the effects of cortactin phosphorylation at S405 and S418 by ERK1/2 have been 
studied at the biochemical and functional level in several systems [29,45,46,47], the 
spatial and temporal evaluation of S405 and S418 phosphorylation have been 
hampered due to the lack of suitable reagents to directly study these sites in cellular 
and tissue contexts.  Our development of anti-pS405 and anti-p418 cortactin antibodies 
has allowed us to examine the localization and signaling pathways regulating these 
cortactin phosphorylation events.  These antibodies, coupled with the use of 
phosphorylation-null mutant constructs, allowed us to validate and extend previous 
findings implicating these sites in the regulation of carcinoma cell motility and 
associated lamellipodia dynamics.  
The localization of pS418 cortactin in carcinoma lamellipodia and invadopodia is 
consistent with the defined and emerging roles cortactin plays in regulating actin 
dynamics within these structures [26,62].  To date, all studies designed to evaluate the 
cellular effects of pS405/418 phosphorylation have relied on the use of phosphorylation 
null or phosphomimetic (S405/418D) constructs.  In pancreatic tumor cells, S405/418A 
and S405/418D both promote lamellipodia protrusion over control levels, whereas 
S405/418A inhibits and S405/418D promotes cell motility [47].  While the ability of 
S405/418A to promote lamellipodia protrusion in these studies is unclear, the remaining 
results are consistent with an activating role for S405/418 phosphorylation in 
lamellipodia dynamics and motility.  Similar results were obtained in the analysis of 
S405/418 on invadopodia function, with S405/418A expression impairing and 
S405/418D promoting ECM degradation activity [29]. Phosphorylation of cortactin S418 
within lamellipodia and invadopodia (Figure 1B) supports these results.  Precisely where 
cortactin is phosphorylated on S405/418 in carcinoma cells remains to be determined, 
although the phosphorylating kinases ERK1/2 and PAK1 have been localized within 
lamellipodia [63,64] and invadopodia [65].  This could suggest that cortactin is initially 
localized to lamellipodia or invadopodia, where it is subsequently phosphorylated on 
S405/418 when associated with the cortical actin networks within these structures.  An 
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analogous mechanism is employed for cortactin tyrosine phosphorylation within 
lamellipodia [40].  
In HNSCC and several other tumor types, cortactin is present in the cytoplasm and is 
enriched at cell-cell junctions [41,66,67].  The localization of pS418 cortactin at regions 
of HNSCC cellular contact within tumors resembles the localization pattern of pY421 
cortactin in this tumor type [68].  The staining pattern of cortactin and its tyrosine 
phosphorylated form is reminiscent of that found in two-dimensional epithelial 
monolayers, where cortactin has been shown to be essential for Arp2/3-mediated actin 
remodeling resultant from E-cadherin homoligation and subsequent Src activity [69,70].  
While the presence of pS418 cortactin at these sites suggests additional functional roles 
for cortactin in E-cadherin-mediated actin regulation within tumors, whether or not 
cortactin S405/418 phosphorylation impacts elements of E-cadherin-based regulation of 
solid tumor behavior (such as tumor cell cohesion, motility or dissemination) remains to 
be examined.  
Selumetinib inhibition of cortactin S405/S418 phosphorylation is consistent with results 
obtained with non-clinical MEK inhibitors [29,45], reinforcing the MEK-ERK1/2 pathway 
as the main signaling route responsible for phosphorylating these cortactin sites in 
tumor cells.  This is supported by direct phosphorylation of cortactin by ERK1/2 in vitro 
[45] along with our data demonstrating concomitant downregulation of active ERK1/2 
resultant of selumetinib treatment. In addition to MEK, PAK1 has recently been shown 
to phosphorylate cortactin at S405/418, regulating N-WASp actin dynamics responsible 
for clathrin- and caveolin-independent endocytosis [48].  PAK1 is activated primarily by 
binding to active Cdc42 or Rac1 [71], although alternative modes of activation have also 
been described [72].  Activated PAK1 also binds and activates MEK, stimulating 
ERK1/2 activation [73].  Since MEK inhibition largely ablates S405/418 phosphorylation 
in most cell types, the impact of PAK1 activity on S405/418 phosphorylation may be 
context dependent, with direct PAK1 phosphorylation of cortactin S405/418 regulating 
actin polymerization required for endosomal trafficking, while MEK-mediated 
phosphorylation (activated by Raf or other MEK activators) may be primarily responsible 
for governing motility-based actin dynamics. In addition, the related kinase PAK3 
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phosphorylates cortactin at S113, an event that downregulates the ability of cortactin to 
bind F-actin and is important in modulating invadopodia function [29,74].  While our 
understanding regarding the interrelationship and regulation between PAK and MEK in 
governing cortactin S405/418 phosphorylation is currently incomplete, it is clear that the 
PAK- MEK-ERK1/2 signaling nexus impinges at multiple levels on cortactin to regulate 
actin dynamics involved in several membrane-based cellular processes.  
Consistent with other reports [44,45], we observed the MEK-dependent EGF-induced 
shifting of cortactin from the 80kDa to 85kDa form by Western blotting.  Direct analysis 
with anti-pS405 and anti-pS418 antibodies indicates that the 85kDa form is almost 
exclusively phosphorylated on these residues, as was determined by 32P labeling and 
tryptic peptide analysis [44,45].  The shift in cortactin Mr is not attributable to bulk 
addition of phosphate, since phosphatase treatment of cortactin immunoprecipitates 
from EGF-treated cells failed to reconvert the 85kDa form to 80kDa (data not shown).  
While the distinct 80kDa and 85kDa bands represent different post-translationally 
modified cortactin forms associated with pS405/418 phosphorylation, mutations at these 
sites have no effect on 80/85kDa cortactin ratios, with the S405/418A mutant displaying 
a similar cortactin electrophoretic pattern to wild type cortactin (Figure 4).  This suggests 
that S405/418 cortactin phosphorylation, while associated with the shift from 80 to 
85kDa, is not necessary for generation of the 85kDa cortactin form.  This is supported 
by the presence of 80kDa and 85kDa cortactin forms produced in kinase-free systems 
[30,75] and by the existence of a single 85kDa form when analyzed by urea denaturing 
SDS-PAGE [75].  
The lack of detailed structural data for cortactin derived by nuclear magnetic resonance 
spectroscopy or X-ray crystallography has hindered the field in understanding 
conformational changes cortactin undertakes in response to post-translational modifying 
events.  The existence of cortactin in a “closed” versus “open” form regulated by 
S405/418 phosphorylation has been proposed to explain the observed 80 to 85kDa shift 
[45].  Support for this is derived from biochemical studies on N-WASp activation by the 
cortactin SH3 domain, where S405/418 phosphorylation enhances N-WASp activation 
and Arp2/3 actin nucleation activity [46].  These studies propose that the “closed” 
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cortactin form undergoes an autoinhibitory conformational state where the carboxyl 
terminal helical proline-rich (HP) domain containing S405 and S418 is altered to render 
the SH3 domain inaccessible to binding N-WASp or other proteins.  Phosphorylation of 
S405/418 results in liberating the SH3 domain, where it in turn is capable of binding and 
stimulating N-WASp activation.  Expression of cortactin S405/418D phosphomimetic 
forms in cells increases branched actin networks in actin tails associated with 
cytoplasmic vesicles, providing support for this model in promoting cellular actin 
polymerization [47].  Initial assessments of cortactin structure by rotary shadow electron 
microscopy revealed cortactin to exist as a rod shaped monomer 220Å in length [76].  
However, a recent biophysical analysis utilizing chemical crosslinking and small angle x- 
ray scattering suggests that cortactin exists in a more globular form, with the carboxyl 
terminal HP and SH3 domains folding back onto the amino terminal actin binding region 
[77].  Such a structure would support a “closed” conformation, although “open” 
structures were not observed, nor were the effects of ERK1/2 phosphorylation 
evaluated.  Additional evidence for an inhibitory function of the amino terminus can be 
inferred from the ability of the cortactin carboxyl terminal domain to promote N-WASP-
dependent cell motility as effectively as wild type cortactin [78], as well as the 
prevalence of the 85kDa form in invasive colorectal cancer [66].  
In the ERK-Src “switch” model proposed for cortactin regulation, cortactin 
phosphorylation by Src at Y421, 470 and 486 serves to downregulate N-WASp activity 
promoted by S405/418 phosphorylation [46].  This model therefore suggests that serine 
and tyrosine phosphorylation of cortactin function in a reciprocal manner to govern N- 
WASp activation [58].  Our data with site-specific phosphorylation antibodies on lysates 
from EGF-stimulated cells indicates that S405/418 and Y421 are co-phosphorylated, 
and analysis of point mutant cortactin constructs does not indicate a reciprocal influence 
between cortactin serine and tyrosine phosphorylation events.  These data suggest that 
cortactin function is not exclusively regulated by a serine-tyrosine “switch” mechanism. 
This view is additionally reinforced by the presence of pS418 and pY421 cortactin within 
lamellipodia and invadopodia.  While our data do not rule out scenarios where such a 
mechanism may be employed at the cellular level, they are consistent with biochemical 
and cellular evidence indicating that tyrosine phosphorylation promotes N-WASp activity 
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through binding of the adaptor Nck1 [37,39], a component that was not present in the 
original assays where the “switch” mechanism was defined.  The ability of cortactin to 
be simultaneously phosphorylated at S405/418 and Y421/470/486 may therefore 
provide cells with the ability to fine-tune the level of N-WASp activation and subsequent 
actin remodeling in response to diverse upstream stimulatory input that triggers motility 
and invasion.  
Consistent with the mechanistic descriptions above, inhibition of carcinoma cell motility 
by MEK inhibition and S405/418A expression indicates that S405/418 cortactin 
phosphorylation is important in promoting and maintaining cell migration.  While similar 
results were observed in wound healing assays with pancreatic cancer cells [47], our 
work extends these findings by evaluating the effects of pS405/418 on lamellipodia 
dynamics.  The inability of MTLn3 cells expressing S405/418A cortactin to maintain 
EGF-stimulated dominant lamellipodia persistence implies that the actin networks within 
these cells fail to maintain proper Arp2/3 nucleation, or are more labile following 
lamellipodia extension.  While N-WASp activation and Arp2/3-mediated actin 
polymerization resultant of cortactin SH3 domain binding has been shown to be 
important in governing motility in multiple cell types [47,78], a detailed study of EGF- 
induced lamellipodia protrusion in this cell type has recently shown that WAVE2 and 
formin proteins, not N-WASp, are responsible for lamellipodia protrusion [14].  These 
results would therefore rule out a role for direct N-WASp activation by pS405/418 
cortactin in MTLn3 lamellipodia extension. In addition to N-WASp, the cortactin SH3 
domain interacts with several other proteins that have the potential to directly or 
indirectly regulate lamellipodia actin dynamics (reviewed in [62]).  In particular, cortactin 
binds and activates the Dbl family guanine nucleotide exchange factor faciogenital 
dysplasia protein 1 (FGD1) [79,80], a potent activator of Cdc42 [50].  Cdc42 activity is 
required for localization of WAVE2 and its activator IRSp53 to the cell membrane, 
where it mediates lamellipodia extension [81].  FGD1 also activates the MEK-ERK1/2 
pathway [50], allowing the potential of a positive feedback loop in stimulating cortactin 
S405/418 phosphorylation through continuous cortactin SH3-mediated FGD1 activity.  
FGD1 binding represents just one possible cortactin SH3 domain ligand with the 
capability to influence WAVE2 localization and lamellipodia dynamics.  Whether such an 
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FGD1-based regulatory circuit or other modes of potential pS405/418 cortactin 
regulation of WAVE2 activity exist in MTLn3 cells remains to be confirmed.  
Previous studies on lamellipodia dynamics in other cells types indicate that cortactin 
removal decreases lamellipodia persistence, which can be rescued by re-expression of 
a cortactin amino terminal fragment lacking the carboxyl terminal region [20], eliminating 
contributions from pS405/418 in this system.  These results differ from our work in 
MTLn3 cells, where cortactin removal results in enhanced persistence that can be 
rescued by re-expression of wild type cortactin.  It is likely that these observed 
differences are due to a combination of different cell types, chemotactic cues, and 
analysis of dominant, initial lamellipodia versus steady-state lamellipodia dynamics [62].  
Interestingly, inhibition of ERK1/2 signaling during macrophage lamellipodia extension 
results in decreased lamellipodia stability, with similar kymograph profiles to EGF- 
stimulated MTLn3 cells with S405/418A expression [64].  These studies provide 
supporting evidence for our observations. 
Through the use of phosphorylation-specific antibodies, we have analyzed the 
localization of cortactin pS405 and pS418 in tumor cells and tissue, as well as the 
signaling pathways regulating pS405/418 phosphorylation.  Through the use of these 
reagents, we have been able to validate and further clarify the role of pS405/418 in 
cortactin-based signaling.  Our functional studies of carcinoma motility and lamellipodia 
dynamics with phosphorylation-null constructs have shed additional light on the role 
these phosphorylation events play in regulating lamellipodia function involved in tumor 
cell movement. 
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Figure Legends  
Figure 1  Specificity and validation of pS405 and pS418 phospho-specific cortactin 
antibodies.  (A) Phospho-specific recognition of anti-cortactin pS405 and pS418 
antibodies.  Clarified lysates (50μg) from 1483 cells transfected with Myc-tagged wild-
type cortactin (WT), Myc-cortactin S405A, Myc-cortactin S418A or Myc-cortactin 
S405A,S418A point mutants were immunoblotted with affinity purified anti-Cort-pS418 
(left) and anti-Cort-pS405 (right) antibodies.  (B) Localization of pS418 cortactin in areas 
of motile and invasive actin dynamics.  UMSCC2 cells (top row) were serum starved for 
16h prior to stimulation with 100ng/ml EGF for 1 h to induce lamellipodia formation, 
while UMSCC1 cells (middle row) were plated on FITC-conjugated gelatin coated 
coverslips (pseudocolored white) for 6 h to promote invadopodia formation.  Cells were 
fixed, permeablized, and labeled with TRITC-phalloidin (Actin), anti-cortactin (Cort) and 
anti-cortactin-pS418 antibodies.  Arrows denote localization of pS418 cortactin with total 
cortactin and F-actin in lamellipodia (top) and to invadopodia (middle) coinciding with 
areas of active matrix degradation.  Bottom panels are magnified views of the indicated 
cellular region.  Bars, 10μm.  (C) Localization of pS418 cortactin in HNSCC tumor 
tissue. Serial sections from a patient with invasive HNSCC were processed for 
immunohistochemistry with control IgG (Ctl), pS418 cortactin (pS418), total cortactin 
(Cort) and phospho-ERK1/2 (pERK) antibodies.  Sections were counterstained with 
hematoxylin. Arrowheads indicate areas of peripheral pS418 cortactin and total cortactin 
enrichment.  Bar, 100μm. 
Figure 2  Growth factor-stimulated Erk 1/2 activation mediates phosphorylation of 
cortactin at serine 405 and 418.  (A) Growth factor-induced phosphorylation of cortactin 
S405 and S418.  Serum starved UMSCC1 cells were stimulated with EGF (left) or FBS 
(right) for the indicated times.  Cells were lysed and analyzed by Western blotting with 
anti-Cort-pS418 and anti-Cort-pS405 antibodies.  Blots were stripped and reprobed with 
a pan-cortactin antibody to confirm equal loading (bottom).  (B) Pharmacologic MEK 
inhibition inhibits cortactin S405 and S418 phosphorylation.  UMSSC1 (left) and 1483 
(right) cells were serum starved in the presence of the indicated selumetinib 
concentrations prior to stimulation with EGF for 20 min.  Cortactin immunoprecipitated 
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from cell extracts was assayed by Western blotting with anti-Cort- pS418 and anti-Cort-
pS405 antibodies.  Blots were stripped and reprobed with pan- cortactin antibody as in 
(A) (bottom panels).  Selumetinib efficacy was verified by the blotting of lyastes from 
selected timepoints with phospho-ERK1/2 (pERK1/2) and pan ERK1/2 antibodies 
(bottom). All blots are representative images from 3-4 independent experiments.  
Figure 3  EGF-induced conversion of cortactin from 80kDa to 85kDa is impaired by Src 
and MEK1/2 inhibition.  EGF induces the p80kDa to p85kDa shift in HNSCC cells. 
Serum starved UMSCC2 (A) and 1483 (B) cells were treated with 100ng/ml EGF for the 
indicated times.  Clarified lysates were assayed by Western blotting with anti- cortactin, 
anti-Cort-pS418, anti-cort-pS405, anti-Cort-pY421, anti-Src-pY418, anti-pErk1/2 and 
total Erk1/2 antibodies as indicated.  Red bars denote the position of the 85 kDa 
cortactin form; black bars denote the 80 kDa form.  (C) Inhibition of Src and MEK1/2 
kinase activity inhibits the cortactin “shift”. UMSCC2 cells were treated with vehicle 
(DMSO), saracatinib, or selumetinib for 16 h in serum free media.  Cells were stimulated 
with 100ng/ml EGF for 1 h, lysed and analyzed by Western blot analysis with an anti-
cortactin antibody.  
Figure 4  Cortactin tyrosine and serine phosphorylation resultant of v-Src activation are 
not interdependent.  (A) Schematic diagram of the cortactin point mutant constructs 
assayed for phosphorylation.  Mutated codons are denoted on the left and displayed 
with the corresponding mutant amino acid at the appropriate position within cortactin in 
red.  (B) Murine fibroblasts lacking endogenous Src, Yes and Fyn (SYF) were 
transfected with murine-specific cortactin siRNA and cultured for 48 h to deplete 
endogenous cortactin.  Cells were subsequently co-transected with the temperature-
sensitive v-Src construct La29 (tsLa29) and wild-type or the indicated myc- tagged 
human cortactin point-mutant constructs at 41°C (non-permissive temperature).  TPM; 
triple point mutant consisting of Y-F mutations at positions 421, 470 and 486.  After 
transfection, cells were cultured at 41°C, then shifted to 35°C (permissive temperature) 
for 2 h to promote v-Src activation.  Recombinant cortactin proteins were assayed by 
immunoblotting with anti-cortactin-pY421, anti-cortactin-pS405, anti-myc, anti-cortactin, 
and anti-β-actin antibodies.  Note that the inability of cortactin to be phosphorylated on 
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Y421 does not impact its ability to be phosphorylated on S405, nor does lack of S405 
phosphorylation impact Y421 phosphorylation.  
Figure 5  Targeted inhibition of MEK1/2 inhibits HNSCC cell motility.  1483 and 
UMSCC1 cells (5x105) were starved for 24 h in the presence of vehicle (DMSO) or 
increasing concentrations of selumetinib as indicated.  Cells were assayed for motility 
by electric substrate impedance sensing (ECIS) following stimulation with complete 
media containing the matched selumetinib concentration for 24 h.  Data is displayed as 
slope values calculated from the linear part of ECIS tracings.  Bars represent mean ± 
SE. *, p < 0.05 compared to DMSO treated control cells.  
Figure 6  Cortactin phosphorylation at serine 405 and 418 regulates carcinoma cell 
migration and adhesion.  (A) Expression of GFP-cortactin constructs in MTLn3 cells.  
MTLn3 cells were transfected with murine-specific cortactin siRNA (Si) for 48 h to 
silence endogenous cortactin expression.  Cells were subsequently transfected with the 
indicated human GFP-tagged cortactin wild-type and the various Erk1/2 
phosphorylation-null point mutant constructs.  Following transfection, cell lysates were 
immunoblotted with anti-cortactin, anti-GFP and anti-β-actin antibodies.  Solid 
arrowheads indicate the position of GFP-tagged cortactin variants; open arrowheads 
denote the position of endogenous cortactin.  (B) Serine 405 and 418 phosphorylation is 
required for efficient carcinoma cell motility.  MTLn3 cells transfected as in (A) were 
analyzed for cell migration by ECIS.  Cell impedance versus time plots for each 
transfected line are shown on the left; slope values calculated from the linear region of 
each plot are displayed on the right.  (C) Carcinoma cell spreading requires 
phosphorylation of cortactin S405 and S418.  Transfected MTLn3 cells were plated, with 
rates of spreading were monitored by ECIS tracings over time left.  Slope values from 
the linear regions are shown on the right.  Bars represent mean ± SE for 3 independent 
experiments.  *, P < 0.05 compared to control (ctl) cells.  
Figure 7  Cortactin phosphorylation at serine 405 and 418 is required for lamellipodia 
persistence.  (A) Kymographic analysis of MTLn3 lamellipodia.  Serum starved MTLn3 
cells (Ctl) or cells transfected with the indicated cortactin siRNA and cortactin constructs 
were monitored for dominant lamellipodia formation by live cell imaging following EGF 
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stimulation.  Quantification of lamellipodia protrusion rates, length of extension, and time 
of lamellipodia persistence are shown for each experimental condition.  > 10 cells were 
analyzed for each group from > 3 independent experiments.  (B) Representative 
kymograms of each cell type.  Kymograms were constructed from 1-pixel wide lines 
drawn from the initial leading edge and in the direction of the dominant lamellipodia.  
Cells were visualized by fluorescent microscopy using mCherry-β-actin as the 
lamellipodia marker.  Images were captured every 5 sec for a period of 15 min.  Black 
lines denote the baseline position of the leading edge prior to EGF stimulation.  Bar; 5 
µm. 
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General Discussion 
 
The successful treatment of CML and GIST patients with imatinib makes it an attractive 
chemotherapeutic agent for solid tumor types with elevated Abl activity (1-5).  
Unfortunately, single agent imatinib phase I and II trials have demonstrated little benefit 
for breast or pancreatic cancer patients. Furthermore, imatinib treatment of prostate, 
NSCLC, and HNSCC patients in clinical trials had deleterious effects, resulting in 
enhanced tumor progression (6-10,10-12).  The poor response rate for chemotherapy 
targeting Abl in solid tumors may be attributed to the consequential oncogenic effects of 
Abl inhibition in these specific diseases. 
On one hand, Abl family kinases enhance tumor proliferation and invasion in breast, 
melanoma, gastric and NSCLC (1,1-5,13-16).  Conversely, Abl family kinases have also 
been shown to inhibit TGFβ induced EMT, tumor growth, and/or motility in breast 
cancer.  Moreover, thyroid cancer cells treated with imatinib results in enhanced cell 
migration. In vivo, imatinib treatment increases breast cancer tumor size in xenograft 
mouse models, and; in vitro analysis of imatinib treated MA-11 breast cancer cells 
demonstrated enhanced migration, elevated Erk 1/2 and Wnt signaling (17-20).  Study 1 
provides additional insight into the divergent roles of Abl in tumor invasion by showing 
that Abl regulates invasive signaling in a tumor type specific manner (21).  This work 
confirmed the published pro-invasive Abl family kinases activity in breast cancer 
invadopodia formation and 3-D collagen invasion utilizing the common MDA-MB-231 
cell line (4,5), as well as demonstrating an opposing role for Abl in HNSCC invasion 
where Abl functions an invasion suppressor.   
Study 1 demonstrates elevated basal activation of Src and EGFR in HNSCC compared 
to MDA-MB-231 cells.  Elevated Src activation in HNSCC can regulate ECM 
degradation and invasion by bypassing Abl family kinase regulation, contrary to the 
proposed EGFR/Src/Arg/Cortactin-mediated regulation of invadopodia maturation 
published by the Koleske group (4).  In HNSCC, Src activity is responsible for the 
increased ECM-degradative activity of invadopodia induced by inhibition of Abl kinase 
activation by imatinib or RNAi.  The regulatory role of Src in HNSCC was further 
examined in Study 2.  The efficacy of the dual Src/Abl inhibitor saracatinib was 
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demonstrated in HNSCC cell lines by Western blot analysis of Src substrate 
phosphorylation sites in FAK, p130Cas and cortactin. Study 2 confirmed the regulatory 
role of Src by the inhibition of invadopodia formation and activity, matrigel invasion and 
metastasis in vivo.  Interestingly, analysis of CML cell lines resistant to the Abl-specific 
inhibitor nilotinib with overexpression of the Src-family member Lyn regained sensitivity 
to nilotinib when Lyn was removed by RNAi (22,23).  Similar results were observed with 
imatinib-resistant human GIST xenograph models, where resistant tumors had integrin-
mediated elevated Src and Lyn activation (24). Collectively, these reports and the 
studies herein indicate that elevated Src kinase activity supersedes any pro- or anti-
invasive role governed by Abl.  In addition, these studies suggest the activation of Src 
resultant from Abl inhibition observed in Study 1 is not specific to HNSCC.   
To determine the molecular mechanism for imatinib-mediated activation of Src in 
HNSCC and subsequent enhanced invadopodia proteolytic activity and invasion, we 
examined the activation of EGFR and Erk 1/2, two key components of invadopodia 
regulation.  In Study 1, EGFR and Erk 1/2 activity were elevated in imatinib-treated 
HNSCC, but not in MDA-MB-231 cells.  The increased Erk1/2 phosphorylation achieved 
with Abl family kinase inhibition is contrary to current dogma, where the 
RAS/RAF/MEK/Erk signaling pathway is activated by either BCR-Abl or integrin-
mediated c-Abl activity (25-27).  Unexpectedly, increased phosphorylation of Erk 1/2 is 
frequently observed in imatinib-resistant CML cells and other tumor types. CD34+,BCR-
Abl+ progenitor leukemic cells treated with imatinib or nilotinib results in enhanced Erk 
1/2 activation (28).  Imatinib also stimulates elevated phosphorylation of Erk 1/2, 
PI3K/Akt, and Stat3 in PDGFRβ expressing glioblastoma cells (29).  Conversely, 
imatinib treated colon adenocarcinoma cells display apoptosis and disrupted F-actin 
cytoskeletal networks (30).  Such studies further highlight the need for better insight into 
the mechanisms utilized by tumors to acquire imatinib or nilotinib resistance if these 
compounds are to be considered for widespread use in solid tumors, as well as for 
current treatment of CML and GIST patients where imatinib and nilotinib forms an 
important part of the standard of care for these individuals.   
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Along these lines, Packer et. al. have examined all known components of the 
RAS/RAF/MEK/Erk1/2 signaling pathway in an imatinib-resistant CML cell line, 
determining that imatinib induces activation of RAF and MEK in addition to Erk1/2.  
Cells lines from solid tumors were compared that contained constitutive inactivation of 
this pathway due to upstream KRAS mutation.  When treated with imatinib, nilotinib or 
dasatinib, the RAF isoform BRAF was inhibited, but the related form CRAF was partially 
activated by heterodimerization with inactive BRAF, presenting a possible mechanism 
for imatinib activation of Erk1/2 (31).  This is supported by the observation of CRAF 
hyperactivation in melanoma and thyroid cancer patients containing inactivating BRAF 
V600E mutations (32).  MDA-MB-231 cells contain an activating KRAS mutation that 
hyperactivates KRAS/RAF/MEK/Erk1/2 and potentially diminishes the effect of imatinib-
induced CRAF activation.  This creates a plausible explanation for divergent effects 
observed with imatinib treatment between our HNSCC cell lines (UMSCC1 and OSC19) 
and MDA-MB-231.  However, this mechanism does not explain the increased ECM 
degradation observed in UMSCC1 cells with Abl knocked-down seen in Study 1.  
Elevated expression and secretion of HB-EGF in imatinib-treated HNSCC cell lines was 
shown by our laboratory (Study 1) and others (33), presenting an alternate mechanism 
for imatinib-mediated induction of EGFR, Src, and Erk 1/2 activity.  Nevertheless, HB-
EGF is likely not the only cytokine up-regulated in HNSCC with imatinib treatment. 
Imatinib exposure enhanced ephrin and osteonectin in BCR-Abl+ leukemic cell lines 
(34,35).  
Cortactin is overexpressed in HNSCC and other cancers and correlates with poor 
prognosis (36-40).  Elevated cortactin tyrosine phosphorylation is associated with 
increased invasion and metastasis (13,14,21,41-46).  Cortactin is also phosphorylated 
by Erk 1/2 at serine sites 405 and 418, but little was known of the effects of cortactin 
serine phosphorylation on invasion and metastasis (47).  Martinez-Quiles et al 
demonstrated cortactin serine phosphorylation increased N-WASp binding to the SH3 
domain of cortactin, enhancing cortactin-mediated activation of Arp 2/3 actin 
polymerization (48).  Study 3 further elucidated the effect of cortactin phosphorylation by 
Erk 1/2 on cancer cell motility and lamellipodia function.  Serine 405/418 
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phosphorylation resulted in increased adhesion and motility with in EGF-stimulated 
HNSCC cells.  This motility enhancement can be attributed in part to an increase in 
lamellipodia persistence.  Our laboratory (Study 3) and others have shown that cortactin 
serine phosphorylation and interaction with p120 catenin are essential for lamellipodia 
persistence and lamellipodial-mediated ECM recycling (49,50).  Cortactin serine 
phosphorylation by Erk 1/2 also modulates invadopodia formation and proteolytic 
activity (51).  These results collectively support a role for Erk 1/2 phosphorylation of 
cortactin in regulating motility structures utilized for amoeboid, mesenchymal and 
collective cell motility and invasion (52). 
Imatinib treatment enhances Erk 1/2, Src, and/or EGFR phosphorylation in HNSCC, 
CML and other tumor types.  Our laboratory and others have demonstrated that imatinib 
can increase or decrease invasion and metastasis by activating or inhibiting key 
components of these processes- namely Erk1/2, Src, and EGFR.  Abl appears to be a 
key component in mediating these divergent effects and can function as an anti- or pro-
oncogenic protein dependent on cellular context.  The regulating mechanism(s) that 
modulate the dichotomous roles of Abl in tumor motility are currently unknown.  An 
understanding of this complex process is crucial as the use of imatinib expands to solid 
tumors in the clinic in order to prevent detrimental effects to patients undergoing 
imatinib treatment.  
Imatinib is the first successful targeted kinase inhibitor that moved from the bench to the 
clinic, ushering in the era of modern targeted therapeutic intervention in cancer.  The 
efficacy of these targeted therapies has been mixed, from the success of imatinib to the 
puzzling lack of response with dasatinib in phase II and III trials where preclinical work 
showed great promise. Why certain targets are more effective than others when 
therapeutically inhibited is not fully understood, nor are the compensatory mechanisms 
tumor cells utilize to overcome targeted therapies in developing drug resistance.   
Drug resistance has been attributed to three main reasons; the heterogeneity of tumors 
that enable a subset of tumors cells (likely tumor initiating stem cells) to survive 
chemotherapeutic agents, the complexity of the microenvironment (cellular and non-
cellular) providing a protective niche for the tumor cells; and tumor cell plasticity (53).  
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Tumor plasticity allows the tumor to reversibly change and adapt their phenotype to 
intrinsic and external cues without permanently altering genomic DNA. EMT confers 
stem cell like properties and chemoresistance in tumor cells.  Transcription factors such 
as Zeb1, Twist, and Snail are key components that regulate EMT and are current areas 
of intense focus in efforts to reverse molecular and phenotypic elements of 
transformation (54).  However, it is clear that EMT is not the sole factor regulating tumor 
plasticity (55), as our work and others indicates that adaptive kinase responses play 
important roles in mediating drug resistance (21,28,29).  Duncan et. al. utilized an 
innovative multiplexed inhibitor beads (MIBs) system that binds over 60% of the kinase 
kinome to examine the rapid kinome reprogramming induced by MEK inhibitor treatment 
of triple negative breast cancer (56).  MIBs are generated by immobilizing several broad 
kinase inhibitors to sepharose beads. MIBs selectively bind active kinases due to the 
general mechanism utilized by kinase inhibitors, blocking the ATP binding sites; this 
allows the monitoring of altered activity of over a hundred kinases simultaneously (56). 
Our work demonstrates kinase “reprogramming” within hours after drug treatment 
enhances HNSCC metastasis and invasion making imatinib an interesting candidate for 
this process.  The dichotomous functions of Abl in different cancer types suggest that it 
may play a key regulatory role in governing tumor plasticity responsible for facilitating 
drug resistance.   
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Supplemental Figure 1  Confocal imaging of additional HNSCC cell lines 
assayed for Src activity and invadopodia-forming capability in Fig 1A. (A) The 
FADU and MSK921 HNSCC cell lines were incubated on FITC-coated gelatin 
(white) coverslips for 12 hours, then fixed and labeled with TRITC−phalloidin 
(red), and cortactin (green) (top panels). Both lines fail to make endogenous 
invadopodia or degrade matrix. (B) FADU and MSK921 cells transfected with 
Src527F−mCh (red) were incubated on FITC-coated gelatin (white) coverslips for 
12 hours, then fixed and labeled with cortactin (green) (top panels). Src-induced 
invadopodia are present and identified by the cortactin aggregates (white arrows) 
that localize with Src527F and the dark holes in the FITC-gelatin (black arrows). 
Scale bars: 10 µm.  
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Supplemental Figure 2  Src regulates invadopodia maturation in OSC19 cells. 
(A) Src protein levels in OSC19 cells treated with with Src shRNA (SrcSh) or a 
shRNA vector control (Ctl). Expression SrcWT (WT) or Src527F (527) in Ctl and 
SrcSh cells evaluated by immunoblotting (B) and confocal microscopy (C). Cells 
were plated on FITC−gelatin-coated (pseudocolored white) coverslips for 10 
hours and immunolabeled with TRITC−phalloidin (red). Scale bars: 10 µm. (D) 
The effect of Src expression on percentage of cells displaying invadopodia, the 
number of invadopodia per cell, and the amount of matrix degradation per cell 
were examined. Data are represented as mean ± s.e.m., groups are statically 
different (*P&λτ;0.01, **P&λτ;0.05).  
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Supplemental Figure 3  (A) Invadopodia are formed in cells expressing tsLa29−GFP at 
the permissive temperature. SYF cells transfected with empty GFP vector (EV) or with 
tsLa29 tagged with GFP on the C-terminus (tsLa29−GFP) were incubated at 41°C or 
35°C. Cells were fixed, permeabilized, and dual-labeled with TRITC-phalloidin and a 
phospho-specific antibody for cortactin Tyr421. Cells were visualized by confocal 
microscopy through 2D and 3D (z-stack) sectioning. (B) Silencing of cortactin with 
siRNA prevents invadopodia formation. SYF cells were transfected with cortactin-
targeted or control siRNA (Ctl) and incubated at 37°C for 2 days. Cells were then 
transfected with tsLa29−GFP and the experiment proceeded as described in A. Cells 
were fixed, permeabilized, and immunolabeled with TRITC-phalloidin and an anti-
cortactin (4F11) antibody. Invadopodia fail to form in cells treated with cortactin siRNA. 
(C) Clarified cell lysates (30µg) from cells transfected with mock siRNA or siRNA to 
knock down cortactin, alone or in combination with tsLa29−GFP, were incubated at 
41°C or 35°C, resolved by SDS-PAGE and immunoblotted with anti-Src-pY418, anti-Src 
(EC10), anti-cortactin (4F11), anti-cortactin-pY421, anti-GFP (JL8) and anti-β-actin 
antibodies. Scale bars: 10 µm.  
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Supplemental Figure 4  Characterization of fluorescent protein-tagged Src constructs. 
(A) Determination of relative Src kinase activity. SYF cells expressing Src-GFP, Src- 
cerulean, Src527F-GFP, Src527F-mCherry, Src295M−GFP, or Src295M-cerulean were 
lysed, resolved by SDS-PAGE and immunoblotted with anti-Src-pY418, anti-Src, and 
anti-β-actin antibodies. Quantification of the relative Src phospohorylation in transfected 
SYF cells was conducted using densitometry. Src-pY18 protein expression was 
normalized to total Src protein levels. (B) Swept-field imaging of fluorescently labeled 
Src constructs. Fixed cells were imaged for expression and localization of GFP, 
mCherry, and cerulean-tagged Src fluorescent proteins by direct fluorescence. GFP, 
green fluorescent protein; CerFP, cerulean fluorescent protein; mChFP, mCherry 
fluorescent protein. (C) Confocal imaging of GFP-tagged SrcWT, Src295M, and 
Src527F. Transfected cells expressing the indicated Src constructs were fixed, 
permeabilized and immunolabeled with TRITC-phalloidin and the anti-cortactin (4F11) 
antibody. Arrows indicate invadopodia in cells expressing Src527F. Scale bars: 10 µm. 
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Supplemental Figure 5   Co-
transfection and localization of 
fluorescent protein tagged Src 
constructs. (A) Representative 
images of non-transfected SYF 
cells (left) and SYF cells co-
expressing WT Src tagged with 
Cerulean fluorescent protein 
(Src-Cer) and GFP-tagged 
Src527F (527F−GFP) (right). 
Cells were fixed, permeabilized 
and immunolabeled with 
TRITC−phalloidin and anti-
cortactin (4F11) antibody. 
Arrows denote invadopodia in 
the 527F−GFP-transfected 
cells. Scale bar: 20µm. (B) SYF 
and SYF+/+ cells expressing 
cSrc527F−mCherry alone or in 
combination with Src−cerulean 
or Src295M−cerulean, were 
lysed and resolved by SDS-
PAGE and immunoblotted with 
anti-Src-pY418, anti-Src, anti-
GFP or anti-cerulean (JL8, does 
not recognize mCherry), anti-
actin, anti-cortactin-pY421 and 
anti-cortactin (4F11) antibodies.  
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Supplemental Figure 6 
Comprehensive SH2 and PTB 
binding assay. An in vitro binding 
assay was performed using 91 GST 
SH2 domains and three GST PTB 
domains, representing nearly the full 
complement of human 
phosphotyrosine-binding domains. 
GST and mutated Abl SH2 domain 
(Abl R>K) were used as negative 
controls. SH2 binding to SYF cell 
lysate was determined by 
densitometric quantification of 
digitally captured 
chemiluminescence images. The 
mean raw binding intensities with 
s.e.m. from two independent 
experiments are shown. Domains 
are ordered from left to right by their 
binding intensity to SYF+/+ cells 
expressing Src527F to reflect rank 
order relevance for invadopodia 
maturation.  
Kelley LC, et al. J Cell Sci 2010 Nov 
15;123(Pt 22):3923-3932.  
 
 
245 
 
Karen E. Hayes 
 
  
CONTACT  401 Ontario Ave, Point Marion, PA 15474  
INFORMATION Home: (724) 725-0729 · Work: (304) 293-3090  
kehayes@hsc.wvu.edu  
 
 
EDUCATION  West Virginia University School of Medicine   2004-present 
Morgantown, WV 
PhD candidate, Cancer Cell Biology  
 
Edinboro University of Pennsylvania      1997 
Edinboro, PA 
B. S., Biology, Cum Laude, Department of Biology                
 
   
RELATED  Free-Col Laboratories, A Division of Modern       1999-2004 
EMPLOYMENT Industries, Meadville, PA  
Laboratory Analyst 
 
Areas of responsibilities include maintaining bioassay cultures, 
reference toxicant analysis, and WET test analysis, wet chemistry 
analysis utilizing spectrophotometer, ion selective electrodes, 
titrations and distillation units. Other responsibilities included 
assisting in the microbiology department and reviewing other 
chemist’s analytical reports.  
 
 
DOCTORAL   Abelson Kinase Based Regulation of Tumor Cell Invasion in 
DISSERTATION HNSCC 
 
   Dissertation Defense Date: December 11, 2012 
 
Laboratory techniques learned and utilized included biochemical 
protein analysis and purification (Western blotting, 
immunoprecipitation, affinity   precipitation, recombinant protein 
production, gelatin zymography, ELISA); cellular migration, 
adhesion, and invasion assays (ECIS, wound healing assays, 
gelatin degradation assay, Boyden chamber based assays, 3D-
Collagen I invasion assay); kinase assays; DNA 
cloning/mutagenesis; fluorescent/confocal microscopy; flow 
cytometry; tissue/cell culture techniques (maintaining cell lines, 
cellular transfection, lentivirus preparation and subsequent cellular 
246 
 
infection); and orthotopic xenografts of oral squamous cell 
carcinoma examining perineural invasion and lymph node 
metastasis. 
 
 
PUBLICATIONS Ableson Kinases Negatively Regulate Invadopodia Function and 
Invasion in Head and Neck Squamous Cell Carcinoma by Inhibiting 
an HB-EGF Autocrine Loop, Karen E. Hayes*, Elyse L. Walk, 
Amanda Gatesman Ammer, Laura C. Kelley, Karen H. Martin, and 
Scott A. Weed Oncogene 2012 Nov; 1(2) online pub 
doi.1038/onc.2012.513. 
 
Quantitative Measurement of Invadopodia-mediated Extracellular 
Matrix Proteolysis in Single and Multicellular Contexts, Karen H. 
Martin*, Karen E. Hayes, Elyse L. Walk, Amanda Gatesman 
Ammer, Steven M. Markwell and Scott A. Weed  J. Vis Exp. (JOVE) 
2012 Aug 27;66. 
 
Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic 
Mouse Model of Oral Squamous Cell Carcinoma, Gatesman 
Ammer A*, Hayes KE, Martin KH, Zhang L, Spirou GA, and Weed 
SA. J. Vis Exp. (JOVE) 2011 Jul; 53:2941. 
 
Revisiting the ERK/Src Cortactin Switch, Hayes KE*, Kelley LC*, 
Ammer AG*, Martin KH, and Weed SA Commun. Integr. Biol. 2011 
Mar;4(2):205-207. 
 
Further Insights into Cortactin Conformational Regulation, Jason V. 
Evans*, Laura C. Kelley, Karen E. Hayes, Amanda Gatesman 
Ammer, Karen H. Martin and Scott A. Weed Bioarchitecture 2011 
Jan;1(1):21-23. 
 
Oncogenic Src Requires a Wild-type Counterpart to Regulated 
Invadopodia Maturation, Kelley LC*, Ammer AG, Hayes KE, Martin 
KH, Machida K, Jia L, Mayer BJ, and Weed SA J. Cell Sci. 2010 
Nov 15;123:3923-3932. 
 
Cortactin Phosphorylated by ERK1/2 Localizes to Sites of Dynamic 
Actin Regulation and Is Required for Carcinoma Lamellipodia 
Persistence, Karen E. Hayes*, Laura C. Kelley*, Amanda 
Gatesman Ammer*, Karen H. Martin, and Scott A. Weed PLoS One 
2010 Nov;5(11):e13847. 
 
Sarcatinib Impairs Head and Neck Squamous Cell Carcinoma 
Invasion by Disrupting Invadopodia Function, Hayes KE*, Ammer 
AG*, Kelley LC*, Evans JV, Lopez-Skinner LA, Martin KH, 
247 
 
Frederick B, Rothschild BL, Raben D, Elvin P, Green TP, Weed SA 
J Cancer Sci Ther. 2009 Nov 30;1(2):52-61. 
 
  * Denotes First Authors  
. 
 
ABSTRACTS The 4th Biennial National IDeA Symposium, Washington, DC, June 
2012, Ableson Kinases Negatively Regulate Invadopodia and 
Invasion in HNSCC, Karen Hayes and Scott Weed. 
 
The American Society for Cell Biology 50th Annual Meeting, 
Philadelphia, PA, December 2010, c-Abl is a Novel Negative 
Regulator of Invadopodia Activity, Karen Hayes, Karen H. Martin, 
Laura Kelley, Mark Culp and Scott Weed. 
 
EJ Van Liere Convocation and Research Day, Morgantown, WV, 
April 2009, A c-Abl -Cortactin Complex Regulates Invadopodia 
Activity, Karen E. Hayes and Scott A. Weed. 
 
4th Annual West Virginia COBRE/INBRE Conference, Morgantown, 
WV, October 2008, A c-Abl-Cortactin Complex Regulates 
Invadopodia Activity, Karen E. Hayes, Karen H. Martin and Scott 
A. Weed. 
 
The 3rd Annual West Virginia COBRE/IMBRE Conference, 
Charleston, WV, November 2007, Role of c-Abl in Cortactin 
Phosphorylation, Karen E. Hayes, Laura F. Gibson, Mark Auble, 
Ann Marie Pendergast, Scott A. Weed. 
 
EJ Van Liere Convocation and Research Day, Morgantown, WV 
May 2007,  Role of c-Abl in Cortactin Phosphorylation, Karen E. 
Hayes, Laura F. Gibson, Mark Auble, Ann Marie Pendergast, Scott 
A. Weed. 
  
The American Association for Cancer Research 98th Annual 
Meeting, Los Angeles, CA, April  2007, Role of c-Abl in Cortactin 
Phosphorylation, Karen E. Hayes, Laura F. Gibson, Mark Auble, 
Ann Marie Pendergast, Scott A. Weed. 
 
 
PROFESSIONAL Organized and hosted guest speaker, Dr Donna Webb, for West  
DEVELOPMENT Virginia University Cell Biology Training Seminar, May 2010. 
 
Imaging Ethics, Acquisition, Post-Processing and Quantification 
Course, taught by Jerry Sedgewick, June 2012. 
 
 
248 
 
MEMBERSHIPS AACR (American Association for Cancer Research)     2010-2012  
ASCB (American Society for Cell Biology)      2006-2012  
West Virginia University Cytoskeletal Signaling Group     2008-2010  
West Virginia University Cell Biology Training  
Consortium            2009-2012 
 
 
 
Supplemental Figure 6 
Comprehensive SH2 and PTB 
binding assay. An in vitro binding 
assay was performed using 91 GST 
SH2 domains and three GST PTB 
domains, representing nearly the full 
complement of human 
phosphotyrosine-binding domains. 
GST and mutated Abl SH2 domain 
(Abl R>K) were used as negative 
controls. SH2 binding to SYF cell 
lysate was determined by 
densitometric quantification of 
digitally captured 
chemiluminescence images. The 
mean raw binding intensities with 
s.e.m. from two independent 
experiments are shown. Domains 
are ordered from left to right by their 
binding intensity to SYF+/+ cells 
expressing Src527F to reflect rank 
order relevance for invadopodia 
maturation.  
Kelley LC, et al. J Cell Sci 2010 Nov 
15;123(Pt 22):3923-3932.  
 
 
